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1. Summary 
Homeostatic control of the surrounding microenvironment is a requirement for proper neuronal 
function. Their high metabolism requires an efficient supply of nutrients (sugars, amino acids, 
nucleosides, etc.) and removal of potentially toxic metabolites. A central role in balancing these 
two processes belongs to the barriers of the central nervous system (CNS). The Blood Brain 
barrier (BBB) is a dynamic interface between the peripheral circulation and the CNS that tightly 
regulates transport of compounds into and out of the brain. According to the currently accepted 
hypothesis the BBB plays a significant role in the production of the brain interstitial fluid (ISF) 
that directly surrounds neurons and other brain cells. However, since the ISF is only ~ 20% of 
the total brain volume and is distributed throughout the brain, it is difficult to sample unlike the 
cerebrospinal fluid (CSF). Therefore, rather less is known about its content. Amino acids (AA) 
are vitally necessary compounds with multiple functions. Additionally, in the CNS AAs are 
neurotransmitters or neurotransmitter precursors. For example, glutamine (Gln) serves as a 
precursor for both the major excitatory (glutamate) and inhibitory (γ-aminobutyric acid 
(GABA)) neurotransmitters and as a result levels are altered during some pathologies. The 
conditionally essential AA Gln is the most abundant AA in plasma and CSF. Moreover, in CSF 
Gln concentration is ~ 80% of that in plasma, while all other standard AAs are ~ 10-fold less 
concentrated [1]. Nevertheless, data about concentrations of Gln and other AAs in brain ISF are 
infrequent and inconsistent. The following Gln transporters: LAT1 (SLC7A5), SNAT2 
(SLC38A2), SNAT3 (SLC38A3), and SNAT5 (SLC38A5), are significantly expressed in the 
BBB [2]. Moreover, LAT1 and SNAT3 have been shown to be localized on both luminal and 
abluminal membranes of BBB endothelial cells [3].  
For my dissertation I focused on the brain ISF AAs (in particular Gln) and possible mechanisms 
of regulation by BBB expressed amino acid transporters (AAT)s. Using in vivo intracranial 
microdialysis in awake freely moving mice we determined the levels of 14 standard and 2 non-
standard AA. For all AAs a ~10 fold concentration gradient between ISF and CSF was observed. 
Furthermore the acute administration of valine by intraperitoneal (IP) injection caused a 
significant increase of its concentration not only in plasma, but also in the brain ISF. In contrast, 
15N2 Gln (hGln) IP administration resulted in an elevation only in plasma, but not ISF. 
Nonetheless this labeled form of Gln represented ~ 4% of total Gln in microdialysate samples. 
Thus, we demonstrated efficient transendothelial transport of both AA from the blood. 
Competitive inhibition of system L and system A AATs in the brain by inhibitors (2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) and α-(methylamino)-isobutyric acid 
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(MeAIB), respectively) introduced via the microdialysis probe led to Gln increase in the brain 
ISF. The Gln elevation produced due to BCH infusion was twice higher than that caused by 
MeAIB. To study whether Gln was released from brain cells or its raise in ISF was due to 
increased BBB transport, IP injection of 15N2 Gln was combined with BCH administration. The 
data showed a significant increase of hGln in the brain ISF in presence of BCH in comparison to 
its IP administration alone indicating that brain perfusion with BCH increased Gln influx via the 
BBB, presumably by transstimulating Gln uptake via obligatory exchanger LAT1. 
Since a high level of Snat5 mRNA was found in BBB its localization in brain endothelial cells 
(BEC) membranes was studied. Unfortunately, an antibody-dependent approach did not allow 
distinction of SNAT5 in the BBB endothelium. 
Therefore, first of all, a steep AA concentration gradient between the brain ISF and CSF was 
demonstrated. Second, the data are consistent with LAT1 playing a major role in the regulation 
of Gln in brain ISF.  Since LAT1 is an obligatory exchanger, we suggest it acts together with 
BBB expressed SNAT3 as key regulators of Gln in brain ISF. We consider that studies using 
inducible endothelial specific SNAT3 knockout animals will clarify the contributions of BBB 
expressed SNAT3 in Gln ISF homeostasis.  
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2. Zusammenfassung 
Homöostatische Kontrolle der angrenzenden Mikroumgebung ist eine Voraussetzung für 
korrekte neuronale Funktion. Der hohe Metabolismus von Neuronen erfordert eine effiziente 
Nährstoffversorgung (Zucker, Aminosäuren, Nukleoside, etc.) und Beseitigung von potentiell 
toxischen Metaboliten. Eine zentrale Rolle für die Balance zwischen diesen beiden Prozessen 
nehmen die Schranken des Zentralnervensystems (ZNS) ein. Die Blut-Hirn-Schranke (BHS) ist 
eine dynamische Verbindung zwischen der peripheren Zirkulation und dem ZNS, welche den 
Stoffaustausch ins und aus dem Gehirn heraus eng reguliert. Gemäss der aktuell akzeptierten 
Hypothese spielt die BHS eine bedeutende Rolle für die Produktion der interstitiellen Flüssigkeit 
des Gehirns (ISF), welche Neuronen und andere Gehirnzellen direkt umgibt. Die ISF macht nur 
~ 20% des gesamten Gehirnvolumens aus und sie ist im ganzen Gehirn verteilt. Im Gegensatz 
zur Zerebrospinalflüssigkeit (ZSF) ist es deshalb schwierig Proben der ISF zu nehmen, 
weswegen weniger über deren Zusammensetzung bekannt ist. Aminosäuren (AS) sind 
lebensnotwendige Komponenten mit mannigfaltigen Funktionen. Im ZNS operieren AS auch als 
Neurotransmitter oder als deren Vorstufen. Glutamin (Gln) dient beispielsweise als Vorstufe für 
den wichtigsten exzitatorischen (Glutamat) sowie den inhibitorischen (γ-Aminobuttersäure 
(GABA)) Neurotransmitter, wobei deren Konzentrationen in manchen Krankheitsbildern 
verändert sind. In dem Plasma und in der ZSF ist die konditionell essentielle Aminosäure Gln 
die höchstkonzentrierte Aminosäure. In der ZSF beträgt die Gln Konzentration ~ 80% des 
Plasmalevels, während alle anderen Standardaminosäuren ~ 10-fach niedriger konzentriert sind 
[1]. Daten über Aminosäure Konzentrationen in der ISF des Gehirns sind jedoch selten und 
inkonsistent. Die Gln Transporter LAT1 (SLC7A5), SNAT2 (SLC38A2), SNAT3 (SLC38A3) 
und SNAT5 (SLC38A5) sind in der BHS massgeblich exprimiert [2]. Des weiteren ist gezeigt 
worden, dass LAT1 und SNAT3 auf der luminalen wie auch der abluminalen Membran von 
BHS Endothelialzellen lokalisiert [3].  
Für meine Dissertation fokussierte ich auf AS der ISF des Gehirns (vor allem Gln) und mögliche 
Mechanismen der Regulation durch die in der BHS exprimierten Aminosäure Transporter 
(AST). Wir bestimmten die Konzentrationen von 14 kanonischen und 2 nichtkanonischen AS 
mit Hilfe von in vivo intrakranieller Mikrodialyse in wachen, frei-beweglichen Mäusen. Es 
konnte für alle AS ein 10-facher Konzentrationsgradient zwischen ISF und ZSF beobachtet 
werden. Des weiteren führte die intraperitoneale (IP) Injektion von Valin zu einem markanten 
Anstieg der Konzentration dieser Aminosäure nicht nur in Plasma, sondern auch in der ISF des 
Gehirns. Hingegen resultierte die IP Applikation von 15N2 Gln (hGln) nur zu einem Anstieg im 
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Plasma, nicht jedoch in der ISF. Gleichzeitig repräsentierte diese markierte Form von Gln 
dennoch ~ 4% des totalen Gln der Mikrodialyse Proben. Somit zeigten wir einen effizienten 
transendothelialen Transport beider AS vom Blut. Kompetitive Hemmung der System-L und 
System-A Transporter im Gehirn durch Inhibitoren (2-Aminobicyclo-(2,2,1)heptan-2-
carbonsäure (BCH) und α-Methylamino-isobuttersäure (MeAIB) beziehungsweise), welche 
durch die Mikrodialyse-Probe appliziert wurden, führten zu einem Gln Anstieg in der ISF des 
Gehirns. BCH führte hierbei zu einem doppelt so hohen Gln Anstieg wie MeAIB. Die IP 
Injektion von 15N2 Gln (hGln) wurde mit einer BCH Applikation kombiniert, um zu eruieren, ob 
Gln aus Gehirnzellen freigesetzt wurde oder ob der Gln Transport über die BHS erhöht wurde. 
Die Daten zeigen einen signifikanten Anstieg von hGln in der ISF des Gehirns in der Präsenz 
von BCH verglichen mit der alleinigen hGln Applikation, was auf eine erhöhte Gln Zufuhr über 
die BHS hinweist, vermutlich durch Transstimulation des Gln Transportes via dem obligaten 
Austauscher LAT1. 
Die Lokalisierung von SNAT5 in Membranen der Endothelzellen des Gehirns wurde untersucht, 
da hohe Levels von Snat5 mRNA in der BHS gefunden wurden. Leider gelang der Nachweis 
von SNAT5 in der BHS durch eine auf Antikörper-basierte Methode nicht. 
Abschliessend, konnten wir zeigen zuerst, dass ein steiler AS Konzentrationsgradient zwischen 
der ISF des Gehirns und der ZSF herrscht. Zweitens, stimmen die Daten damit überein, dass 
LAT1 eine Hauptrolle in der Regulation von Gln in der ISF des Gehirns spielt. Da LAT1 
zwingend ein Austauscher ist, schlagen wir vor, dass LAT1 zusammen mit SNAT3 als 
Hauptregulator von Gln in der ISF des Gehirns agiert. Wir nehmen an, dass Studien mit 
induzierbaren Endothel-spezifischen SNAT3 Knockout Mäusen den Beitrag, welcher SNAT3 in 
der Gln Homöostase der ISF leistet, klären werden.    
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3. Introduction 
3.1. Barriers of the CNS 
The central nervous system (CNS) integrates diverse information obtained both from external as 
well as internal environment and coordinates adequate responses of the whole body to the 
challenges. The brain is the organ with the most complex organization in the body and controls 
under normal conditions all other organs and vital processes. Neurons, glial cells 
(oligodendrocytes, astrocytes, microglia) and pericytes together occupy the major brain volume 
(80%), while the brain endothelial cells represent not more than 3% of the total brain volume [4, 
5]. The excitability of neurons together with the specificity of their anatomical structure allows 
them to receive, process and transmit information. These nervous system functions are 
associated with changes in membrane potential and, consequently, ion concentration and 
chemical gradients in the extracellular fluid. Additionally, these functions are highly energy 
intensive and as a result 15-20% of the body’s basal metabolic rate is due to brain metabolism 
[6]. Homeostatic control of the microenvironment of neurons is an essential requirement for 
normal physiological function. Conversely, the demanding brain metabolism requires a constant 
supply of nutrients and oxygen from the blood and the consequent removal of metabolic wastes.  
A crucial role in the establishment and maintenance of normal homeostasis in the extracellular 
brain milieu is carried out by the barriers of the CNS (Figure 1): the Blood-Brain Barrier (BBB) 
protects the brain from possible changes within blood plasma, while the blood-CSF barrier 
(BCSFB) and the arachnoid barrier separate cerebrospinal fluid (CSF) from the blood [7, 8]. 
Interestingly, there is an additional barrier between the brain interstitial fluid (ISF) and the CSF, 
formed by neuroependymal cells during early development [9]. The main role of this barrier 
might be the establishment of a special environment for the developing brain. For instance, small 
molecules such as sucrose can penetrate the barrier, while large molecules like proteins cannot. 
However, in the adult organisms ependymal cells lining the ventricles are joined only by gap 
junctions that allows free communication between ISF and CSF. 
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Figure 1. Barriers of the CNS (source [10]) 
A. The BBB is composed of the endothelial cells (Endo) of cerebral microvasculature, which together with pericytes 
(Peri) are surrounded by the basement membrane (bm). All together the mentioned structures are wrapped in 
astrocytic processes.  
B. Choroid plexus epithelial cells (Ep) form the BCSF barrier. The endothelial cells of CP are fenestrated and 
substance exchange (dashed arrows) between blood vessel (bv) and CSF takes place.  
C. The outer layer of the arachnoid membrane (Arach) has tight junctions (TJ) and establishes the barrier between 
subarachnoid space (SAS), containing CSF, and the overlaying structures. The blood vessels between the arachnoid 
membrane and the pial surface (PIA) also have TJ (not shown). 
D. Neuroependymal cells are connected by strap junctions (arrows) and form the barrier at the early stages of 
development. 
E. Ependymal cells in the adults do not form proper barrier and molecules can freely exchange (dotted arrows) 
The black arrow indicates presence of TJ. 
The arachnoid barrier is composed of two layers, separated by trabeculae. Epithelial cells of the 
outer layer have tight junctions (TJ), which prevent free diffusion of molecules into the 
subarachnoid fluid, while cells of the inner layer are linked by “punctate” junctions and provide 
the main route for CSF drainage [11]. Conversely, the major communication interfaces between 
blood and brain extracellular fluid (ECF), which includes brain ISF and CSF, are represented by 
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surfaces of the BCSFB and BBB. The BCSF barrier consists of epithelial cells, while the BBB is 
composed of endothelial cells. Despite the fact that brain endothelial cells are the anatomical and 
functional units of the BBB, these cells must closely cooperate with other cell types in the brain 
such as neurons, glial cells, and pericytes in order to maintain their specific structural features 
and regulate the neuronal microenvironment properly. Consequently, the concept of 
neurovascular unit (NVU) was introduced to describe the close structure-functional association 
of brain endothelium, extracellular basement membranes, pericytes, astrocytes, microglia, and 
neurons [12]. Despite the differences in morphology, expression profile of molecule subsets and 
functions, the BBB and BCSFB share many similarities in structural organization.   
3.1.1. Junctional complexes as a basement for the barrier function 
One of the distinguishing structural features of both barriers is the presence of complicated, well-
organized junctional complexes, which include TJ and adherens junctions (AJ) (Figure 2). TJ 
and AJ include transmembrane as well as cytoplasmic proteins, which link the complexes to the 
actin cytoskeleton [13]. 
 
Figure 2. Structure of tight junctions (TJ) (source [14]) 
A simplified scheme of TJ structure of brain endothelial cells is presented. The principal organization of junctional 
complexes is similar for endothelial and epithelial cells and includes a transmembrane component (occludin, 
claudins, junctional adhesion molecules and/or adherent proteins) and a cytoplasmic component (first and second-
order adaptor proteins). The main difference between the BBB and BCSFB is the set of claudins expressed by each 
barrier. 
Occludin, claudins and junctional adhesion molecules (JAM-A, B and C) belong to the 
transmembrane component of TJ. Occludin is a phospho-protein, which consists of two 
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extracellular loops, four trans-membrane domains and three cytoplasmic domains. The N-
terminal domain plays an essential role in TJ assembly, since upon its deletion TJ are still 
formed, but paracellular diffusion increases significantly, while C-terminus anchors the protein 
to the cytoskeleton via zonula occludenes (ZO) proteins [13, 14] and interacts with regulatory 
proteins. A range of kinases and phosphatases regulate occludin’s conformation and, thus, TJ 
association [15, 16]. Claudins belong to a family of 24 small transmembrane phospho-proteins 
and are essential for the formation of barrier properties [17]. Homophilic claudin-claudin 
interactions between neighboring cells create a skeleton for TJ formation.  All members of the 
family possess two extracellular loops that determine diffusion of different sized molecules. 
Thus, expression of a subset of claudins determines paracellular ion movement and as a result 
transepithelial electrical resistance (TEER) of barriers. Difference in expressed claudins between 
BBB and BCSFB is considered to be the main reason for differences in their TEER and function 
[12, 17-21]. A long C-terminal domain interacts with cytoplasmic proteins, particularly, ZO 
proteins [13]. JAMs (JAM-A, JAM-B, JAM-C, JAM-4 and JAM-L) are glycoproteins with two 
immunoglobulin folds in the extracellular domain. These proteins form heterodimers in TJ 
complexes [22]. Their role in TJs is still under investigation, however due to the presence of C-
terminal sites for interactions with different cytoplasmic proteins such as ZO-1 and cingulin, 
JAMs are believed to assign the position of ZO-1 and occludin proteins in TJs [23]. The 
cytoplasmic component of TJs includes a wide range of proteins, which are different in size and 
function, and that together form a cytoplasmic plaque. The following proteins are referred to the 
first class of plaque proteins: adaptor proteins ZO proteins; Ca2+ dependent serine protein kinase 
(CASK); membrane-associated guanylate kinase with inverted orientation of protein-protein 
interaction domains (MAGI-1, MAGI-2, MAGI-3); the portioning defective proteins (PAR3, 
PAR6). The second class of plaque proteins consists of regulatory and signaling proteins and 
their regulators (for instance, the regulator of G-protein signaling 5 (RGS5)) [14]. The ZO 
proteins (ZO-1, ZO-2, ZO-3) are membrane associated gunylate kinases (MAGUK) with many 
protein-protein interaction sites, and their main function is to anchor transmembrane TJ proteins 
to the cytoskeleton. Interaction with actin occurs either directly via binding sites or via a myosin-
like protein called cingulin. Additionally, ZO proteins control the spatial distribution of claudins 
[13].  
Adherens junctions (AJs) stabilize cell-cell interaction in the junctional complexes. Cadherins 
are transmembrane proteins of AJs, while the cytosolic component is presented by catenins. 
Cadherin-10 and vascular endothelial cadherin 5 (VE-Cadherin 5) are expressed in the BBB and 
BCSFB. Moreover, VE cadherin is additionally expressed in brain microvessels without barrier 
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properties [13]. The C-terminal domain of cadherins links to catenins: α, β, χ and p120. β or 
p120 catenins can bind directly to cadherins and via α catenin link the whole complex to the 
actin. The effect of AJ on integrity of junctional complexes happens via VE-cadherin, which has 
been reported to promote claudin 5 expression [24], or via β-catenin through the Wnt signaling 
pathway [25]. 
3.1.2. Blood-Cerebrospinal Fluid Barrier 
The BCSFB is a monolayer of polarized choroid plexus epithelial (CPE) cells that produce 
cerebrospinal fluid (CSF). The choroid plexuses (CP) are leaf-like intensively vascularized 
structures located in the walls of four brain ventricles with a combined surface area of 200 cm2 in 
human. The blood vessels of CP are leaky and allow the fluent exchange of substances, while 
epithelial cells possess TJ [11, 13]. Two morphologically different parts of CP – epithelial 
monolayer and stroma – come from different embryonic layers, the ectoderm and the mesoderm, 
respectively [26]. During the development the formation of CP is reported to start around E10 
for mice, since at this time transthyretin (Ttr), known as the CP marker, is expressed. Ttr, Wnt, 
the transcription factor, Otx2, as well as, the BMP and Notch signaling pathways are reported to 
be important for CP formation and differentiation [27]. As soon as CP is determined as a 
structure consequent morphological changes take place and finally result in the formation of 
mature structures. The CP is considered to be the most important source of vital substances from 
the blood into the brain during early development [9]. CPE cells have TJs on the apical side and 
due to this fact are able to a certain extent control the flow of substances from blood into the 
CSF. CPE cells are known to express claudin 1, 2, 3 (the most abundant) and 11[15, 21, 28] and 
this set of molecules is believed to determine CP epithelium as “leaky” type that secretes large 
fluid volumes with little energy consumption [11, 13]. As a result, TEER values for BCSFB are 
in the range of 50-150 Ω/cm2. Additionally, ZO proteins of CP (ZO-1, 2 and 3) are relatively 
short and concentrated close to the apical (CSF) side of the tissue, while in BBB they are 
localized at cell-to-cell interfaces. Among AJ molecules epithelial cells of BCSF barrier express 
mainly cadherin-10 and catenins α and β [13].  
3.1.3. Blood-Brain Barrier 
BBB is an extensive network of cerebral microvessels, which tightly regulates the access of 
diverse substances from blood into the brain and transport of metabolites in the opposite 
direction. Interestingly, the total surface area of brain microvessels in the human brain is about 
3. Introduction
13
  
15-25 m2, while their total length reaches 600 km [29]. The process of the BBB formation starts 
during the early stages of development (for mice E10, for rats E11), when vascular sprouts 
invade the neuroectoderm and give rise to new vessels during a process called angiogenesis [30]. 
When these sprouts initially enter the ectoderm, they do have TJs, but are permeable to small 
molecules, however possibly still not macromolecules. However, by E18 (rats) the TJs become 
complex and by birth are associated with the protoplasmic face (P-face) and are tight to small 
polar molecules [30]. The BBB of E21 rats already demonstrates high TEER levels [31]. Thus, 
BBB maturation is a progressive process that is complete by birth, while angiogenesis continues 
to P20 (for example, in rats). The process of the BBB maturation is believed to be initiated by 
signals from neuronal progenitor cells [32], however for the further induction of the brain 
endothelial phenotype signals from astrocytes, pericytes, and microglia are also essential [33, 
34]. Both BBB formation and angiogenesis are controlled by Wnt/β-catenin signaling [25], while 
Hedgehog pathway plays an important role in maturation [35]. Brain endothelial cells (BEC) of 
adult organisms possess several distinguishing structural features that differ them from 
endothelial cells in the rest of the body. First, the presence of well-organized TJ complexes is 
unique. The BBB expresses claudins 3, 5, 12 and probably 1 and this combination of proteins is 
believed to be associated with high TEER values (1500-8000 Ω/cm2) [36]. The expression of 
claudin 5 is believed to be essential for proper barrier function. For example, in claudin 5 knock-
out mice brain microvessels develop normally and do not have morphological changes, but are 
permeable to substances with molecular weight less than 800 D. Interestingly, these mice die 10 
h after birth and increased BBB permeability for small molecules might be involved in their 
early death [17]. Out of five known JAMs JAM-A, JAM-B and JAM-C are found in TJ of the 
BBB [14]. AJ components cadherins (VE-Cadherin 5, cadherin-10) and catenins (α, β, χ and 
p120) are expressed in brain endothelial cells [13, 37]. Second, the cerebral endothelium has 
increased number of mitochondria comprising 10-14% of total cell volume in comparison with 
other endothelial cells (2-6% total cell volume) [38, 39]. The high number of mitochondria is a 
necessary source of energy for the maintenance of the chemical gradients existing across the 
BBB. Finally, cerebral endothelial cells contain reduced numbers of vesicles, which results in 
the limited transcellular movement of substances [40, 41]. The BBB performs a dual function in 
living organisms, since, on the one hand, it protects the brain from possible strong chemical 
fluctuations in blood, but, on the other hand, it provides a constant supply for the brain of vitally 
necessary substances. Several main pathways exist to deliver compounds into the brain and to 
remove metabolic products from the brain (Figure 3). 
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Figure 3. Transport pathways across the BBB (source [42]) 
A. Paracellular transport; B. Passive diffusion of lipid soluble molecules; C. Carrier-mediated influx via solute 
carriers (SLCs); D. Active efflux mediated by ABC-transporters; E. Receptor-mediated transcytosis; F. Adsorptive 
transcytosis; G. Cell-mediated transcytosis. 
Substances can enter the brain via the BBB paracellularly or transcellularly. The presence of 
complex well-organized TJs almost completely restricts paracellular transport and only few 
substances (for example, water or dissolved in plasma gases such as O2, CO2) can diffuse into 
the brain in this way. For instance, it has been shown that under normal conditions the BBB is 
impermeable to chemicals with a molecular weight (MW) of 562 Da or larger [17]. Therefore, 
most compounds have to cross the brain endothelium either passively or actively to reach the 
brain. Generally passive diffusion takes place for lipophilic substances that fulfill certain criteria:  
1. MW less than 500 Da;  
2. high lipid solubility and have logPoct in the range 2-4; 
3. Polar surface area (PSA) must be lower than 80 A2;  
4. The cumulative number of hydrogen bounds is less than 7 [8, 43-45].  
Additionally, positively charged molecules penetrate the BBB more efficiently than negatively 
charged molecules due to the negatively charged glycocalix and phosphate groups of lipid 
bilayer. As a result, for instance, many lipophilic molecules (ethanol, nicotine, caffeine) as well 
as steroid hormones passively diffuse through the BEC. The majority of all other compounds, 
which do not meet the mentioned above requirements like, for instance, sugars or amino acids, 
are transcellularly transported across the BBB by carrier-mediated transport, active efflux 
transport, or by receptor-mediated, or adsorptive transcytosis. Carrier-mediated and active efflux 
types of transport are mediated by special proteins and happen passively (along the concentration 
3. Introduction
15
  
gradient) or actively, using ATP (primarily) or electrochemical gradient (secondarily) as energy 
source. Around 36 genes of Solute Carriers (SLC) family (see the detailed description in the 
section 3.4.) are significantly expressed in the BBB [46, 47] and their main function is to deliver 
amino acids, sugars, nucleosides and some other small charged essential compounds into or out 
of the CNS. Some of SLC members are expressed on both membranes of endothelial cells, while 
others are found only on luminal (blood-facing) or abluminal (brain-facing) sides of the BBB, 
which results in preferential transport of some substances from blood to the brain or from the 
brain to blood. Active efflux transport is performed by members of ATP-binding cassette (ABC) 
family, which use the chemical energy of ATP to pump diverse lipid-soluble compounds from 
CNS [8]. These proteins transport both potentially dangerous xenobiotics, as well as, drugs. The 
following ABC members are reported to be expressed in the BBB: P-glycoprotein (Pgp, 
Multidrug Resistance Protein, ABC B1), the Multidrug Resistance-Assosiated proteins (MRPs, 
ABC C1, 2, 4, 5 and possibly 3 and 6), Breast Cancer Resistance Protein (BRCP, ABC G2), 
ABC A1, ABC G1 (both cholesterol transporters) and ABC A2 (connected with drug resistance). 
Transcytosis represents a special pathway, which allows macromolecules such as proteins, and 
peptides to get into the CNS and can be receptor or adsorptive mediated. Molecules as 
transferrin, insulin, lipoprotein bind to their receptors expressed on BBB; then the complex 
ligand-receptor is pinched from the cell membrane as a vesicle and internalized. After 
acidification of the endosome, the ligand-receptor complex disassociates and the ligand is 
released on the opposite side of endothelial cells [48]. If there are no cerebral endothelial cell 
receptors for a protein or if proteins contain positively charged sites, they still can be transported 
into the CNS. Positive residues on a protein interact with the negatively charged membrane 
surface and trigger pinocytosis. This adsorptive-mediated transcytosis (AMT) has a lower 
affinity, but higher capacity than a receptor-mediated (RMT). AMT was described for cell 
penetrating peptides [49] and considered to be as a potential way for new drug delivery 
technologies [50]. Finally, under normal conditions lymphocytes and monocytes cross the BBB 
by a process, called diapedesis. In diapedisis a mononuclear cell creates an opening on the 
luminal membrane of BEC, enters the cell, closes the opening and only afterwards exits the 
endothelial cell through the abluminal side [51]. During this process the TJ are not damaged, 
however during inflammatory processes disruption of tight junctions takes place and 
agranulocytes enter the CNS not only by a transcellular path, but as well paracellularly [52, 53].  
Thus, the BBB is not only a physical barrier between blood and CNS due to the presence of 
well-structured TJs, but also a transport barrier by reason of specific diverse transport 
mechanisms. Moreover endothelial cells are characterized by the expression of a wide range of 
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enzymes involved in the disposition of drugs and xenobiotics [54], which allows the BBB 
additionally functioning as a metabolic barrier.  
3.1.3.1 Components of neurovascular unit (NVU) 
Neurovascular unit (NVU) defines structure-functional interactions between vascular cells, 
extracellular basement membrane, pericytes, astrocytes, microglia and neurons [12].  
Extracellular basement membrane 
The extracellular basement membrane (EBM) is a thin layer of 20-200 nm, which surrounds 
endothelial cells and pericytes. It is composed of fibronectin, laminin (411, 421 and 511), 
collagen type IV, heparan sulfate proteoglycans (perlecan, agrin) and the nidogens [55, 56]. 
Endothelial cells, astrocytes and leptomeningial cells produce different laminin chains (α4 and 5, 
α1, α2). Collagen type IV was demonstrated to be essential for structural integrity of small 
vessels [57, 58]. The basement membrane is suggested to function as an anchor for endothelial 
cells [12], as well as, to be involved in TJ maintenance. Minor components of the EBM such as 
collagen types VII, XV and XVIII, fibulin 1 and 2, and thrombospondin 1 and 2 are believed to 
also play a role in the structure and function of the EBM [56].  
Pericytes 
Pericytes are contractile, motile cells that wrap the capillaries in a tunic-like fashion [37], and are 
separated from endothelial cells and astrocytic endfeet by a thin basement membrane [55]. The 
ratio of pericytes to endothelial cells varies, depending on the species. For instance, in rat brain 
this ratio is 1:5, while in mouse brain 1:4 and in human brain is 1:3-4 [37]. One of specific 
features of pericytes is their pluripotentiality, which allows them to differentiate into several cell 
types (fibroblasts, smooth muscle cells, macrophages), depending on the signaling molecules in 
the microenvironment. The following molecules are used as markers for brain pericytes: 
PDGFR-β receptor, desmin, γ-glutamyl transpeptidase, Sca-1, nestin, ATP-sensitive potassium 
channel (kir6.1). Additionally, during the development a positive staining for proteoglycan, 
NG2, is a good surface pericytic marker [56]. Interaction of pericytic PDGFR-β receptor with 
platelet-derived growth factor B (PDGFR-B), expressed by BEC, is required for recruitment and 
proliferation of pericytes [55].  
Being contractile cells, pericytes control the diameter of capillaries and, thus, regulate the blood 
flow [59, 60]. Moreover, pericytes were shown to regulate the development and transport 
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activity of the BBB [61]. Interestingly, if pericytes are differentiated by TGFβ, they decrease 
barrier properties of the BBB, while differentiation by BFGF causes an increase of the BBB 
resistance [55]. 
Astrocytes 
Astrocytes are star-shaped glial cells with multiple processes that have dilated end-feet almost 
completely wrapping the cerebral microvessels as well as forming contacts with the neuronal 
synapses [37]. Astrocytes represent around 20% of total glial cell population in the human brain 
[4]. The intermediate filament glial fibrillary acidic protein (GFAP) and S100 calcium binding 
protein B (s100β) are considered to be typical astrocytic markers. Based on GFAP staining 
cortical astrocytes can be subdivided into four different morphological groups: protoplasmic, 
interlaminar, polarized and fibrillary [62]. It is interesting to note that glial cells establish the 
BBB in invertebrates (such as insects, crustacea, representatives of molluscan class Cephalopoda 
moluscs) as well as in primitive vertebrates (cartilaginous fish (sharks, rays, skates)) [63]. As 
evidenced by the presence of an intermediate barrier formed by pericytes and smooth muscles in 
cephalopods; during evolution a shift of the barrier functions from glial to endothelial cells took 
place [64]. Factors such as the need for an ionic homeostasis around central integrating synapses, 
a physical barrier to protect the brain ISF from plasma fluctuations, and the separation between 
neurotransmitters in the CNS and the peripheral nervous system (PNS) may have driven the 
evolution of the BBB as a multitasking barrier formed by endothelial cells. However, the 
remnants of a glial barrier (ependymo-glial barriers formed by tanycytes, retinal pigment 
epithelium,) are still present in the modern mammalian CNS [7]. In the mammalian brain 
astrocytes perform multiple functions such as the regulation of water and ion transport, matching 
oxygen and glucose transport to neuronal activity (metabolic coupling to neuronal activity), 
control of proliferation of stem cells and the number of synapses [14, 65-71]. Due to close 
association of astrocytes with endothelial cells, it is not surprising that they have significant 
impact on the BBB maintenance [14, 69]. For instance, co-culture of brain endothelial cells with 
astrocytes or with astrocyte-conditioned media leads to the improvement of such barrier features 
as TJ formation and as a result higher TEER values and an increase in expression of 
characteristic BBB enzymatic and transport systems [72-79]. Some factors released by astrocytes 
that induce barrier properties in BEC have been identified. Such astrocytic derived factors as 
glial-derived neurotrophic factor (GDNF), basic fibroblast growth factor (bFGF), angiopoetin-1 
(ANG-1), angiotensinogen, and interleukin-6 were shown to induce certain barrier properties 
[14, 34, 69, 79-83]. 
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Microglia 
Microglia, which are specialized macrophages of haemotopoetic origin in the CNS, are another 
type of glial cells (7% of total glial cells) [4]. Microglial cells are innate immune cells with 
special ramified branches, by which they communicate with surrounding neurons and other glial 
cells [84]. Evidence has been recently obtained about the importance of the resident microglia in 
angiogenesis, vascularization of the CNS and the regulation of the BBB properties during 
embryogenesis and disease [36, 85, 86]. Additionally, microglia become activated by brain 
injury and immunological stimuli to undergo several alternations from a resting state to an 
activated state [87]. Activated microglia produce many pro-inflammatory mediators (cytokines, 
chemokines, reactive oxygen species (ROS) and nitric oxide) that are involved in the clearance 
of pathogen infectious [84]. Microglia activation and consequent neuroinflamation are reported 
to be involved in the progression of neurodegenerative diseases (Alzheimer disease (AD), 
multiple sclerosis (MS)) and impairments of the BBB [88]. 
Neurons 
Neurons are highly metabolic active cells, which closely cooperate with astrocytes, and are not 
more than 10-20 nm distant from capillaries [89]. This close cooperation allows the 
neurovascular and neurometabolic coupling that maintains an adequate energy supply to neurons 
under conditions of increased neuronal activity. Neurovascular coupling, or heperemia, is the 
coupling of vessel diameter and, consequently, blood flow with nutrients, including glucose, to 
regions of high neuronal activity [90-92] It has been shown that active neurons communicate 
with brain endothelial cells via astrocytes and, as a result, vasodilation takes place [93]. 
Neurometabolic coupling occurs between neurons and astrocytes, when increased neuronal 
activity elevates glutamate (Glu) concentration in the brain ISF. The consequent Glu up-take by 
astrocytes leads to an increased glucose metabolism and, as a result, lactate production, which is 
released by glial cells and consumed by neurons for further breakdown [66, 94-96]. 
Interestingly, Leybaert suggested distinguishing another type of coupling between neurons and 
endothelial cells, which can be called the neurobarrier coupling [97]. In this case increased 
neuronal activity causes changes in glucose transport through the BBB according to the 
increased metabolic demands. It has been shown that seizure induction leads to acute increase of 
glucose transport through the BBB in the rat brain [98]. Moreover in the earlier studies increased 
GLUT1 expression following chronic seizures was detected [99]. Since BEC have an 
intracellular pool of Glut1 mRNA, which is ~40% of the total Glut1 mRNA [100], redistribution 
of this mRNA in response to neuronal activation is suggested to be a mechanism for the rapid 
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increase of glucose transport via the BBB [101]. The phospholipase C (PLC) pathway (via level 
of inositol triphosphate (InsP3), Ca2+, diacyl glycerol (DG)) or the protein kinase C (PKC) 
pathway, which are both known to be involved in astrocytes and endothelial cell interactions, 
may be also signaling pathways for neurobarrier coupling [102, 103]. Thus, it can be suggested 
that neurons might regulate expression of other molecules in the BBB.  
3.1.4. Circumventricular organs 
 A group of specialized structures, the circumventricular organs (CVO), is localized along the 
midline of the brain ventricles and, thus, takes a strategically important position [104]. In early 
studies with intravital administration of dyes, such as trypan blue, these organs were shown to be 
stained in contrast to the rest of the brain. The following eight structures are referred to CVO in 
mammals: the subfornical organ (SFO), organum vasculosum of the lamina terminalis (OVLT), 
median eminence (ME), neurohypophysis (posterior pituitary), intermediate lobe of pituitary, 
pineal gland (PI), subcomissural organ (SCO), area postrema (AP) [105]. Some authors classify 
CP as CVO, but it is not a generally accepted point of view [104]. All CVOs are surrounded on 
their ventricular surface by ependymal cells, which have an irregular, flattened or elongated 
shape with only few cilia. The CVOs are highly vascularized with extensive perivascular spaces. 
However, their capillaries in contrast to the BBB are fenestrated, which allows substances to 
exchange with the blood [104]. Nevertheless, the CVOs are isolated from the CNS due to the 
presence of TJ between ependymal cells of the CVOs and tanycytes, which are specialized 
ependymal cells that lack cilia, but have multiple long processes [30, 105]. This barrier 
established by tanycytes is regarded as a remnant of the glial barrier [7, 105]. The CVOs are 
subdivided into ependymal (SCO) and paraependymal organs (all the rest) [104]. Ependymal 
organs are composed of one or more layers of ependymal cells, which can be modified and 
vascularized. Paraependymal organs additionally include subependymal elements and are further 
classified into sensory and secretory organs. The sensory organs (SFO, OVLT, AP) sense and 
deliver information to other brain regions. The secretory organs (neurohypophysis, median 
eminence, PI) secrete hormones and glycoproteins into the blood stream based on messages from 
peripheral organs and the brain environment, and thus, regulate the function of the whole body 
[104, 106-108]. For instance, hypothalamic peptide hormones are released via neurohypophysis 
and median eminence and affect anterior pituitary function and several organ systems (renal, 
reproductive, cardiovascular) [108]. It is important to note that the SCO also exhibits secretory 
activity [104, 108]. 
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Generally, CVOs can be named as “windows of the brain” that allow communication between 
the CNS and blood and the rest of the body [105]. The CVO are involved in a number of 
functions such as maintenance of the body fluid balance, blood pressure, temperature, 
respiration, energy balance, mediation of immune responses, pain modulation, protection against 
ingested toxic substances, biological rhythms, reproduction, parental behavior, lactation, growth, 
sleep, and arousal and attention [105]. These broad functions are possible due to the presence of 
receptors for a number of humoral factors in the CVO: angiotensin II, atrial natriuretic peptide, 
relaxin [104]. Additionally, the direct exchange of substances makes the control over the whole 
body possible. Thus, the absence of the BBB in CVOs allows the CNS to detect changes in 
peripheral circulation. 
3.2. Fluids of the CNS 
Conditionally the brain volume can be subdivided into two large compartments – the 
parenchymal, or cellular, that occupies more than 60% of total brain volume and the fluid one, 
which includes blood of cerebral vessels and extracellular fluid (ECF) [109]. Brain ECF is 
represented by two fluids, which have different origin and are spatially separated – cerebrospinal 
fluid (CSF) and brain interstitial fluid (ISF).  
3.2.1. CSF: formation and control of secretion 
The CSF is a clear colorless fluid that is mainly produced by CPE with ~25% contribution of ISF 
across ependymal cells of ventricles [110-112]. The estimated CSF volume in the adult human is 
around 125-150 mL (or 8-9% of total brain volume), the majority of which is in the cortical and 
cerebellar subarachnoid spaces and the basal cisterns of the brain, while ventricles contain only 
23 mL [11]. Rates of CSF production are rapid and vary for different species, for example, for 
mice this parameter is 0.325 μl/min, for rats it is 2.1 μl/min and for human roughly 350 μl/min 
[113]. Another important parameter of CSF formation is a turnover rate (the volume of CSF 
produced in 24 hours divided by the volume of the CSF space). Human CSF is renewed about 4 
times per day, while for young adult rats this parameter reaches 11 times. The CSF turnover rate 
decreases with age [110]. The process of CSF production includes two main steps: the passive 
filtration of fluid across capillaries of CP stroma and following after this active secretion across 
CPE ([110]; Figure 4). 
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Figure 4. CSF formation (source [110]) 
A. General route of secretion; B. Ion movements; C. Ion transporters and channels involved in CSF secretion 
During the first step the plasma filtrate is formed due to the fenestrated nature of choroidal 
capillaries in contrast to the majority of brain capillaries [114]. Filtration rate is proportional to 
the hydrostatic pressure gradient between the blood and the fluid of CP interstitium. As a result, 
high levels of intracranial pressure (ICP) as well as reduced blood flow to the CP are known to 
reduce plasma filtration. With mean arterial pressure of 100 mm Hg and normal CSF 
hydrodynamic parameters (pressure around 10 mm Hg) a sufficient volume of plasma filtrate is 
formed and reaches basolateral surface of CPE for the next step of CSF production [115]. The 
epithelial cells of CP possess apical TJs (chapter 3.1.1.), which restrict the free movement of 
substances from the newly formed plasma filtrate into the CSF. CPE are not only structurally 
polarized cells, but also functionally polarized. The expression of different transporter sets on 
apical and basolateral membranes is necessary for CSF production. Basically, the net transport of 
Na+, Cl-, K+, HCO3- and water from plasma to CPE and then to CSF leads to CSF production 
[110]. The Na+/H+ and HCO3-/Cl- (SLC4A2, anion exchanger 2, AE2) exchangers as well as 
Na+/ HCO3- cotransporter (SLC4A7, NBCn1, NBC2) and Na+-dependent HCO3-/Cl- exchanger 
(SLC4A10, NBCn2/NBCE) are expressed on basolateral membrane of CPE and bring Na+, Cl- 
and HCO3- into epithelial cells. The driving force for the Na+-coupled transporters is the Na+ ion 
gradient formed due the constant Na+ discharge into the CSF at the apical cell membrane [116-
118]. While the activity of cellular carbonic anhydrase leads to the HCO3- generation, which 
drives Cl- transport into the cell [119, 120]. The apically localized Na/K/ATPase, K+/Cl- 
(SLC12A7, KCC4) and Na+/K+/2Cl-(SLC12A2; NKCC1) cotransporters, Na+/HCO3- exchanger 
(SLC4A5, NBCe2, NBC4) as well as K, HCO3 and Cl channels release ions into the newly 
formed hypertonic CSF. The Na/K/ATPase is the most important Na+ extruder and provides the 
driving force for secretion. Three ATPase subunits are detected in CPE: a1 (ATP1A1), b1 
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(ATP1B1) and b2 (ATP1B2) [121]. Due to the higher concentrations of K+, HCO3- and Cl- 
inside the CPE than in the ventricle space, their release is along their concentration gradients 
[116, 122-126]. Water diffusion through mainly expressed apically aquaporin-1 (AQP1) 
channels occurs according to chemical potential gradient and completes CSF secretion [127].  
The CSF, formed in the lateral, third and fourth ventricles, flows through the subarachnoid space 
around the brain and drains through the superior sagittal sinus and the nasal pathway (Figure 5). 
The direction of CSF flow is mainly determined by the cisterna magna and the cisterna basalis. 
The cisterna magna directs CSF flow back and upward around the cerebellum or forward around 
the brain stem to the cisterna basalis. In turn, from the cisterna basalis CSF moves into two 
different directions. In the first case, it flows forward and then directly drains through the 
anterior part of the sinus. Alternatively, the CSF progresses back between the cerebrum and 
cerebellum, where it joins the fluid at the back of the brain, which moves upwards around the 
cerebellum from the cisterna magna, and then drains in the superior saggital sinus, from where it 
exudes into the venous system [109]. Historically valve-like structures, the arachnoid 
granulations, of the subarachnoid space have been considered to be the main outflow route for 
CSF from the CNS into the venous sinus. The driving forces are the hydrostatic gradient and 
colloid osmotic pressure between CSF and venous blood [128]. However, based on experiments 
with various animal models (rats, pig, sheep, non-human primate) over last years this point of 
view is changing [129-134]. Currently, the olfactory and optic nerves, cribriform plate, nasal 
submucosa and cervical lymphatics are regarded as the main routes for CSF drainage from the 
brain. For instance, around 50% of CSF is drained along the olfactory nerves to the nasal 
submucosa, which is enriched with blood vessels and lymph pathways [132, 135]. Generally, the 
flow rate for CSF is roughly 1500 times less than the blood flow in the brain [109]. 
 
Figure 5. Direction of CSF flow in the brain (source [109]) 
Choroid plexus (CP) produces CSF, which moves around the brain (red arrows) towards cisterna magna and cisterna 
basalis (yellow) and drained through the superior saggitalis sinus and the nasal pathway (blue) 
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The CSF performs a number of important functions in living organisms. First, it plays an 
important protective role, surrounding the brain and, thus, reducing effective brain weight, as 
well as, decreasing possibility of mechanical injury. Since it originates as a plasma filtrate, the 
CSF is also a source of nutrients for the CNS. Finally, a main function of the CSF is the removal 
of waste metabolite products and excess neurotransmitters from the brain [110]. 
3.2.2. ISF: origin and regulation of production 
The brain interstitial fluid (ISF) is a direct microenvironment for cells in the brain. The ISF 
occupies 12-18% of total brain volume; in human brain the ISF volume is around 200-250 mL 
[109]. ISF is a sizeable volume fraction and its volume changes in response to such factors as 
active neuronal activity and glial cells swelling. 
There are three main hypotheses concerning the origin of the brain ISF. According to the first 
theory, the ISF is believed to be a fraction of the CSF flow. In this case part of ventricular CSF 
flows into the subarachnoid space (SAS), from where it moves along ventral perivascular 
channels back to the brain, simultaneously permeating through the parenchyma, and then flows 
out the brain along venular perivascular spaces [136] Thus, in this case ISF is a recycled CSF 
with different substances, including possible toxic wastes, which have been excreted by the 
brain. The second hypothesis states that the water produced during intensive oxidation of the 
brain’s main energy fuel, glucose, is the source of the brain ISF. However, the formed fluid is 
estimated to be only 10% of the required volume and additionally lacks ions. Finally, the third 
hypothesis is that the ISF originates from the BBB, which has a surface area of ~ 25 m2. In this 
case water and ions come from plasma and the polarized distribution of transporters in BEC 
regulates the composition of the formed ISF. As in case of CSF secretion, the net transport of 
such ions as Na+, Cl-, K+, HCO3- is key for ISF formation (see section 3.2.1). The Na+/K+/2Cl-
cotransporter (SLC12A2, NKCC1), localized on luminal (plasma facing) membranes, provides 
the flux of Na+ and Cl- ions into the BEC [137]. Additionally, the two isoforms of Na+/H+ 
exchanger (SLC9A1 (NHE1) and SLC9A2 (NHE2)), possibly involved in intracellular pH 
control, are localized on the same membrane. The driving force for not only Na+, but also for 
other ions and water movement is provided by the activity of the mainly abluminally positioned 
Na/K/ATPase (ATP1 family) [138, 139]. Three alpha-(ATP1A1-3) and two beta-(ATP1B1-2) 
subunit isoforms are found in the rat endothelium, therefore six isoforms of the enzymes can be 
expressed in the BBB [121]. Some other transporters and channels such as chloride-bicarbonate 
exchanger (SLC4A1), potassium channels Kv1 and Kir2 are localized on both endothelial 
membranes [140, 141]. The Cl-/HCO3- exchanger is believed to participate in endothelial cell 
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regulation of pH. In vitro experiments with acid loaded BEC demonstrated that small acid load is 
neutralized by HCO3- influx via Cl-/HCO3- exchanger, while a large acid load is eliminated due 
to Na+/H+ exchanger [142]. Since changes in K+ concentration impacts resting membrane 
potential, maintenance of its homeostasis is required for proper neuronal function. However, 
there are still open questions about K+ flux through the BBB. Potassium transporters and 
channels localized on the BBB membranes are believed to efflux K+ from the brain and, thus, 
lower its concentrations in the ISF [143]. On the other hand, potassium mainly fluxes into CPE 
during CSF secretion (Figure 4), however its levels are around 2.5-3 mM. Therefore, the BBB is 
believed to play if not the main, but at least a partial role in high K+ levels in CSF. However, a 
detailed investigation is still required. The comparative analysis of ISF in animals at different 
levels of organization gives additional evidence for the brain endothelium as a main producer of 
ISF. For example, the cuttlefish Sepia, which lacks CP, ventricles, or CSF, has brain 
microvessels, the BBB at capillary level, and an ISF flow rate similar to those of rat [136]. Thus, 
currently ISF is regarded as a mixed fluid, produced mainly by the BBB with minor contribution 
from active brain cell metabolism and recycled CSF.  
Multiple experiments injecting different sized radiolabeled substances into the brain parenchyma 
have been carried out to test whether the ISF is a static or dynamically flowing fluid. Since 
clearance from the brain of administrated molecules does not depend on size, the main route of 
tracers’ distribution in the brain parenchyma is convective flow, rather than a simple diffusion 
[144]. The estimated rate of the ISF secretion is ~ 0.1-0.3 μl/g*min in the rat brain, which is 
approximately 10 times less than CSF secretion rate, while the surface area of the BBB is ~1000 
greater than CP [144, 145]. Consequently, ISF has lower turnover rate than CSF (10 h vs 2.5h) 
[128]. The main pathways for ISF flow in the brain are the perivascular spaces and the white 
matter tracts [146, 147]. Ventricular-cisternal perfusion of horse-radish peroxidase (HRP) [148, 
149] or administration of radiolabeled inulin [150] and injection studies [151, 152] identified the 
paravascular ISF circulation route (Figure 6). ISF is formed partially from flow of the CSF into 
the brain along arteries penetrating the outer surface of the brain and back out along large-caliber 
draining veins. Interestingly, recent studies with different molecular weight fluorescent 
substances administrated into the lateral ventricle or cisterna magna of transgenic mice not only 
confirmed the described ISF circulation route, but also demonstrated significant difference in 
brain parenchyma penetration for compounds, depending on the molecular size and applied route 
of injection [153]. Paravascular ISF circulation is most probably driven by difference in pulse 
pressures between para-arterial and para-venous pathways [149, 154, 155]. Investigation of the 
mechanisms involved in coupling of para-arterial CSF flux into the brain interstitium and 
3. Introduction
25
  
paravenous ISF clearance might be important for future CNS drug development. For instance, 
studies in AQP4 knock-out mice showed that abolishment of this water channel leads to a 
significant decrease of clearance from the brain parenchyma and the authors suggest that 
astroglial water transport is essential for ISF clearance [153]. Along these lines, the described 
ISF paravascular route is important for the fast exchange between CSF and ISF. 
 
 
Figure 6. Suggested paravascular ISF route (source [156]) 
Para-arterial CSF flux together with paravenous ISF clearance are suggested to serve as lymphatic system in the 
brain and to be called “glymphatic” system [153] 
Another possible exchange mechanism between these two fluids is diffusion, which is a slow 
process that operates over short distances. Diffusion occurs according to concentrations gradient 
and depends on volume fraction, tortuosity and chemical molecular weight [157-159]. 
Ependymal cells lining the ventricles walls do not have proper TJs and as a result exchange 
between CSF and ISF takes place in both directions. Since diffusion of compounds is dependent 
on molecular weight, for example, it has been estimated that 109 hours are required for albumin 
(MW 66.5 kDa) to diffuse one cm [160, 161]. Thus, ISF bulk flow might become more 
important than diffusion in larger brains.  
ISF flow is believed to eliminate concentration gradients in brain tissue. However, the brain is an 
active structurally and functionally heterogeneous organ and the latest measurements of basal 
neurotransmitter concentrations in different nuclei with high spatial resolution demonstrated the 
existence of gradients. Statistically significant difference in dopamine concentrations between 
the ventral tegmental area and the red nucleus of the midbrain region was detected in awake rats. 
Glutamate was distributed in similar pattern, but with rather higher variability [162].  
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3.2.3. CSF and ISF content  
There is a substantial amount of data in the literature about CSF content (Table 1), which is 
consistent for different species. CSF is a fluid, originated from plasma and, consequently, it is 
not surprising that ion concentrations in these two fluids are very comparable. 
 
Table 1. Content of different solutes in plasma and CSF 
Three letter abbreviations for AA are provided. The table was adapted from [163, 164] 
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Levels of such ions as Mg2+ and Cl- are higher in CSF than in plasma, while for K+ the situation 
is opposite. Potassium levels are tightly regulated, which can be explained by its importance for 
neuronal depolarization and astrocytic swelling [165, 166]. For nutrients, such as glucose and 
amino acids (AAs), a gradient between the CSF and plasma is observed. CSF glucose levels 
represent ~2/3 of plasma glucose in healthy subjects. The concentration of most proteinogenic 
AAs (alanine, asparagine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, 
tyrosine, valine) are 10X lower in CSF than in plasma, while for tryptophan, glycine, cysteine 
and proline this difference reaches up to 20-160 times (Table 1). Interestingly, glutamine (Gln) is 
the only AA, for which CSF levels represent 80% of plasma values [1]. Generally, the CSF is 
characterized by lower levels of proteins in comparison to plasma. Nevertheless, albumin, the 
most abundant plasma protein, is also the most common protein in CSF and represents 56-76% 
of total CSF proteins [163]. Among the proteins normally found in the CSF are lipocalin-type 
prostaglandin-D-synthetase (L-PGDS, or previously known as β-trace protein), immunoglobulin 
G (IgG), transthyretin and transferrin. 
Unfortunately, unlike for CSF there is not much known about solutes content of the brain ISF. 
CSF level of K+ correlates well with the measured in the brain ISF of ~ 3.3 mmol/L by 
microelectrode in anesthetized rats. The data about nutrient concentrations in the ISF show a lot 
of variation. For example, reported glucose levels in the ISF are in the range of 0.35-1 mmol/L 
in striatum, when measured by microelectrode, and between 0.3-0.5 mmol/L in the same brain 
region as estimated by in vivo microdialysis in freely moving animals [167-169]. Additionally, 
there is an almost ten fold difference in glucose concentration between cortical and striatal 
regions, when determined by the same method (Table 2). Glucose levels of 1.6 mmol/L are also 
reported in the brain ISF in non-epileptic areas of conscious patients with complex partial 
seizures [170]. It is intriguing to note a gradient in glucose concentration not only between 
hippocampal ISF and plasma (ISF/plasma ratio is 0.13), but also between ISF and CSF (ISF/CSF 
is 0.19) in rats (Table 2). There were also several attempts to determine concentration of 
different amino acids in the brain ISF, particularly, glutamine (Gln) and such neurotransmitters 
as glutamate (Glu) and GABA. Lerma and co-authors collected fractions at different flow rates 
during microdialysis in hippocampal region of the anaesthetized rats, determined concentrations 
of AAs in the collected fractions and then estimated the actual concentrations in the ISF using a 
non-liner model [171]. The reported level of Gln in the ISF was approximately 190 μmol/L and 
the authors observed a concentration gradient between ISF and plasma (ISF/plasma is 0.23), as 
well as, between ISF and CSF (ISF/CSF is 0.37) (Table 2). Additionally, the level of the major 
excitatory neurotransmitter, Glu, in the rat hippocampus was 2.9 μmol/L, while the concentration 
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of the major inhibitory neurotransmitter, GABA, was ~ 0.8 μmol/L. In the later microdialysis 
experiments Gln level was determined as 385 μmol/L in the cortico-striatal ISF [172]. This 
concentration is two times higher than reported by Lerma, but still lower than in CSF. In the 
same study Kanamori also reported no difference in Gln concentration between such brain 
regions as hippocampus, somato-sensory cortex and thalamus in the fractions collected at the 
same flow rate [172]. Recent microdialysis studies testing Glu and GABA concentrations in the 
rat brain ISF report levels of 1.8-5.6 μmol/L and 0.0327 μmol/L, respectively, depending on the 
brain region. Thus, Glu level in the ISF determined by Lerma is in a good agreement with the 
current studies, while GABA level may be overestimated [171]. Therefore, contemporary 
experimental data demonstrate a difference in the solute content between ISF and CSF and, 
moreover, provide evidence of possible gradient between the ISF in different brain regions. 
 
Table 2. Solute concentrations in different fluid compartments in the brain  
Glucose concentrations in plasma of fasted and fed awake rats (A [173]) and normoglemic anaesthetized rats (B 
[174]), CSF (C [175]) and ISF in different brain regions determined by microdialysis (in neocortex of anaesthetized 
rats (D [176]); striatum of awake rats (E [168] and F [169]); hippocampus of freely moving rats (G [177]); 
hypothalamus of freely moving fasted and fed rats (H [173])) or by a microelectrode (in cingulate cortex (I [174]) 
and striatum (J [167]) 
Glutamine levels in plasma (rats K [178] and L [171]), CSF (rats K [178] and L [171]) and brain ISF in different 
regions evaluated by microdialysis (cortico-striatal region of awake rats (M [172]) and hippocampus of 
anaesthetized rats (L [171])). 
Glutamate concentrations in plasma (rats K [178] and L [171]), CSF (rats K [178] and L [171]) and ISF determined 
by microdialysis (hippocampus of anaesthetized rats (L [171]); striatum of freely moving rats (N [179])) or by push-
pull perfusion sampling (O [162]). 
GABA concentrations determined in ISF by microdialysis in striatum (non-hibernating squirrels (P [180]), 
hippocampus (anaesthetized rats (L [171]) and basal forebrain (nucleus accumbens (Q [181]) 
 
3.3. Amino acids 
Amino acids (AA) are a class of organic compounds with amine (-NH2) and carboxylic acid (-
COOH) functional groups and a side chain. Currently more than 500 AA are known to occur in 
nature (Figure 7) [182]. Depending on which carbon atom the two groups are attached, AAs are 
classified as α-, β-, γ- or δ-amino acids. The α-amino acids have particular importance in the 
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living organisms, since they are building blocks for proteins. Further, α-amino acids are 
stereoisomeric chemicals, which occur as D- or L-isomer, but with the exception of a few 
bacterial proteins, only L-amino acids are found in proteins [183]. For instance, 21% of total 
body weight in humans is composed of proteins and, thus, AAs [184]. The recommended daily 
consumption of essential and non-essential AAs is 0.18 g/kg and 0.48 g/kg, respectively [185]. 
There are 23 proteinogenic AAs, out of which 20 are encoded by genetic code. 
 
Figure 7. General structure of α-amino acid (un-ionized form). 
The source of figure is http://www.hcc.mnscu.edu/chem/V.27/pageid17100.html)  
3.3.1. Classification 
There are several different AA classification systems, for example, according to the polarity of 
the side chain proteinogenic AA are subdivided into three groups: nonpolar, polar, or charged 
(positively or negatively) (Figure 8). Classification by the chemical structure of a side chain, or 
R-group, results in the following AA groups: aliphatic (Ala, Gly, Ile, Leu, Pro, Val), aromatic 
(Phe, Trp, Tyr), acidic, which posses extra -COOH group (Asp, Glu), basic with two –NH2 
groups (Arg, His, Lys), hydroxylic (Ser, Thr) and sulfur-containing (Cys, Met, Tau). Another 
important type of AA classification is based on their necessity in nitrogen balance and growth. 
Correspondingly, AAs are divided into two groups – essential (indispensible) or non-essential 
(dispensable).  Essential AA either cannot be synthesized de novo in the organism or are 
produced, but in insufficient amounts compared to the body needs, and as a result must be 
supplied with the food. For humans His, Ile, Leu, Lys, Met, Phe, Thr, Trp and Val are essential 
amino acids. Additionally, Arg, Cys, Tyr are essential in children [186]. Non-essential amino 
acids are synthesized de novo in the organism in adequate amounts. It is important to note that 
under specific conditions some non-essential AA can become conditionally essential. For 
instance, Gln is regarded to be a conditionally essential AA, since under such conditions as 
stress, major trauma, sepsis, this AA must be additionally supplied [187]. 
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Figure 8. Classification of 20 α-proteinogenic AAs based on the charge of the side chain (R). Trivial names as well 
as one and three letter abbreviations for AAs are provided (the figure is taken from 
http://www.uic.edu/classes/bios/bios100/lectures/aminoacids01.jpg)  
 
3.3.2. Roles of amino acids in the whole organism and the CNS 
While serving as building blocks for proteins is one of the most important functions of AA, it is 
not their exclusive role in organisms. Additionally, AAs perform energetic, metabolic, structural, 
protective, and regulatory functions. For instance, Gln is an energetic fuel for actively 
proliferating cells, including cancer cells, while Ala is involved in gluconeogenesis and Glu in 
the Krebs cycle [187-190]. The complete catabolism of an AA produces acetyl-CoA, which is 
oxidized to CO2 and H2O, however, during this process multiple intermediate metabolites are 
formed. Thus, some AAs are precursors for the synthesis of other AAs. For example, Thr is 
involved in Gly synthesis, and Glu in Gln, Cit and Arg synthesis, Ile and Val in Ala and Gln 
production, and Gln is a source for Arg, Asn, Cit, Orn, and Pro [187, 191, 192]. Additionally, 
AAs are an important source of nitrogen, for example, Gln is considered to be a nitrogen 
reservoir, while Ala and Asp are transaminated to pyruvate and oxaloacetate, respectively [189, 
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192, 193]. On the other hand, ammonia detoxification occurs via the urea cycle, in which such 
AA as Cit, Asp, Arg and Orn are synthesized [194]. Furthermore, AAs are precursors for other 
compounds such as nucleotide bases, e.g., Gln, Gly and Asp participate in biosynthesis of 
purines and pyrimidines. While Gly along with succinyl-CoA forms the heme ring in 
hemoglobin. Additionally, AAs are also important structural components in proteins, for 
example, His maintains the structure of hemoglobin [183, 192]. Some AAs, like Arg, are 
themselves antioxidants [195], while others form dipeptides (creatine formed by Arg and Gly) or 
tripeptides (glutathione consists of Cys, Glu and Gly) with antioxidant properties [196, 197]. 
Furthermore, AA or their metabolites can perform regulatory functions in cells. For instance, 
Arg and Gln were shown to regulate gene expression in vitro, and potentially in vivo [193, 198-
203], moreover these AAs along with Leu (via mTORC1 pathway) regulate protein turnover in 
cells [204-207]. Other AAs directly control enzyme activity, for example, Ala inhibits pyruvate 
kinase regulating gluconeogenesis and glucolysis [208].  
In addition, AAs can affect the whole body’s function, e.g. AA or AA metabolites function as 
neurotransmitters.  For instance, nitric oxide (NO) is a product of Arg metabolism with well-
known neurotransmitter functions [209-211] and Gly, GABA, Asp, and Glu are classical CNS 
neurotransmitters [212]. Gly is an inhibitory neurotransmitter, which binds glycine inhibitory 
receptors in the spinal cord and brainstem [213, 214]. However, it is also a co-agonist of N-
methyl-D-aspartate (NMDA) sensitive glutamate receptors in the cortex, hippocampus, 
cerebellum and brainstem [215]. Gly is released from the presynaptic membrane to the synaptic 
cleft and then either transferred into presynaptic neurons or transported into astrocytes by Glyt1 
(SLC6A9) and Glyt2 (SLC6A5) [216]. There is a special glycine cleavage system (GCS) in 
astrocytes, which effectively degrades glycine and, thus, provides the gradient for glycine 
movement from ISF into the cells [217-219]. Unfortunately, the data about Gly alterations as a 
result of various pathological conditions are inconsistent. For example, a Japanese group showed 
a correlation between extracellular Gly concentrations and ischemic injury in mice with altered 
GCS [220]. However, data concerning Gly concentrations in the CSF of patients with Parkinson 
disease (PD) are unclear. In most cases Gly levels were reported to be unaltered, however two 
groups reported elevated Gly concentrations in CSF and one group observed decreased levels 
[221]. 
GABA is a major inhibitory neurotransmitter in the CNS. This AA is reported to serve as the 
primary inhibitory neurotransmitter for 20% to 44% of cortical neurons [222, 223]. GABA is 
formed from glutamate in the reaction catalyzed by glutamic acid decarboxylase (GAD) and, 
thus, is involved in glutamate/GABA-glutamine cycle (Figure 9). GABA is metabolized to 
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succinate by actions of GABA-transaminase (GABA-T) and succinic semialdehyde 
dehydrogenase (SSADH) [224]. It binds to its ionotropic receptors, GABA(A) and GABA(C), 
which are ligand-gated chloride channels, and a metabotropic receptor, GABA(B) [225]. The 
reported GABA levels in the brain ISF vary from 30-100 to 800 nmol/l, depending on the region 
and detection method used [162, 171, 181]. GABA-transporters are localized both on neurons 
and glial cells. They function to terminate GABA-ergic transmission, maintain low ambient 
extracellular concentrations of GABA and recycle GABA for re-use by neurons. Plasma 
membrane localized GABA transporters belong to the SLC6 family and in mammals they are: 
SLC6A1 (GAT1 in mouse, rat and human), SLC6A11 (GAT4 in mouse; GAT3 in rat and 
human), SLC6A12 (GAT2 in mouse; BGT-1 in rat and human preferable transports betaine) and 
SLC6A13 (GAT3 in mouse; GAT2 in rat) [226]. Reduced GABA levels in CSF and brain 
hippocampal ISF were reported in patients with epileptic syndromes [227, 228]. In some studies 
GABA levels in CSF were found to be decreased in patients with PD, while others reported these 
levels to be normal [221].  
Aspartate and glutamate are both excitatory neurotransmitters. The ability of Asp to result in 
depolarization was shown on feline spinal motoneurons and observed to be similar to glutamate 
[229]. Aspartate was found to co-localize with glutamate in synaptic vesicles and to be released 
by exocytosis. It is not easy to differentiate glutamate and aspartate neurotransmission since both 
neurotransmitters affect many of the same receptors and share many presynaptic mechanisms. 
Furthermore, Asp is believed to be similarly distributed as Glu, but in lower concentrations. 
Distribution of possible asparaginic synapses is thought to be limited in the brain (to certain 
cortical, hippocampal and cerebellar neurons) and, thus, in excitatory neurotransmission Asp is 
considered to play minor role in comparison with Glu [230, 231]. In cells aspartate is used for 
conversion of 2-oxoglutarate to glutamate by aspartate aminotransferase [232]. Aspartate levels 
in brain ISF were estimated to be approximately 2 μmol/L [171].  
Glutamate, the major CNS excitatory neurotransmitter, is involved in learning and memory, and 
synapse induction and elimination during the development. The following families of glutamate 
receptors are expressed in the CNS: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA), kainate and metabotropic [233]. Since Glu 
demonstrates an “excitotoxicity” effect on neurons [234], after release into the synaptic cleft the 
Glu concentration must be rapidly brought to basal levels by re-uptake either by pre-, or post-
synaptic cells or other non-neuronal cells. Several Glu transporters are expressed in mammalian 
CNS: EAAT2 (GLT-1; SLC1A2), EAAT1 (GLAST; SLC1A3), EAAT3 (EAAC1; SLC1A1), 
EAAT4, EAAT5 [235-238]. Members of SLC1 family co-transport 1H+, 3Na+ and 1K+ with one 
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molecule of substrate [239-242], while representative of SLC7 family acts in electroneutral 
manner, exchanging 1 Glu for 1 Cys [243, 244]. It is interesting to note that EAAT4 and EAAT5 
have the largest chloride conductance [245, 246] and due to this may function mainly as 
inhibitory glutamate receptors [247, 248]. The mentioned transporters are detected in neurons 
(EAAT3; EAAT4) [249-254], astrocytes (EAAT1, EAAT2) [253, 255-260] or in several cell 
types. For instance, EAAT2 is found not only in astrocytes, but also in retinal neurons [261] as 
well as on growing axons [262] and axonal terminals in CA1 region of hippocampus [263-266], 
EAAT3 is highly expressed not only in neurons, but also in endothelial cells [2] and EAAT4 is 
additionally expressed in cerebellar Purkinje [236]. Simultaneously, EAAT5 is preferentially 
expressed in retina [235, 267]. 
Consideration of the glutamate/GABA-glutamine cycle (Figure 9) is essential for understanding 
neurotransmitter homeostasis in the brain ISF. Neurons lack pyruvate-carboxylase and cannot 
synthesize Glu and GABA de novo from glucose [268-272], as a result, an alternative 
mechanism exists in the CNS to restore pools of these two important neurotransmitters [273].  
 
Figure 9. Glutamate/GABA-glutamine cycle (source [274]) 
In glutamatergic synapses released Glu is taken up by glutamate transporters expressed on 
astrocytes and metabolized by glutamine synthetase (GS) to Gln [273]. Newly produced Gln is 
released from astrocytes via system N transporters of SLC38 family – SLC38A3 and SLC38A5  
– and then taken up by neurons [275-280]. Since LAT2 (SLC7A8) and ASCT2 (SLC1A5) were 
identified in cultured astrocytes, these transporters might also mediate Gln flux from astrocytes 
[281]. System A transporters – SLC38A1 and SLC38A2 – uptake Gln into neurons, where it is 
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transformed to Glu by phosphate-activated glutaminase (PAG) and, thus, the cycle starts again 
[277, 278, 282-284]. In case of GABAergic synapses the sequence of events is similar, released 
GABA is taken up by astrocytes via membrane-expressed transporters, as described above. In 
astrocytes consequent action of GABA-T and SSADH enzymes leads to succinate synthesis 
from GABA. Citrate is formed from succinate via the tricarboxylic acid cycle (TCA), next 
citrate is transformed to α-ketoglutarate, from which Glu is synthesized. Astrocytic GS produces 
Gln from Glu, which is released into the extracellular space via system N transporters. Then Gln 
is taken up by neurons, where it is metabolized by PAG to Glu, which glutamate decarboxylase 
(GAD) converts to GABA [273].  
Glu levels in the brain ISF in animals are reported as ~ 3 μmol/L (see table 2) and they are 
reported to be affected during some pathologies: elevated Glu levels were shown in animal 
models with Huntington disease [285] and epilepsy [286-289], while decreased glutamatergic 
neurotransmission was observed in patients suffering from Alzheimer disease [290] or animals 
with cerebral ischemia [291, 292]. It is important to note that disturbances in Glu levels do not 
occur alone and usually are a result of an improperly functioning glutamate-glutamine cycle. 
Moreover, three groups described decreased levels of Glu in CSF from PD patients [221], while 
most investigators found levels to be normal [221].  
Taurine (2-aminoethanesulphonic acid (Tau)) is a non-standard AA heterogeneously distributed 
in mammalian brain [293-295]. Tau is released from cells under hypoosmotic stimuli and 
regulates cell volume [296-299]. On the other hand, release of Tau was reported in the feline 
cerebral cortex as a response to stimulation of the reticular formation [300]. Currently, Tau is 
regarded as neuromodulator and neurotransmitter in the brain [301]. Application of Tau causes 
increase of Cl- conductance and evokes hyperpolarization in neurons [302, 303]. Tau is released 
in response to NMDA and high concentrations of K+ [304-309] and impacts the release of 
neurotransmitter AAs and intracellular Ca2+ homeostasis [301, 310]. Tau uptake is carried out by 
the transporter TauT (SLC6A6), which is expressed in neurons and astrocytes (at least under 
culture conditions), as well as, in the BBB [2, 311, 312]. Tau is reported to be protective against 
the neurotoxicity caused by Glu [313] and is suggested to be an inhibitory neurotransmitter like 
Gly. Nevertheless, the target of Tau action and the origin of its release must still be identified. 
As determined in rat striatum by microdialysis, Tau levels in brain ISF are ~25 μmol/L [314]. 
However, this level is higher than any other neurotransmitters. Two groups reported decreased 
Tau concentrations in CSF of patients suffering from PD, while three other groups made the 
opposite observation [221]. Interestingly, decreased basal Tau in brain ISF was suggested to be a 
good predictor of an irreversible lesion after ischemia [291]. 
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AAs are essential in the CNS not only as neurotransmitters, but also as precursors for 
neurotransmitters. Trp, Phe and Tyr are precursors for the synthesis of the monoamine 
neurotransmitter, serotonin, and the catecholamines: dopamine (DA), norepinephrine (NE), and 
epinephrine (Figure 10) [315, 316]. Neurotransmitter synthesis and release rates are directly 
influenced by brain concentrations of the respective AA precursors (Trp, Phe, Tyr), which in 
turn depend on plasma AA concentrations [317, 318]  
 
  
Figure 10. Biosynthetic pathways of catecholamines and serotonin from aromatic amino acids in the brain (source of 
the pathways is http://www.pharmacorama.com)  
Glutamine is the most abundant AA not only in plasma, but also in CSF and brain ISF (Table 2). 
In addition to roles in gene expression regulation, and energetic and metabolic pathways 
(gluconeogenesis, urea cycle, lipogenesis), protein synthesis, and cell proliferation; in the CNS 
Gln is a precursor for Glu and GABA neurotransmitters [192, 193]. Reported Gln levels in the 
brain ISF vary from 190 to 390 μmol/L (Table 2). Since this AA is involved in synthesis of Glu 
and GABA via glutamate/GABA-glutamine cycle, it is not surprising that increased Gln levels 
are found in such cases as Huntington disease, ischemia and epilepsy [285, 286, 291, 319]. In 
most PD patients Gln levels in CSF are normal, while only one group reported increased levels 
in PD [221]. Levine observed a trend for increased Gln in the CSF of depressed patients in 
contrast to healthy subjects [320]. Brain Gln levels are also affected during a group of 
neurological disorders, called hyperammonemic encephalopathies. Viral or toxic liver damage 
(fulminant hepatic failure (FHF)) is accompanied by secondary complication, called 
hyperammonemia, or hepatic encephalopathy (HE), which can develop into brain edema and 
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mortality in patients with acute HE [321-323]. During HE, NH3 and Gln are the key elevated 
metabolites. In patients with HE and experimental animals cerebral Gln levels increase 3-4 fold 
compared to normal values [322, 324-330]. Elevated Gln levels in liver and extrahepatic tissues 
are called hyperammonemia [322]. Extreme ammonia challenge of experimental FHF animal 
models leads to a maximal increase in brain ISF Gln to ~ 2.5 mmol/L, which is in a good 
agreement with CSF Gln levels reported for patients with FHF [331, 332]. The development of 
brain edema is considered to be caused by Gln accumulation in glial cells due to osmotic 
properties of Gln and cerebral hyperemia [322, 333, 334]. Disturbances in Gln concentrations in 
the brain during HE might be an additional reason for excessive extrasynaptic accumulation of 
Glu and increased synaptic release of GABA, since these three AA are involved in 
glutamate/GABA-glutamine cycle [321]. Moreover, elevated Gln brain concentrations favor the 
influx of aromatic AA (Trp, Tyr) into the brain via transporter proteins expressed in the BBB 
and, consequently, result in changes of serotonin and dopamine levels [321, 326]. 
3.4. Amino acid transporters 
AAs are vital chemicals involved in many cellular functions; however, to perform these diverse 
functions, AAs must get inside cells. Since AAs are polar molecules, they cannot directly cross 
the cell membrane lipid bilayer and, thus, are transported via special transporters. Amino acid 
transporters (AAT) belong to a superfamily of Solute Carrier (SLC) proteins, which control 
exchange through membranes of different substances such as nutrients, hormones, 
neurotransmitters, metabolites, inorganic cations and anions, organic anions, bile salts, essential 
metals, vitamins, biogenic amines, nucleosides, fatty acids, lipids, drugs, and toxins [335]. 
Currently this superfamily includes ~400 genes, assigned to 52 different families based on 
protein structure, comprising the largest group of ATP-independent transporters. They are 
further categorized by substrate specificity, subcellular localization and mechanism of transport 
(http://SLC.bioparadigms.org/). All SLC family members have in common a structural motif of 
one or more transmembrane (TM) domains. SLC transporters are localized in various cell 
compartments: mitochondria, vesicles, peroxisomes, lysosomes and cellular membranes [335]. 
Products of more than 50 SLC family genes are AATs. They are distributed in nine families 
(there is an additional SLC3 family with two members, which are the accessory proteins for 
heterodimeric AATs). AATs use passive or active transport (Figure 11), e.g. facilitated diffusion 
is a passive transport in which AAs are moved along their concentration gradient. Examples of 
SLC family members, which use this mechanism, are the AATs transporting aromatic AAs, e.g. 
SLC16A10 (TAT1), or large neutral AA (LNAA), e.g. SLC43A1 (LAT3) and SLC43A2 
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(LAT4). An active transporter uses the concentration gradient of another compound or ion as 
driving force for translocation. The AA substrate transport occurs either in the same (symport) or 
opposite (antiport) direction as the molecule providing the driving force. Heterodimeric AATs 
such as SLC7A5 (LAT1) and SLC7A8 (LAT2) are obligatory exchangers that catalyze the 
sequential influx and efflux of AA substrates. Many transporters, e.g. SLC38A1 (SNAT1), 
SLC38A2 (SNAT2) and SLC38A4 (SNAT4) couple Na+ transport to provide a driving force for 
the symport of AA substrates.  In contrast, other classes of AATs symport one ion type and 
antiport another type of ion. An example is the neurotransmitters (Glu and Asp) transporters, 
SLC1A1 (EAAT3), SLC1A2 (EAAT2), SLC1A3 (EAAT1), SLC1A6 (EAAT4) and SLC1A7 
(EAAT5), which symport 1 AA, 3 Na+ and 1 H+ and antiport K+. There are also some 
heteromeric AATs that in absence of Na+ act as exchangers and in presence of Na+ may function 
as symporters. For instance, SLC7A6 (y+LAT1) and SLC7A7 (y+LAT2) can exchange cationic 
AA (Arg, Lys) for neutral AAs, while in the presence of Na+ they might symport this ion 
together with neutral AA (Gln, Leu) [336]. 
 
Figure 11. Types of transport carried out by AAT.  
Uniport is a passive transport that occurs along the concentration gradient. Co-transport is a type of an active 
transport, when as the source of energy for transport the concentration gradient of other chemical is used. If the 
transported molecule and co-transportes molecule move in the same direction, the transporter is called symporter, if 
in opposite direction, then it is anti-porter (exchanger). The figure is taken from [183] 
The first studies of AA transport date back to 1960, when different AA transport systems were 
described in Erhlich cells [337-339]. It became clear that these transport systems transported 
groups of AAs rather than individual AAs. The following systems were identified: system L, 
which prefers Leu and other large hydrophobic neutral AA, system A prefers Ala and other polar 
small AA, and system ASC, which transports mainly Ala, Ser and Cys. The studies of AA 
transport over the next decades identified similar systems in different cell types and 
characterized them in terms of substrate selectivity, thermodynamic properties, inhibitors, etc. 
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[337, 340, 341]. A nomenclature was introduced to simplify the naming of AA transport 
systems, in which X stands for anionic, Y for cationic and Z for neutral (zwitterioninc) AAs 
[342]. This nomenclature was suggested to be useful for AAT systems that can transport both 
neutral and anionic AA. Lowercase acronyms indicate Na+-independent transporters and 
uppercase acronyms are used for Na+-dependent transporters. Moreover, superscript 0 indicates 
transport of neutral AA and is used alone or in combination with + or -, depending on the net 
charge of AA transported. A major step in the study of AATs occurred when the first GABA 
[343] and cationic AATs were cloned [344, 345]. Cloning and the consequent expression of 
mammalian transporter genes in simple expression systems, such as Xenopus laevis oocytes, 
began a new era in the field of AAT studies. This work resulted in the assignment of SLC genes 
to the already identified AAT systems and improved characterization of transport activities 
(substrate preferences, pH dependence, etc.). Currently most SLC genes coding AATs localized 
in cellular membranes have been assigned by substrate preferences, sensitivity to inhibitors, and 
transport mechanism to 18 AAT systems: A, ASC, asc, B0, B0,+ , b0,+, β, Gly, IMINO, L, N, 
PAT, PROT, T, XAG-, XC-, y+ and y+L [336, 346]. Nevertheless, there are AATs that are not 
assigned to any AAT system. One example is a SLC7A13 (AGT1, XAT2) transporter, 
associated with an unidentified heavy chain, that is expressed in kidney and preferentially 
transports Glu and Asp in Na+-independent manner [347]. AGT1 is suggested to act as an 
exchanger or uniporter. Moreover, AATs are also expressed in mitochondria (members of SLC 
25 family: SLC25A12, 13, 15, 18, 22 and 38) and vesicles (SLC32A1) 
(http://SLC.bioparadigms.org/). 
3.4.1. Amino acid transporters involved in glutamine transport in the brain 
There are seven AAT systems involved in Gln transport in mammalian cells: system A (SNAT1, 
SNAT2, SNAT4), system ASC (ASCT2), system B0 (B0AT1, B0AT2), system B0,+ (ATB0,+), 
system L (LAT1, LAT2), system N (SNAT3, SNAT5) and system y+L (y+LAT1, y+LAT2) [278, 
348, 349]. Since Gln plays an important role in the CNS as a precursor for two main 
neurotransmitters, Glu and GABA, Gln transporters are widely expressed in the brain. However, 
to understand Gln homeostasis it is necessary to know which AATs are expressed in which cell 
types. The data about Gln AATs in the brain are presented in Table 3. 
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Table 3. Glutamine amino acid transporters expressed in the brain 
Km parameter for Gln transport for different AAT is from: 1 – [350], 2 – [283], 3 – [351], 4 – [352], 5 – [353], 6 –
[354], 7 –[355], 8 – [356], 9 – [357], 10 – [358], 11 – [359], 12 – [360], 13 – [361]; in some case Km was not 
determined (nd) or not found (nf).  
AAT is detected (+) or not detected (–) in different brain cells by PCR, in situ hybridization, immunofluorescence or 
by several methods simultaneously: 1 – [350], 5 – [353], 13 – [361], 14 – [362], 15 – [363], 16 –[364], 17 –[365], 
18 – [366], 19 – [367], 20 – [368], 21 – [276], 22 – [279], 23 –[2], 24 – [369], 25 – [370], 26 – [46], 27 – [371], 28 – 
[281].  
Since BBB endothelial cells and BCSFB epithelial cells are polarized cells, AAT can be expressed on abluminal 
(AB) and/or luminal (L) membranes of the BBB and on apical (A) and/or basal (B) sides of the BCSF barrier. In the 
table data about localization on membranes of the BBB or BCSF barriers are presented; data were obtained from 
transport studies in situ perfusion (27 – [371]), isolated membrane vesicles (31 – [372], 32 – [373]) or by antibody-
dependent methods (29 – [374], 30 – [3]).  
? – the information is not available 
Thus, six AAT systems can be potentially involved in the regulation of Gln concentrations in the 
brain.  
System A includes three well-described members, SLC38A1 (SNAT1), SLC38A2 (SNAT2) and 
SLC38A4 (SNAT4), which are sodium dependent electrogenic transporters [375]. This system 
was originally described by Oxender in 1963 and the name system A was given due to a 
substrate preference for Ala and other small aliphatic AA, including Gln [339]. A 
nonmetabolizable AA analog, α-(methylamino)-isobutyric acid (MeAIB), is a substrate for 
system A and efficiently competes with other natural substrates [339, 376, 377]. System A is pH 
sensitive and is regulated by a number of factors including hormones, starvation, and hypertonic 
conditions [368, 378]. SNAT1 was the first member of system A cloned based on the sequence 
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homology with the vesicular inhibitory AAT [283]. This AAT is highly enriched in neurons and 
believed to play an important role in the glutamate/GABA-glutamine cycle [277, 278, 283]. 
Moreover, SNAT1 was found in luminal membranes of ependymal cells and large diameter 
vessels in the brain, but not in the BBB [2, 3, 350]. SNAT2 and SNAT4 were identified a bit 
later [351, 379]. SNAT2 is found in many different organs, including the brain, where it was 
identified in neurons and the BBB [2, 351, 362, 375]. Expression of SNAT2 in astrocytes was 
confirmed by immunofluorescence as well as PCR [362, 368]. However based on 
immunofluorescence studies in the brain tissue SNAT2 appears less expressed in astrocytes than 
in neurons [368]. In the BBB SNAT2 is believed to efflux AAs from the brain to blood [139, 
372, 373, 380]. So far, SNAT4 is found to be expressed in liver, skeletal muscle, pancreas and 
kidney, but not in the brain [375]. 
B0AT2 (SLC6A15) also known as SBAT1, NTT73 or V 7-3 was identified the first time in 1992 
[381]. B0AT2 is a Na+-dependent AA transporter with wide substrate specificity (Met, Pro, Val, 
Ile, Leu) expressed in neurons and astrocytes [354, 382]. This transporter is a low affinity Gln 
transporter and is thought to be more important for branched chain AA than Gln transport in vivo 
[364]. 
System N is another transport system highly expressed in the brain and participating in Gln 
transport. This system was originally characterized as a pH and Na+-dependent system, 
preferring Gln, Asn, and His [352, 383, 384]. The stoichiometry of system N transport is 
cotransport of 1 Na+ and AA and simultaneous antiport of H+, as a result the transport is 
electroneutral and pH dependent [280, 385]. Thus, both pH and substrate concentration can 
determine the transport direction. On the one hand, it has been observed that cells transfected 
with SNAT3 needed ~400 μmol/L Gln in the medium to maintain intracellular pH ~ 7.4. In this 
case efflux of AA occurred together with H+ movement in opposite direction [386]. This 
mechanism might have particular importance in vivo, since, in astrocytes during synaptic 
transmission intracellular pH increases due to the action of Na+/HCO3- cotransporter, as result, 
system N transporter mediates efflux of Gln into the brain ISF to bring H+ into the cell and 
normalize pH [387, 388]. On the other hand, depending on the substrate concentration in the 
uptake solution SNAT5 expressed in oocytes either influx or efflux Gln [352]. Thus, system N is 
believed to provide net movement of amino acids across the plasma membrane into and out of 
the cells. In contrast to system A, members of system N do not accept MeAIB as a substrate and 
the transport is Li+ tolerant [383, 384, 389]. Currently, the system includes two members SNAT3 
and SNAT5. However, the recently described transporter SNAT7 despite co-transporting 1AA : 
1 Na+ was suggested to be a new member of the system N due to its substrate specificity. 
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SNAT3, which was cloned in 1999 from a rat brain cDNA library, was the first identified 
member [386]. SNAT3 is expressed in liver, kidney, brain, retina, pancreas and adipose tissue 
[375, 390] and was found in astrocytes as well as in the BBB and BCSFB [2, 46, 276, 281, 391]. 
SNAT5 was cloned in 2001 and was identified in stomach, brain, retina, liver, lung, small 
intestine, spleen, colon, kidney, and pancreas [375, 390, 392]. In the brain, SNAT5 is found in 
astrocytes, BBB and BCSFB [2, 279, 370, 391]. SNAT7 was recently identified in neurons 
[366]. Originally, system N was believed to be expressed exclusively on abluminal BBB 
membranes [372, 373], however, functional experiments by Ennis together with recent 
localization studies by Ruderisch and co-workers showed SNAT3 localizes on both luminal and 
abluminal BBB membranes [3, 393]. Such localization of SNAT3 in the BBB might have a 
strategically important role for regulation of Gln flux in the brain.  
The ASC (Ala, Ser, Cys) system was identified in the 1960s and described as an exchanger 
capable of mediating net influx or efflux [339, 394]. ASC system transporters are electroneutral 
Na+-dependent exchangers, since an obligatory AA exchange occurs together with Na+/Na+ 
exchange [353, 395].  However, recently Zander and co-authors based on experiments and 
computational modeling suggested that two Na+ must be co-transported with AA and, thus, 
electrogenic character of the transport [396]. ASCT2 transports Gln and its mRNA was 
identified in astroglial primary cultures during attempts to clone a new member of EAAT/ASCT 
family. ASCT2 is expressed in lung, skeletal muscle, large intestine, kidney, testis, adipose 
tissue [395]. High levels of ASCT2 mRNA are detected in primary cultures of astrocytes, while 
levels are lower in embryonic and adult brain [281, 353]. Recent immunostaining studies did not 
detect ASCT2 signal in astrocytes, nor in neurons [363]. This AAT was shown to be essential for 
Gln efflux from cultured astrocytes in vitro, however in vivo its impact is not clear. ASCT2 was 
also detected in freshly isolated BEC and is expected to be localized on abluminal membranes 
[2, 372, 373]. 
System L and y+L are heteromeric AATs, which perform their functions only in association with 
heavy chain, 4F2hc (CD98) [397]. Members of system L mediate Gln exchange, rather than net 
uptake in a Na+-independent manner. L system was described in 1960s as transporting large 
neutral hydrophobic AA as well as 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) 
[339, 398] . The light chain, which interacts with 4F2hc, in order to form functioning system L 
was independently identified by two groups and named LAT1 [356, 399]. Then another member 
of the system was identified and named as LAT2 [357-359, 400]. LAT2 demonstrates broader 
substrate selectivity as well as higher apparent affinity for such AAs as phenylalanine and 
glutamine when compared with LAT1 [358]. LAT1 is widely expressed in such organs as 
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spleen, brain, thymus, testis, skin, liver, placenta, skeletal muscle, stomach [397, 401]. However, 
it is important to note that the BBB has the highest expression of LAT1, which is localized on 
both membranes [2, 3, 369, 372, 374]. LAT1 was detected in primary cultures of neurons and 
astrocytes, although in vivo the highest LAT1 expression levels occur at birth [365]. LAT2 is 
found in kidney, small intestine, testis, prostate, ovary, brain, skeletal muscle, and placenta 
[401]. LAT2 has the same expression pattern as LAT1 in neurons and astrocytes with decreased 
expression in adulthood [365]. This AAT is highly expressed in cultured astrocytes [402]. In the 
BBB LAT2 is detected at lower levels than LAT1 [2]. LAT2 is suggested to localize on both 
BBB membranes [372, 373].  
The y+L system was identified as transporting positively charged and neutral amino acids in 
erythrocytes [403]. The transport of dibasic AA occurs in Na+-independent manner, while in the 
presence of Na+ this system transports neutral AA, including Gln [404]. This system currently 
includes two members y+LAT1 and y+LAT2 [405, 406]. y+LAT1 is expressed mainly in kidney 
and small intestine, however it is still detected in liver, spleen, leucocytes, pancreas, epididymis, 
testis, placenta, ovary, lung, thyroid [397, 401]. Generally, y+LAT1 is poorly expressed in the 
brain, its RNA was found in neuronal cell line and the BBB [2, 367]. y+LAT2 is detected in 
small intestine, kidney, lung, thymus and heart, while in the brain, testis and parotids its mRNA 
is more abundant [397]. y+LAT2 is highly expressed in cultured neurons and astrocytes, as well 
as in embryonic brains, but in the adult brain level is decreased [361]. This AAT is found in both 
barriers, the BBB and BCSFB [2, 46]. Members of y+L system believed to be localized on both, 
luminal and abluminal, membranes of the BBB [373]. 
Taken together all the mentioned above facts, the net Gln movement in the CNS might be 
regulated by 12 identified AATs (Table 3). Interestingly, these AATs have overlapping 
expression patterns in neurons, astrocytes, BBB, and BCSFB cells. While some AATs like 
SNAT1, are expressed mainly in neurons, others are preferentially found in astrocytes and BBB 
(SNAT3, SNAT5). Whereas, other AATs like SNAT2, are expressed in all three CNS cell types. 
Thus, in the CNS Gln homeostasis is controlled simultaneously not only by different AATs, but 
also by different cells, and investigation of the role of each AAT in this complex regulation is 
not a trivial task. 
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3.5. Thesis projects 
1. SNAT5 localization in the BBB 
In this project we attempted to localize SNAT5 in the brain endothelial cells based on antibody-
dependent approaches. 
2. Investigation of AA concentrations in the brain ISF and possible mechanisms of their 
regulation  
Here we compared levels of 16 different AAs in the brain ISF, CSF and plasma and discovered 
the existence of concentration gradients between all these three fluid compartments. Next we 
investigated possible mechanisms of Gln concentration regulation in the brain ISF under several 
different challenges (competitive inhibitor infusion into the brain ISF and/or peripheral bolus 
AA IP injection). The results of this project are summarized in the manuscript “Brain interstitial 
fluid glutamine homeostasis is controlled by blood-brain barrier SLC7A5/LAT1 amino acid 
transporter”. 
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4. SNAT5 localization in brain endothelial cells 
4.1. Materials and Methods 
4.1.1 Antibodies 
Table 4 summarizes information about anti-mSNAT5 antibodies as well as other primary and 
secondary antibodies used for western blot and immunofluorescence studies.  
 
 
Table 4. Primary and secondary antibodies used for western blot and immunofluorescence assays.  
 
4.1.2 HEK 293T cell-line 
Human embryonic kidney cells (HEK293T) were kindly provided by Dr. D. Schümperli from 
University of Bern. Cells were routinely cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
catalog no. E15-810, GE Healthcare) supplemented with 10% fetal bovine serum FBS (Sigma-
Aldrich), 2 mM L-Glutamine and 1% non essential amino acids at standard cell culture conditions 
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(37°C, 95% relative humidity and 5% CO2). At  80-90% confluence, cells were passaged with 0.25% 
trypsin in PBS and at a final density of 10%. 
4.1.3 Animals 
All experiments were performed with male C57BL/6J mice (Charles River (Crl), Germany) that 
were handled in accordance with the Swiss federal and cantonal law and with the approval of the 
Cantonal Veterinary Office Zürich. 
4.1.4 Vectors and transfection 
The mouse Snat5 coding sequence was subcloned in the pLCPX (part of N631511, Clontech, 
Lab. Inc, USA) or peGFP-C1 (N 6084-1, Clontech Lab. Inc., USA) vectors. The vectors and 
constructs were prepared by transforming DH5α E.coli cells, followed by maxi or midi-prep 
DNA extraction kit (Qiagen).  
For transfection HEK293T cells were seeded at 2·106 cells per well in 6 well plate (N92406, TPP 
Techno Plastic Products AG, Switzerland) and allowed to attach overnight. The next day, before 
transfection cells were washed twice with Optimem medium (11058021, Gibco, Life 
Technologies) and then kept in 1 mL of the same medium. The transfection was performed using 
X-treme GENE 9 transfection reagent (06365787001, Roche Diagnostics, Mannheim, Germany) 
as follows: 9 uL of X-treme GENE 9 in Optimem and 3 ug of DNA of interest (pLCPX, pLCPX-
mSnat5, peGFP-C1 or mSnat5-eGFPC1) in Optimem were incubated separately for 5 min at 
room temperature, next mixed and incubated for 30 min, added to 800 uL DMEM and then 
applied to HEK cells. After 24 hours the cell medium was replaced by complete medium and 48 
or 72 hours later HEK cells were used for lysate preparation or fixed for immunocytochemistry. 
4.1.5 Cell lysate preparation  
For lysate preparation transfected HEK cells were washed three times with ice-cold PBS, 
scraped in 1 mL of ice-cold PBS and centrifuged at 800 g for 1 min at 4°C. The cell pellet was 
homogenized by vigorous pipetting in 200 μL of ice-cold mannitol buffer (300 mM mannitol, 2 
mM EDTA, 20 mM HEPES-Tris, pH 7) containing complete EDTA-free proteinase inhibitor 
cocktail (Roche Diagnostics, Mannheim, Germany) and 2 mM phenylmethanesulfonylfluoride 
(PMSF) and incubated for 30 min on ice. Cell debris was pelleted with centrifugation at 100 g 
for 10 min at 4°C. Part of the supernatant was used for determination of protein concentration, 
while the rest was centrifuged at 41000 rpm (RP45A rotor, SORVALL RC M120EX) for 1 hour 
4. SNAT5 localization in brain endothelial cells
46
  
at 4°C. The supernatant containing the cytosolic fraction was kept for further analysis. The pellet 
that mainly contained membrane proteins was resuspended in 200 uL of resuspension buffer 
(mannitol buffer supplemented with 0.1% triton-X 100 and 0.5% Na+-deoxycholate). The protein 
concentration for all samples was determined using the BCA protein assay kit (Thermo 
Scientific). 
4.1.6 Cell surface biotinylation  
HEK cells were transfected as described above and grown on 6 cm dishes for 48 hours. Cells 
were washed once with 3 mL PBS, incubated with the same volume of biotin (EZ-link sulfo-
NHS-LC-Biotin, 21335, PIERCE, Thermoscientific) solution for 40 min at 4°C, followed by 100 
mM glycine for 20 min. Cells were washed once with PBS for 20 min, scraped in 1 mL of PBS, 
transferred to an eppendorf tube and pelleted at 1000g for 1 min at 4°C. The supernatant was 
aspirated, cells were lysed in 100 uL of Radio-Immunoprecipitation Assay (RIPA) buffer (150 
mM NaCl, 50 mM Tris pH 7.4, 1% NP-40, 0.5% Na+-Deoxycholate) for 40 min on ice and 
centrifuged for 10 min at 2040 g at 4°C. Twenty percent of the supernatant (5 uL) was saved for 
western-blotting analysis. The remaining supernatant was added to pre-washed streptavidin 
agarose beads (original volume 50 uL; 20347 PIERCE, Thermoscientific), rocked overnight at 
4°C and then pelleted at 943 g for 30 seconds. The supernatant (non-biotinylated proteins) was 
saved for western blotting, while the pellet was washed three times for 10 min with 1 mL of IP 
buffer (50 mM NaCl, 50 mM HEPES, pH 7.4, 1% NP-40, 5 mM EDTA) and finally once with 1 
ml of PBS. Twenty microliter of 2x Lammli buffer containing DTT was added to the 
biotinylated protein pellets and samples were incubated for 40 min at 60°C and stored at -20°C 
for further analysis.  
4.1.7 Tissue lysate preparation 
Tissues (brains or pancreas) were homogenized in ice-cold homogenization buffer (200 mM 
mannitol, 80 mM HEPES, 41 mM KOH, 1 tablet complete EDTA-free proteinase inhibitor 
cocktail (Roche Diagnostics, Mannheim, Germany), pH 7.5) using a disperser (Polytron PT 
1200C, Kinematica AG, Switzerland). Homogenates were sonicated (Labsonic 1510, 
Bender&Hobein, Switzerland) and centrifuged for 20 min, 2000 rpm at 4°C. Part of the 
supernatants was kept for western-blotting as total lysate sample, the rest was ultracentrifuged 
for 1 h 41000 rpm (RP45A rotor, SORVALL RC M120EX) at 4°C. The supernatant containing 
the cytosolic fraction was saved, and the pellet containing the membrane proteins was dissolved 
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in homogenization buffer and further sonicated. Protein concentrations were determined as 
mentioned above. 
4.1.8 Brain microvessels isolation 
After decapitation 5-10 brains were collected in buffer A (103 mM NaCl, 4.7 mM KCl, 2.5 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 15 mM HEPES, pH 7.4) containing complete EDTA-
free proteinase inhibitor cocktail and cerebella were removed. Then homogenization was 
performed using a Dounce glass homogenizer with 55 up and down strokes in 8 ml of buffer B 
(buffer A supplemented with 25 mM NaHCO3, 10 mM glucose, 1 mM Na+ pyruvate and 10 g/L 
dextran). The homogenate was mixed with 16 mL of 26% dextran, centrifuged at 5600 g at 4°C 
for 10 min. The pellet was resuspended in 10 mL of fresh buffer B, filtered through a 60 μm 
nylon mesh and centrifuged at 3000 g at 4°C for 10 min. The pellet containing brain 
microvessels was used for lysate preparation or immunofluorescence.  
 4.1.9 Brain microvessels lysate preparation 
Lysates from the brain microvessls were prepared as previously described (3.1.6). The pellet 
enriched with microvessels was resuspended in 1 mL of homogenization buffer and 
homogenized with a disperser (Polytron PT 1200C, Kinematica AG, Switzerland) on ice for 15 
sec each 15 min during 1 hour. Homogenates were centrifuged at 10000 g at 4°C for 10 min. 
Part of each homogenate was saved for western-blotting as a total lysate fraction, while the rest 
was ultracentrifuged for 90 min at 41000 rpm (RP45A rotor, SORVALL RC M120EX) at 4°C. 
The newly formed supernatant was kept as cytosolic fraction, and the pellet was resuspended in 
50 μl of resuspension buffer (3.1.6). 
4.1.10 Gel-electrophoresis and Western Blotting 
For SDS-PAGE separation, 20 or 50 μg of cell, tissue or microvessel lysates were diluted with 
4x Lämmli buffer, containing 100 mM dithiothreitol (DTT) (Juro Supply, Lucerne) and 
incubated for 5 min at 95°C or for 30 min at 25°C. Biotinylated samples from cell surface 
biotinylation were prepared as described (3.1.5). For SDS-PAGE separation, 10 µL of unbound 
fraction (10% total volume) was mixed with 15 µL of RIPA buffer and 25 µL of 2x Lämmli 
buffer containing DTT and incubated for 40 min at 65°C. For the total fraction samples, 5 uL 
(20% total volume) were treated in the same way using 20 µL RIPA buffer and 25 µL of 2x 
Lämmli buffer. Samples were loaded on 8.5% or 10% polyacrylamide gels. After separation, 
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proteins were transferred to PVDF membranes (Immobilion-P, Millipore) and blocked for 1 h at 
room temperature (RT) in either 2% TOP-BLOCK in TBS, 0.1% Triton X-100 (TBS-T) or 5% 
milk in TBS, 0.1% Tween-20 (TBS-t) and incubated overnight at 4°C with the primary antibody 
diluted in 1% TOP-BLOCK in TBS-T or 5% milk in TBS-t. Washes were performed with either 
TBS-T or TBS-t, respectively. Secondary antibodies diluted in 1% TOP-BLOCK in TBS-T or 
5% milk in TBS-t were incubated with the blot for 1 hour at RT. For probing with several 
antibodies membranes were stripped with glycine, pH 2.2 (Abcam protocol stripping for 
reprobing), blocked and reprobed with the necessary antibody. Detection was performed by 
chemiluminescence and visualised with Immobilion Western Chemiluminescent horseradish 
peroxidase (HRP) substrate (Millipore) or CDP-Star (Roche) on a Fuji LAS-4000 camera 
(Bucher Biotec, Basel, Switzerland).  
4.1.11 Immunocytochemistry 
Transfected HEK cells were grown on polyester transwell inserts (3470, Transwell Costar, 
Corning Inc, USA) for 48 hours and fixed in 3% PFA, 0.1% TritonX100 for 10 min. Afterwards 
the filters were washed once in ice-cold PBS, 0.1% SDS in PBS for 5 minutes, washed once with 
PBS, 0.1% Triton-X (PBS-T) and blocked with serum from the host species of secondary 
antibody at 10% serum, PBS-T (blocking buffer) for 1 hour at RT. All wash steps were in PBS-
T. Primary and secondary antibodies were diluted in blocking buffer and incubated for 1 hour, 
RT. Nuclei were labeled with Diamidino-2-Phenylindole Dihydrochloride (DAPI, Life 
Technologies) diluted 1:5000 in the same buffer as antibodies. All the incubation steps were 
performed in humidified chambers. Finally, filter pieces were mounted with DAKO Glycergel 
(DAKO North America, Inc., USA) on slides and examined under the fluorescent microscope 
Nikon eclipse TE 300.  
4.1.12 Immunofluorescence on free-floating sections 
Mice were anesthetized with ketamine (ketanarkon)/xylazin (Streuli Pharma AG, Uznach, 
Switzerland) cocktail (10 mg and 1 mg/ mL/100g, respectively) and perfused with PBS, pH 7.4, 
followed by fixation in 2% PFA and 0.2% glutaraldehyde in PBS. Then the brains were post-
fixed for 2 h, kept in PBS overnight and stored in 0.02% PFA, 4°C. For immunofluorescent 
staining, brains were cut sagittaly into 20 μm sections using a vibrating microtome (Leica VT 
1000S; Leica, Heerbrugg, Switzerland). Sections were agitated in PBS 0.5% Triton X-100 for 
30 minutes, blocked for 10 minutes (Protein Block Serum-Free; Dako, Carpinteria, CA, USA), 
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and incubated with primary antibodies overnight at 4°C. All wash steps were done in PBS with 
agitation. The next day sections were incubated with secondary antibodies for 30 – 45 min, 
followed by 10 minutes in 4% PFA. Nuclei were counterstained with PO-PRO-1 iodide (1:400; 
Invitrogen) for 5 min. Sections were mounted on polylysine slides (Menzel Gläser, 
Thermoscientific, Braunschweig, Germany) in a Vectashield mounting medium (Vector 
Laboratories, Burlingame, CA, USA) and then examined under a Leica TCS SP2 confocal laser 
scanning microscope (Leica) using a 63x objective (oil, numerical aperture of 1.4, pinhole set to 
1.0 airy unit). 
4.1.13 Immunofluorescence on paraffin sections  
Deeply anaesthetized mice were transcardially perfused with ice-cold PBS, pH 7.4, then brains 
were collected, incubated in 4% PFA in PBS at 4°C overnight. Paraformaldehyde-fixed brains 
were paraffinized (Shandon Xylene Substitute, Thermoscientific), cut coronally into 5 μm thick 
slices using a microtome (RM 2235, Leica), mounted on polylysine slides and kept at +4°C for 
staining. Paraffin slides were deparaffinized for immunofluorescence (Microm/Histocam AG, 
Thermoscientific). 
Antigen retrieval was performed using the proteinase K antigen retrieval method (incubation of 
sections in proteinase K solution (proteinase K 20 μg/ml in 50 mM Tris base 1.0 mM EDTA, 0.5 
% Triton X-100, pH 8.0)) at 37°C for 10 min. Slices were blocked for 1 h at RT using blocking 
buffer (5.0% donkey or goat serum in PBS, 0.3 % Triton X-100). Blocked slices were incubated 
overnight at 4°C in incubation buffer (PBS, 1% BSA, 0.3% Triton X-100) containing primary 
antibodies. Secondary antibody incubations were carried out for 1-2 h at RT. PBS was used for 
washes between incubation with primary and secondary antibodies. Nuclear counterstaining was 
performed with DAPI (1:500), brain sections were mounted with DAKO-Glycergel with 
coverslips and examined as previously described. 
4.1.14 Immunofluorescence on isolated microvessels 
Pellet enriched with microvessels (3.1.7) was resuspended in PBS, and a small drop of 
suspension carefully distributed on a slide (Superfrost Plus, Menzel Gläser, Thermoscientific, 
Braunschweig, Germany) and incubated at RT for 20 min in a humidified chamber. The PBS 
was removed and the adhering microvessels were washed three times with PBS and fixed with 
3% PFA for 30 min. After five wash steps with PBS, microvessels were permeabilized with 
0.1% Triton X-100 for 30 min, blocked in blocking buffer (3.1.10) for 1 hour and incubated with 
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primary antibodies for 2 hours, RT. Microvessels were washed three times with PBS and 
incubated in secondary antibody 1 hour, RT. Nuclei counterstaining and mounting were 
performed as described above (3.1.10). 
4.2. Results 
4.2.1 Test of anti-SNAT5 antibodies in HEK cells heterologously expressing mSNAT5 
Since the SNAT5 knockout animals have not yet been generated, we tested anti-SNAT5 
antibodies (Ab) using HEK cells exogenously expressing mouse SNAT5 (mSNAT5) (Figure 
12). The predicted molecular weight (MW) of the mSNAT5 protein is 55 kDa. The anti-
mSNAT5 Ab from Santa Cruz (SC) recognized a band with an apparent MW of 55 kDa in 
lysates from both transfected and non-transfected cells. However, additionally in transfected 
cells only, diffuse bands between 43 and 55 kDa were detected (Figure 12A). Staining using an 
Ab raised against rat SNAT5 (Abcam) resulted in a strong band at ~55 kDa and a faint band at 
~50 kDa in both transfected and non-transfected HEK cell lysates. Both anti-mSNAT5 Abs from 
Everest Biology (EB) 11595 and 11596 recognized multiple bands in transfected as well as non-
transfected cell lysates. However, a unique band was detected by EB11595 at ~43 kDa and the 
band at ~50 kDa was significantly stronger in cells transfected with pLCPX-mSnat5 construct, 
than in non-transfected or transfected with a vector alone cells (Figure 12A). The EB11596 Ab 
recognized a similar set of proteins as EB11595 although with an apparent lower affinity. 
Furthermore, by immunocytochemistry both EB Abs detected apparent plasma membrane 
proteins in HEK cells transfected with pLCPX-mSNAT5 (Figure 12B).  
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Figure 12. Testing anti-SNAT5 antibodies. Antibodies were tested by (A) western-blotting and (B) 
immunocytochemistry in HEK cells transfected with pLCPX-mSNAT5. Panel (A) shows representative western 
blots for lanes: anti-mSNAT5 SC (1:1000), anti-rSNAT5 Abcam (1:1000), anti-mSNAT5 EB 11595 (1:500), anti-
mSNAT5 EB 11596 (1:500). 20 ug of cell lysates (72h after transfection) were incubated at 95°C for 5 min in 
Lämmli buffer with DTT prior to gel-electrophoresis. β - actin (SC, Abcam) or GAPDH (EB11595, EB 11596) were 
used as loading controls. Anti-mSNAT5 SC and Abcam antibodies were tested on the same gel, while EB 11595 
and 11596 on different gels. Panel (B) shows representative immunofluorescence images. For 
immunocytochemistry cells were fixed 48 h after transfection and stained with anti-mSNAT5 antibodies as follows: 
(III) EB 11595 1:100 and (IV) EB 11596 1:50. Scale bar is 20 µm. Arrows indicate staining of anti-mSNAT5 Ab.  
T – transfected cells, V – cells transfected with vector alone, N – non-transfected HEK cells. 
Next the antibodies were tested using HEK cells transfected with mSNAT5-eGFPC1 (Figure 
13). The mSNAT5-eGFPC1 product is expressed as fused protein of mSNAT5 with GFP, 
4. SNAT5 localization in brain endothelial cells
52
  
therefore the expected apparent MW is ~85 kDa (GFP is 30 kDa). Anti-mSNAT5 SC Ab 
identified a set of diffuse bands between 55 and 72 kDa with a significant enrichment in the 
membrane fraction. However this is lower than the predicted MW for the fusion protein (Figure 
13A). By immunocytochemistry the SC Ab apparently stained cell plasma membranes and an 
unidentified cellular compartment, in which the signal partially co-localized with GFP (Figure 
13B). Similarly, Abcam anti-rSnat5 Ab detected bands between 55 and 72 kDa, however the 
signal was weaker in comparison to SC Ab. Conversely, the Abcam Ab did not give a specific 
signal above background by immunocytochemistry (Figure 13B). The EB11595 Ab recognized a 
band at ~72 kDa in total lysates and membrane fractions, where the signal was enriched (Figure 
13A). By immunocytochemistry, the EB11595 signal was observed at the plasma membrane 
where it did not co-localize with GFP as well as in an intracellular compartment co-localized 
with GFP (Figure 13B). Anti-mSnat5 EB11596 detected diffuse bands that were enriched in the 
membrane fraction at an apparent MW between 55 and 72 kDa. For the same amount of protein 
lysate and Ab dilution the signal from EB11596 was lower than EB11595 in case of western-
blotting, however by immunocytochemistry both antibodies showed similar staining (Figure 
13A, B). Additionally all four Abs detected a band at an apparent MW rather greater than ~95 
kDa (upper part of the gel) in total cell lysate and membrane fractions, that was also present in 
HEK cells transfected with peGFP-C1 vector alone. 
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Figure 13. Anti-mSNAT5 antibody validation. Antibodies were tested by (A) western-blotting and (B) 
immunocytochemistry using HEK cells transfected with eGFPC1 and eGFPC1-mSNAT5. Panel (A) shows 
representative western blots for lanes: anti-mSNAT5 SC (1:1000), anti-rSNAT5 Abcam (1:1000), anti-mSNAT5 EB 
11595 (1:500), anti-mSNAT5 EB 11596 (1:500). 20 ug of cell lysates (72h after transfection) were incubated at 
95°C for 5 min in Lämmli buffer with DTT prior to gel-electrophoresis. β - actin (SC, Abcam) or GAPDH (EB 
11595, EB 11596) were used as loading controls. T – total cell lysate, C – cytosolic fraction, M – membrane 
fraction. For immunocytochemistry cells were fixed 48 h after transfection and stained with diluted anti-SNAT5 
antibodies as follows: SC 1:200, Abcam 1:200, EB 11595 1:100 and EB 11596 1:50. Scale bar is 20 um. Arrows 
indicate co-localization in membrane. 
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Next the specificity of the signal detected by anti-mSnat5 SC and EB11595 Abs in the 
membrane fractions was examined by surface biotinylation of HEK cells expressing mSNAT5-
eGFPC1, or pLCPX-mSNAT5, or the corresponding vector alone. The band at ~95 kDa was 
specifically recognized by anti-mSnat5 SC Ab in the biotinylated fraction of transfected HEK 
cells (Figure 14A), but not in the same fraction of non-transfected cells. The extent of the surface 
labeling with biotin was confirmed by incubation with streptavidin-HRP conjugate. To estimate 
whether biotin accessed only cell surface and did not label cytosolic proteins the blot was 
incubated with anti-GAPDH Abs. No GAPDH staining was detected in the streptavidin bound 
fraction in contrast to the total lysate and unbound fractions. The EB11595 Ab recognized a 
diffuse band in the biotinylated fraction of pLCPX-mSNAT5 transfected cells, but not in the 
absence of biotin (Figure 14B) or in cells transfected with vector alone. The efficiency of 
biotinylation procedure and absence of biotin labeling in the cytosolic fraction was tested as 
described above.  
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Figure 14. Detection of mSNAT5 by western blot with SC or EB11595 anti-SNAT5 antibodies on SDS-PAGE 
fractionated lysates from surface biotinylated cells. After incubation with biotin (+ biotin) or with buffer alone (-
biotin) transfected cells were lysed and biotinylated proteins pulled-down using neutravidin agarose beads. For 
SDS-PAGE, 5 µL of total protein lysate (T), 10 µL of unbound proteins (U) and 20 µL of neutravidin-agarose-
bound proteins (B). For panel A western blots were probed with: (I) anti-mSNAT5 SC (1:1000), anti-β-actin 
(intracellular marker) antibodies, and (II) streptavidin-HRP. For panel B blots were probed with (I) anti-mSNAT5 
EB11595 (1:500), anti-GAPDH (intracellular marker) antibodies, and (II) streptavidin-HRP. 
4.2.2 Application of tested anti-SNAT5 antibodies in brain tissue 
The anti-mSNAT5 Abs were tested on brain tissue by western-blotting and immunofluorescence. 
High levels of Snat5 mRNA were reported in brain endothelial cells and in pancreas [2, 407]. 
Therefore, anti-mSNAT5 SC, EB11595 and EB11596 Abs were tested on brain and pancreas 
tissue lysates (Figure 15ABC).  
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Figure 15. Testing anti-mSNAT5 antibodies on mouse tissue lysates. Representative western blots of SDS-PAGE 
fractionated mouse lysates from brain (BRAIN), and pancreas (PANCREAS) as follows: membrane (M), cytosolic 
(C) and total (T) fractions. Membranes were probed with anti-mSNAT5 antibodies as follows in panels: (A) SC 
anti-mSNAT5 Ab (1:1000), (B) EB11595 anti-mSNAT5 Ab (1:100), and (C) EB11596 anti-mSNAT5 Ab (1:500). 
The anti-mSNAT5 SC Ab detected a band at ~55 kDa at a similar intensity in brain total, 
cytosolic, and membrane lysates. Additionally, a faint most likely non-specific band was 
detected at an apparent MW of 55 kDa in all pancreatic lysates. This band was suspected to be 
staining of amylase, which is very highly expressed in pancreas and has an expected MW of 
~55kDa. Additionally the SC Ab detected a very faint diffuse banding between 55 and 72 kDa in 
the pancreas membrane fractions. The EB11595 Ab stained a similar set of diffuse bands in 
pancreas total lysates that were enriched in the membrane relative to the cytosolic fractions 
(Figure 15B). However, in the brain samples a 55 kDa band was enriched in cytosolic fraction 
vs. in total lysates or membrane fractions, and therefore regarded as non-specific. Additionally, 
EB11595 detected the band at ~72 kDa in the brain membrane fraction, which may be specific 
staining of SNAT5 however it is difficult to distinguish from a band migrating at nearly the same 
MW in all brain lysate fractions. Unfortunately, EB11596 recognized an intensely stained 50 
kDa band in all pancreas fractions, possibly amylase and, thus, non-specific, while no signal was 
observed in the brain samples (Figure 15C). By immunofluorescence on brain section multiple 
thread-like staining with SC antibody, staining in astrocyte like structures with EB11595, and 
peri-nuclear staining with EB11596 was observed (Figure16 A, B, C).  
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Figure 16. Immunofluorescence staining of paraffin-fixed mouse brain sections with anti-mSNAT5 antibodies. 
Representative images are shown for anti-SNAT5 (green) staining with (A) Santa Cruz antibody, (B) EB11595, and 
(C) EB11596, all antiboides were diluted at 1:100, and nuclei are co-labeled (blue), arrows indicate mSNAT5 
signal.  Scale bar is 50 µm. 
Since EB11595 resulted in a possible SNAT5 specific signal, a more detailed analysis of the 
structures recognized by this antibody in vivo was carried out (Figure 17A-R). The EB11595 
antibody detected structures in close association with microvessels, but not co-localized with 
laminin, a marker for microvessels (Figure 17A-I). However, the signal co-localized with 
astrocyte marker GFAP (Figure 17 J-L). Since Snat5 mRNA was found in choroid plexus 
epithelial (CPE) cells, EB11595 was used for immunofluorescence staining of choroid plexus 
tissue sections. In contrast to the anti-SNAT3 Ab, no specific signal was observed by EB11595 
staining of choroid plexus in brain tissue sections (Figure 17 M-O).  
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Figure 17. Representative immunofluorescence images of paraffin brain sections. Panels (A–I) are stained with 
EB11595 anti-mSNAT5 (1:100, green) and anti-laminin (1:200, blue) antibodies. Panels (A-C) low magnification 
images of a brain section (30 µm scale bar); panels (D-F) capillary cross-section (5 µm scale bar); panels (G-I) 
longitudinal capillary section (10 µm scale bar); nuclei in yellow. Panels (J–L) are double-stained with anti-
mSNAT5 (1:100, green) and anti-GFAP (1:200, red) antibodies (50 µm scale bar), nuclei are stained with DAPI 
(blue). Panels (M-O) are stained with anti-mSNAT5 (1:200, green), anti-mSNAT3 (1:200, red) and anti-laminin 
(1:200, blue) antibodies (30 µm scale bar, nuclei (blue)). Panels (P-R) are stained with anti-mSNAT3 (1:200, green) 
and anti-laminin (1:200, red) antibodies (5 µm scale bar, yellow nuclei). Arrows indicate staining of anti-mSNAT5 
EB 11595 Ab. 
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Previously, anti-mSNAT3 antibodies were shown to be successfully used for 
immunofluorescence staining with a strong signal to noise using fresh fixed free-floating mouse 
brain sections, therefore, the anti-mSNAT5 antibodies were tested on fresh fixed vibrotome 
sections. Staining with neither SC nor EB11596 antibodies resulted in a specific signal under 
these conditions (data are not shown). However, staining with EB11595 resulted in a similar 
labeling pattern as previously observed for paraffin-fixed brain sections in structures near to, but 
not overlapping with microvessel marker staining (Figure18A-F). 
  
Figure 18. Representative immunofluorescence images of free-floating brain sections. Immunofluorescence was 
performed with 1:200 dilutions of antibodies as follows: A-F -‒ anti-mSNAT5 EB 11595 (green) and anti-laminin 
(blue) antibodies; A-C -‒ low magnification (30 µm scale bar), D-F -‒ a capillary cross-section (5 um scale bar); G-I 
-‒ staining of anti-mSNAT3 (green) and anti-laminin (red) antibodies (5 um scale bar). Nuclei are shown as yellow. 
Arrows indicate staining of anti-mSNAT5 EB11595 Ab in the brain sections. 
4.2.3 Application of tested anti-SNAT5 antibodies in isolated microvessels 
The EB11595 anti-mSNAT5 antibody was further tested on isolated microvessels by western 
blot and immunofluorescence (Figure 19A-C). As for total brain fractions EB11595 recognized a 
band at ~72 kDa that was enriched in the membrane fraction. Since the glucose transporter 
GLUT1 (SLC2A1) is highly expressed in the BBB, the blot was probed with anti-GLUT1 
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antibodies. An enrichment in GLUT1 (MW~50 kDa) staining was detected in isolated 
microvessels. Nevertheless, a strong signal for an astrocyte marker GFAP was also detected in 
the microvessel lysate preparations by western blot. In isolated microvessels EB11595 staining 
resulted in punctate immunofluorescence signals, while anti-GLUT1 and anti-laminin 
immunofluorescence resulted in uniformly distributed signals. 
  
Figure 19. Testing anti-mSNAT5 EB11595 on isolated microvessel preparations. Panel (A) shows representative 
western blots of microvessel lysates (total lysates (T), cytosolic (C) and membrane (M) fractions) probed with anti-
mSNAT5 EB11595 (1:100 dilution), anti-GLUT1 (1:1000) and anti-GFAP (1:500) antibodies. Panels B, C are 
representative immunofluorescence images of isolated microvessels stained with anti-mSNAT5 EB11595 (1:50, 
green), anti-GLUT1 (1:200, red) and anti-laminin (1:200). Nuclei are shown in yellow. For (B) 20 µm scale bar; (C) 
5 µm scale bar. Arrows indicate punctate EB11595 staining. 
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4.3. Discussion 
Both SNAT3 and SNAT5 transporters are Na+-dependent pH sensitive Gln transporters. High 
levels of Snat5 and Snat3 mRNAs were reported in freshly isolated highly pure brain endothelial 
cells. However, a brief in vitro culture significantly decreased their expression, suggesting they 
play an important role in vivo, for example, in BBB transendothelial AA transport [2, 370]. 
Hawkins and colleagues postulated that all Na+-dependent AATs are localized only on abluminal 
BEC membranes, however recently SNAT3 expression was identified on both luminal and 
abluminal membranes [3, 373]. Therefore, SNAT5 localization on the BBB membranes was 
investigated. Both commercially available as well as in-house produced anti-SNAT5 antibodies 
were tested for SNAT5 specificity (Table 4). Preliminary tests in HEK cells heterologously 
expressing mSNAT5 indicated that SC, EB11595, and EB11596 antibodies were potentially 
good candidates for specific SNAT5 staining. However, by western blot of brain tissue lysates 
the SC antibody recognized a band of the same intensity in all three brain fractions without any 
enrichment in the membrane fraction (Figure 15A). Moreover, by immunofluorescence the SC 
antibody stained unidentified thread-like structures (Figure 16A). The EB11595 antibody 
detected a diffuse band in brain and microvessels samples between 55 and 72 kDa that was 
enriched in the membrane fraction (Figure 15B, 19A). However, even considering the single 
suggested glycosylation site (residue 236, http://www.uniprot.org /uniprot/Q3U1J0) the apparent 
MW of the band is greater than the expected 55 kDa MW for SNAT5. Anti-mSNAT5 EB11595 
antibody also did not stain brain endothelial cells or choroid plexus epithelial cells in brain 
sections where previously significant mRNA levels were reported. However co-localization of 
EB11595 staining with anti-GFAP staining was observed (Figure 17J-L), which is in an 
agreement with previously published SNAT5 expression in the rat brain [279]. In summary, anti-
mSNAT5 antibody, EB11595, gave a specific signal in cells heterologously expressing 
mSNAT5. This antibody also detected SNAT5 expression in astrocytes, but not in microvessels 
or CP.  
Unfortunately, since SNAT5 knockout animals have not yet been generated, EB11595 antibody 
cannot be validated in in vivo and, thus, the specificity is still questionable. Conversely, 
EB11595 anti-mSNAT5 antibody signal co-localized with the astrocyte marker GFAP. 
Therefore, the absence of signal for SNAT5 in brain endothelial cells may be explained by 
several reasons that have either biological or methodological origin. Unfortunately, cases of lack 
of correlation between mRNA and protein levels are not rare in literature. For instance, no 
positive correlation between immunohistochemistry and Affymetrix gene expression profile of 
CD31 was observed in endothelial cells from human prostate isolated by magnetic cells sorting 
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(MACS) [408]. Generally, a higher mRNA level significantly increases the probability of protein 
detection [409]. However, the correlation between protein concentration and corresponding 
mRNA level is reported to be on average 20-40 % [409-411]. The 60% variability can be 
explained by several factors. For instance, for both mRNAs and proteins the rate of degradation 
and synthesis are important. On average, for mammals the mRNA production rate is ~two copies 
per hour, while proteins are synthesized at a rate of ~dozens of molecules per hour. Moreover, 
the half-life of mRNA (2.6 - 7 hours) is significantly less than the average protein half-life of 46 
hours [412, 413]. Additionally, protein abundance is believed to depend on their functions in the 
cell, for example, structural or housekeeping proteins are considered to be long-lived proteins 
versus regulatory proteins [409]. Taken together, both synthesis and degradation rates increase 
the chance of detecting protein expression of a membrane transporter such as SNAT5.  However, 
additionally post-transcriptional regulation impacts protein abundance. For instance, Vogel 
describes example of an opposite correlation between length of mRNA and protein concentration 
in yeast [409]. Another example is that in cancer cells highly expressed proteins have shorter 3’ 
untranslated regions (UTR). These UTR regions usually contain micro RNA (miRNA)-binding 
sites and miRNA are known to mediate translational repression [414, 415]. In addition to 
biological factors, methodological aspects such as sensitivity and signal to background influence 
the interpretation of the experimental results. Crosschecking experiments, when the same result 
is confirmed simultaneously by different techniques or methods, have particular importance. For 
instance, to confirm anti-mSNAT5 antibody EB11595 specificity, the immunofluorescence 
signal in brain tissue could be compared with the in situ hybridization signal [366]. Moreover, 
mass spectrometric analysis of the band detected by EB11595 in the brain and microvessel 
samples can be used for confirmation of this antibody specificity.  Unfortunately, the localization 
of SNAT5 is not yet determined in the brain endothelial cells and further studies are required.  
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Abstract 
L-glutamine (Gln) is the most abundant amino acid (AA) in plasma and cerebrospinal fluid 
(CSF) and a precursor for the main central nervous system excitatory (L-glutamate) and 
inhibitory (γ-aminobutyric acid (GABA)) neurotransmitters.  Concentrations of Gln and 13 
other brain interstitial fluid (ISF) AAs were measured in awake, freely-moving mice by 
hippocampal microdialysis using extrapolation to zero flow rate method. ISF levels for all 
AAs including Gln were ~5-10 times lower than in CSF. Although the large increase in 
plasma Gln by intraperitoneal (IP) injection of 
15
N2-labeled Gln (hGln) did not increase total 
ISF Gln, low levels of hGln were detected in microdialysis samples. Competitive inhibition 
of system A (SLC38A1&2; SNAT1&2) or system L (SLC7A5&8; LAT1&2) transporters in 
brain by perfusion with α-(methylamino)-isobutyric acid (MeAIB) or 2-aminobicyclo-
(2,2,1)-heptane-2-carboxylic acid (BCH) respectively, was tested. The data showed a 
significantly greater increase in ISF Gln upon BCH than MeAIB treatment. Furthermore, 
brain BCH perfusion also strongly increased the influx of hGln into ISF following IP 
injection consistent with transstimulation of LAT1-mediated transendothelial transport. 
Taken together the data support the independent homeostatic regulation of AAs in ISF vs. 
CSF and the role of the blood-brain barrier expressed SLC7A5/LAT1 as a key ISF 
gatekeeper.  
Introduction  
The blood-brain barrier (BBB) is an extensive microvascular network controlling entry and exit 
of substances between the blood and the brain by both physical and metabolic barriers to free 
exchange. Unlike in the periphery, brain endothelial cells form a tight barrier through expression 
of contiguous, well-organized tight junctions and lack of transcellular channels and fenestrations. 
Furthermore, the endothelium exhibits a polarized (luminal vs. abluminal) distribution of 
proteins including transporters
1-3
. The BBB endothelium in association with pericytes (within a 
common basement membrane), astrocytic endfeet (with an associated parenchymal basement 
membrane), and neurons form “the neurovascular unit”1. 
All AAs, whose diverse metabolic and regulatory functions include serving as neurotransmitters 
and neurotransmitter precursors, are tightly controlled in the central nervous system (CNS). 
Since testing cerebrospinal fluid (CSF) is less invasive than sampling brain interstitial fluid 
(ISF), CSF is more thoroughly characterized than ISF. Therefore, CSF is commonly used for 
diagnostic and drug development as a proxy for ISF. Although, there are known similarities 
between CSF and ISF, for example, in the ionic composition (i.e. K
+
, Ca
2+
, Na
+
, Cl
-
), it is unclear 
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whether this is a valid assumption for many solutes. CSF concentrations for most AAs are ~6 to 
10 times lower than in plasma. One exception is the most abundant plasma AA, L-glutamine 
(Gln), which is nearly as high in CSF as in blood
4
. However, in brain ISF the reported Gln levels 
vary ~two fold
5, 6
. Gln is a precursor for the major excitatory L-glutamate (Glu) and inhibitory 
neurotransmitters (γ-aminobutyric acid (GABA))7. Furthermore, levels are altered during 
neuropathologies such as Huntington disease, ischemia, and epilepsy
8-10
, and hyperammonemia, 
or hepatic encephalopathy (HE)
11
. Therefore, Gln concentrations must be efficiently regulated in 
the ISF.  
In general, AA’s do not freely diffuse across membranes instead specialized membrane proteins 
or solute carriers (SLC) transport AAs across membrane barriers. Prior to their molecular 
identification AA transporters (AAT) were classified as “systems” based on substrate specificity 
and dependence (or lack of) on Na
+
 for activity. Figure 1 illustrates expression of known Gln 
transporters in the CNS. The Na
+
-dependent system A transporters SLC38A1 (SNAT1) and 
SLC38A2 (SNAT2) expressed by neurons
12, 13
 participate in Gln uptake for Glu or GABA 
synthesis
7
, however some other Gln transporters were also found in neurons
14-17
. Astrocytes 
express a wide range of Gln transporters such as SLC1A5 (ASCT2), SCL38A2 (SNAT2), 
SCL38A3 (SNAT3), SLC38A5 (SNAT5), SLC7A6 (y
+
LAT2), SLC7A5 (LAT1) and SLC7A8 
(LAT2)
14, 18-21
. Although in adults ASCT2 and y
+
LAT2 levels are minimal
18, 22
. The abundantly 
expressed Na
+
-dependent pH sensitive SNAT3 and SNAT5 are thought to be the main astrocytic 
transporters for Gln efflux to neurons for the Glu/GABA-Gln cycle
7
. The BBB also expresses 
several different AAT involved in Gln transport
23
. Due to abundant expression and endothelium 
membrane localization LAT1 and SNAT3 may perform central roles in the BBB modulated 
control of brain ISF homeostasis for Gln and other AAs
2, 23
.  
A central aim of the current study was to accurately measure the ISF AA concentrations. 
Hippocampal ISF AA content was quantified and AA regulation investigated by in vivo 
microdialysis in freely-moving mice. Here we report a quantitative comparison of AA levels in 
ISF vs. CSF and plasma. Furthermore, responses to acute peripheral and/or parenchymal 
challenges support a central role for BBB expressed LAT1 transporters in regulation of Gln 
homeostasis in the ISF. 
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Materials and Methods  
Animals  
All animal experiments were conducted in accordance with the Swiss federal and cantonal law 
and were performed with the approval of the Swiss Veterinary Council. For all experiments 12-
14 week old male C57BL/6J mice (Charles River (Crl), Germany) (22–29 g) were used. Prior to 
surgeries mice were adapted for one week to food ad libitum during the active period (night) and 
food restriction during the inactive phase (day), with water ad libitum at all times. 
Microdialysis  
Microdialysis materials and chemicals 
Microdialysis guide cannulas (CMA 7, P000138,) and probes (CMA 7: 6 kDa MW cut-off, with 
1.0 mm (cat. #P000082) or 2.0mm (cat. #P000083) membranes were purchased from CMA 
Microdialysis AB, Kista, Sweden. Dental acrylic cement (CE 0086) was purchased from Pattern 
Resin LS, Powder & Liquid, GC America Inc., USA. FEP (fluorinated ethylene propylene) 
tubing, and tubing adapters were purchased from Microbiotech/se AB (Stockholm, Sweden). 
Samples were collected in a temperature-controlled fraction collector (EFC-82, Eicom, Dublin, 
Ireland). Norleucine (NLeu), α-(methylamino)-isobutyric acid (MeAIB), 2-amino-2-
norbornanecarboxylic acid (BCH), L-glutamic acid-γ–monohydroxamate (GAH), L-glutamine 
(Gln), L-valine (Val), sulphosalicylic acid (SSA), and cresyl violet acetate were purchased from 
Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). 
15
N2 heavy labeled L-glutamine (hGln) and 
fully labeled L-glutamine 
13
C5
15
N2, were obtained from Cambridge Isotope Laboratories Inc. 
(Tewksburry, Masschusetts, USA). 
In vitro microdialysis 
The relative recovery (RR) and mass transfer coefficient (K0) were estimated for 1 and 2 mm 
CMA7 probes in vitro (Suppl. Tables 1 and 2). Probes were placed in a solution with 15 standard 
AAs with and without NLeu. Artificial cerebrospinal fluid (aCSF, composition in mM: NaCl 
147; KCl 4.03; CaCl2 2.52; pH 7.4) or aCSF with 100 µM NLeu was used for perfusion as 
indicated. For K0 determination the fractions were collected at four flow rates (0.1, 0.5, 1, and 2 
μl/min) with adequate equilibration between flow rate changes. Samples were stored at -80°C for 
UPLC. 
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Intracerebral microdialysis in awake, freely-moving mice 
Surgery 
Mice were deeply anaesthetized by an intraperitoneal (IP) injection (10 μl/g body weight) of 
fentanyl 50 μg/ml, midazolam 5.0 mg/ml and medetomidin 1 mg/ml in 0.9% sterile saline. Eye 
cream (Viscotears, Novartis Pharma Schweiz AG, Bern, Switzerland) was applied, and body 
temperature controlled at 37°C. Using a stereotactic frame guide cannulas were implanted in the 
hippocampus at AP: −3.1; L: +2.9; V: −2.324 and supported by screws and dental acrylic cement. 
After surgery the anesthetic was antagonized by IP injection of 10 μl/g body weight 0.4 mg/ml 
naloxon, 0.1 mg/ml flumazenil and 5.0 mg/ml atipamezol in 0.9% sterile saline. For two days 
post-surgery an analgesic was administered in drinking water (200 µg/50 ml temgesic) and mice 
fed ad libitum. Thereafter and for the duration of microdialysis experiment food restriction was 
resumed with drinking water ad libitum. Food restriction was instituted to preemptively reduce 
variability in microdialysate AAs. Mice were weighed daily and mice that lost more than 10% 
body weight were excluded. Additionally, comparisons between 1 µ/min 24 hour microdialysate 
collection failed to show any significant changes in AAs with or without food restriction (data 
not shown). Eighteen hours before experimental microdialysate collection, microdialysis probes 
were inserted and for the first 4-6 hours perfused at 1 μl/min, followed by an overnight perfusion 
at 0.1 μl/min (Suppl. Fig. 1). During microdialysis mice were subjected to normal 12 h light and 
dark cycles. They were singly housed in cages equipped with swivels that allowed free 
movement. Unless otherwise noted, 30 minute samples were collected at 1 μl/min and stored 8-
12 hours at +4°C and at -80°C until measurement (Suppl. Fig. 1). 
Determination of brain interstitial fluid amino acid concentrations  
Amino acid concentrations in brain ISF were determined using an extrapolation of 
microdialysate concentrations to “zero flow” rate (Flow-rate method)25. The extrapolation is 
based on the inverse relationship between flow rate and the transfer of molecules (mass transfer 
rate). Relative recovery is a function of flow rate, probe surface area, and the mass transfer 
coefficient (K0), due to the chemical and physical properties of the solute and the matrix. The AA 
concentrations in 30 μl volumes of microdialysates collected at four flow rates (0.1, 0.5, 1, 2 
μl/min) were extrapolated to original concentrations (C0) using the equation:  
C0=CISF-[CISFexp(-K0A/F)]        (eqn1),  
where CISF is the concentration in the brain interstitial fluid, K0 is the average mass transfer 
coefficient, A is the area of the semipermeable probe membrane (0.75 μm2 for 1 mm probe) and 
F is flow rate.  
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To constrain the solution for C0, the mass transfer coefficient (K0) for the non-standard AA 
NorLeucine, (NLeu) was determined in vivo for each mouse
26
. Flow-rate experiments were 
performed twice: initially with aCSF perfusate, and repeated with aCSF +100 μM NLeu. K0 for 
NLeu vs. other AAs of interest was determined in vitro and found comparable. NLeu K0 for each 
mouse was applied for calculation of C0  of all other AAs using eqn 1 (Suppl. Fig. 2B).  
Microdialysis sampling during intraperitoneal AA injection or/and competitive inhibitors 
perfusion 
For experiments with AA IP injection mice were prepared for microdialysis as described, 
initially 3-4 control samples were collected (baseline), then vehicle (0.9% sterile NaCl) injected 
IP and 30 minute samples were collected at 1 µL/min for four hours. Half of the mice received 
1.3 g/kg of hGln IP and the other half 240.5 mg/kg Val IP. Samples were collected as before for 
four hours (Suppl Fig. 1C).  
For experiments with perfusion with competitive inhibitors, after baseline samples were 
collected for two hours, probes were perfused with aCSF + 20 mM methylaminoisobutyric acid 
(MeAIB) or 20 mM 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH). After a 40-minute 
equilibration with inhibitor (time until inhibitor has reached the microdialysis probe in the brain 
and then fraction collector), 30 minute samples were collected for three hours, then aCSF was re-
introduced into the probes, equilibrated for 40 minutes and sampling was resumed for 3-4 hours 
(Suppl Fig 1D). 
For simultaneous IP AA administration with inhibitor infusion, baseline samples were collected 
for two hours, probes equilibrated for 40 min perfusion with aCSF + 20 mM inhibitor.  
Following inhibitor equilibration, hGln (1.3 g/kg, in 0.9% NaCl) was administrated IP and 
microdialysate samples were collected for 2 hours. Following cessation of inhibitor perfusion 
probes were equilibrated with aCSF for 40 min and samples collected for 3 hours (Suppl. Fig 
1E).  
To calculate the total influx of Gln into the brain from the plasma following IP injection with 
heavy labeled Gln (hGln) the following calculation was used: (hGln /total Gln in microdialysis 
sample)/(hGln/total Gln in plasma) = total Gln influx to the brain from plasma.  
Organ and tissue collection 
Plasma collection  
At chosen time points ≈ 20 µl blood samples were collected from tail tip cuts into Na+-
heparinized microhematocrit tubes (Provet AG, Switzerland). Samples were centrifuged 
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(10000g, 10 min, 4°C) in heparin containing vials (B. Braun Medical AG, Sempach, 
Switzerland), frozen on dry ice, and stored at −80°C for measurement.  
Terminal CSF, plasma, and brain collection  
CSF samples were collected prior to terminal perfusion as previously described
27
. Briefly, mice 
were anaesthetized with IP ketamine (100 mg/kg) and xylazine (10 mg/kg), and an incision made 
in the skin inferior to the occiput. Under a dissection microscope, the dura mater of the cisterna 
magna was penetrated and CSF collected into a pulled glass capillary, frozen on dry ice, and 
stored at -80°C. CSF samples visibly contaminated with blood were discarded. 
Blood was drawn by cardiac puncture, transferred to heparin containing tubes, and centrifuged to 
separate plasma (10000g, 10 min, +4°C). Mice were transcardially perfused with ice-cold PBS 
(10 mM Na2HPO4, 2.5 mM NaH2PO4, 150 mM NaCl, 3 mM KCl, pH 7.4), brains harvested and 
cut into hemispheres. Left hemispheres were incubated in PBS with 4.0% PFA at +4°C 
overnight, and subsequently paraffin embedded for probe position verification, and right 
hemispheres were snap-frozen in liquid nitrogen and stored at −80°C. 
Amino acid measurements 
Ultra Performance Liquid Chromatography (UPLC) amino acid measurements 
The analysis of AA concentrations was performed at the Functional Genomic Center Zurich 
(FGCZ) using the Mass Track Amino Acid Analysis Application Solution by ACQUITY ultra 
performance  liquid chromatography (UPLC; Waters, Milford, USA) according to the 
manufacturer’s protocol. Microdialysis and CSF samples were analyzed without 
deproteinization, and plasma samples were diluted 1:1 with 10% sulfosalicylic acid (SSA) for 
deproteinization prior to UPLC.  
Mass spectrometry for heavy isotope labeled glutamine quantification 
Heavy labeled Gln (hGln) was detected in microdialysis and plasma samples by liquid 
chromatography mass spectrometry (LC-MS) using a Q Exactive Hybrid Quadrupole-Orbital 
Trap mass spectrometer (Thermo Scientific, USA) coupled with a nanoAcquity liquid 
chromatograph (Waters, USA). For quantification 2.5 μM of totally labeled glutamine (13C5
15
N2) 
was added as an internal standard (IS) to dialysate samples. After thawing, samples were diluted 
5-fold with 50 mM ammonium in acetonitrile - methanol 9:1, vortexed and analyzed 
immediately. For each independent set of samples, hGln and total Gln calibration curves (10, 5, 
2.5, 0.5 μM) containing 2.5 μM IS were measured. Quantification was calculated based on the 
response factor from calibration curves. 
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After precipitation with 10% SSA plasma samples were diluted 10 times with borate buffer (500 
mM, pH 9), precipitated with methanol 4:1 and analyzed as above. Baseline ratio of hGln/Gln 
measured by liquid chromatography mass spectrometry (LC-MS) before IP injection was 6.6 ± 
2% in plasma and 0.13 ± 0.3% in microdialysates. The higher baseline hGln levels detected in 
plasma may have been an artifact of the LC-MS analysis since the naturally occurring frequency 
of the 
15
N isotope is 0.1-0.5%
28
 LC-MS may have over-estimated hGln in plasma but not in 
microdialysis samples. 
Immunohistochemistry 
Paraformaldehyde-fixed brains were paraffin embedded (Shandon Xylene Substitute, 
Thermoscientific), 5 μm coronal sections prepared using a microtome (RM 2235, Leica) and 
stored at +4°C for staining. Nissl staining was performed for probe position validation. Paraffin 
sections were deparaffinized (Microm/Histocam AG, Thermoscientific) to 100% ethanol, 
extensively rinsed in water, and incubated 15 min in warm 2% cresyl violet. Excess cresyl violet 
was removed, sections dehydrated in 100% ethanol twice, and destained twice with xylene 
(Shandon Xylene Substitute, Thermoscientific). Nissl stained sections were imaged by a 
handheld USB digital Firefly GT800 microscope (Belmont, USA). 
Statistical Analysis 
Sample data were plotted at the collection midpoint and, as indicated, sample time was adjusted 
for the time required to reach the fraction collector from the probe and reported as “time in the 
brain” (Suppl. Fig. 1). 
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, USA). Unless 
otherwise stated between-group comparisons were performed by Students t-test or two-way 
analysis of variance ANOVA (two independent factors: treatment and time), followed by 
Dunnett, Bonferroni or Sidak post-test as stated. Statistical significance was accepted at P < 0.05 
or as indicated. All data are presented as mean ± standard deviation (SD) or mean ± standard 
error of the mean (SEM). 
Results 
Measurement of Hippocampal interstitial fluid amino acid levels 
Hippocampal ISF AA concentrations (C0) were extrapolated from microdialysis measurements 
using a method of extrapolation to “zero flow” (Flow-rate method, Methods, eqn (1))25. To reach 
a unique solution for C0, the mass transfer coefficient (K0) for each mouse was determined using 
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retro-dialysis of a known concentration (100 µM) of the L-leucine analog, Norleucine (NLeu), 
(Suppl. Fig. 2, Suppl. Tables 1 and 2). In vitro experiments verified NLeu K0 is comparable to K0 
for detected AAs (Suppl. Table 2). To test whether perfusion with aCSF depletes AA in the ISF, 
samples gathered at 1 µL/min on 3 – 4 sequential days were compared for eight mice from two 
experiments (Suppl. Fig. 3). Mean levels for 10 detected AAs did not decrease significantly over 
four days. (Suppl. Fig. 3A-E).  
Using the flow-rate protocol brain ISF concentrations (C0) of 14 standard and 2 non-standard 
AAs (measured by UPLC) were determined (Table 1). As previously reported, AAs were lower 
in CSF than in plasma (mean ≈ 11-fold lower)4. Although, as expected, Gln level in CSF was 
nearly as high as in plasma (Table 1). Additionally, AAs were significantly lower in ISF than 
CSF (mean ≈ 6-fold lower). For example, the branched neutral AA L-valine (Val) was 18 times 
lower in CSF than plasma and ISF level was a third of CSF concentration. Similarly, ISF Gln 
was a sixth of CSF value although in CSF it was 86% plasma level. Additionally, L-glutamate 
(Glu), like Gln was nearly as concentrated in CSF as in plasma (21 ± 4 vs. 37± 7 µM) while in 
ISF Glu was a sixth the CSF concentration (4.1 ± 0.3 µM). Gln was the most abundant AA in 
ISF (80 ± 16 μM) with the next most abundant AAs being L-lysine (10.2 ± 3.1 μM) and L-serine 
(9.8 ± 2.6 μM). Furthermore, taurine (Tau), the highest AA in plasma (735 ± 51 μM), was 9 
times lower in CSF (79.5 ± 8.6 μM) and 16 times lower in ISF (4.9 ± 0.9 μM) than CSF (Table 
1).  
ISF responses to large transient elevations in plasma levels of L-valine vs. L-glutamine  
We next tested how acute increases in the plasma concentrations of two LAT1 substrates, Val 
(Fig. 2A), and Gln (Fig. 2B) affected ISF levels. Mice were injected intraperitonealy (IP) with an 
amount of each of these AAs corresponding to ~200 times their amount in blood. Within 5 – 10 
minutes after IP injection with Val plasma levels significantly increased to 674 ± 259% of the 
control value (Fig. 2A). Similarly following Gln IP injection, plasma Gln increased to 381± 42% 
(Fig. 2B). Levels of all other AAs remained stable (data not shown) and IP injection of vehicle 
alone (0.9% saline) had no effect on Val or Gln levels (Fig. 2A, B). Additionally, following Val 
IP injection, Val levels in microdialysis samples rose rapidly to 395 ± 175% of baseline (25’ 
post-IP) (Fig. 2A). In contrast there was no significant increase of total Gln in microdialysates at 
any time after IP with Gln. Rather within one hour of Gln IP injection the non-significant trend 
was for decreasing ISF Gln levels (Fig. 2B). 
To test Gln transendothelial transport from the blood into the brain, Gln labeled with two heavy 
nitrogens (
15
N2) (hGln) was used for IP injections. Figure 2B shows total Gln in plasma and 
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microdialysates measured by UPLC. Additionally, total and labeled Gln in microdialysate and 
plasma samples collected after hGln IP were analyzed by liquid chromatography mass 
spectrometry (LC-MS) (Suppl. Fig. 4). Figure 2C shows a time course for percent hGln vs total 
Gln (hGln/Gln) in plasma and microdialysis samples. After IP injection ~2/3 of total plasma Gln 
(64 ± 2% baseline) was labeled, while in microdialysates hGln increased to only 3.8 ± 0.9% of 
total Gln (25’ post-IP) (Fig. 2C). Since following IP injection with hGln, 64% of the plasma Gln 
was labeled therefore, in total 1.6 Gln (labeled and unlabeled) must have been influxed to the 
brain from the plasma for every hGln recovered by microdialysis (1 / 0.64 = 1.6). This indicates 
post-IP injection approximately 6% of the Gln in the ISF originated from the plasma (0.04 hGln 
in ISF ∕ 0.6 hGln in plasma = 0.06 total Gln in ISF was from plasma). In plasma hGln decreased 
~10% in the first hour and after 3 hours ~30% of Gln was still labeled. hGln levels in the ISF 
were stable for one hour before being slowly cleared (Fig. 2C).  
Competitive inhibition of system L vs system A transporters in the brain 
To test the relative contributions of system A (SNAT1&2) vs. L (LAT1&2) transporters in 
regulating Gln in ISF, known competitive inhibitors for each transport system type were perfused 
into the brain through the microdialysis probe. The microdialysate concentrations were 
normalized to baseline and the time of collection corrected by the time required to reach the 
fraction collector. Figure 3A and B shows time courses before, during, and after perfusion with 
20 mM of the system A (SNAT1/2) inhibitor, methylaminoisobutyric acid (MeAIB) for the 
system A substrates glycine (Gly) and Gln, and non-substrates, Val and Tau
12, 29
. After 50 
minutes of MeAIB perfusion Gly increased 256 ± 90% while Val did not change significantly 
(105 ± 37%) (Fig. 3A). Whereas Gln levels exhibited unstable behavior, transiently peaking at 80 
minutes (219 ± 75%), returning to near baseline at 110 minutes, and rising again at 140 minutes 
(147 ± 35%) (Fig. 3B). After 140 min of perfusion levels of the osmolyte, taurine (Tau) also 
doubled (182 ± 48%). Following inhibitor removal all AAs returned to near baseline after 120 
minutes of aCSF perfusion.  
Figure 3C shows the time course pre-, during, and post-perfusion with 20 mM of the system L 
inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) for the system L substrates, 
Val and Gln, and non-substrates, Glu and Tau
30
. Within 50 minutes of BCH treatment levels for 
Val (515 ± 54%) and Gln (371 ± 27%) rose significantly vs. baseline (Fig. 3C). By 80 minutes of 
BCH Val plateaued at 579 ± 131% and Gln at 430 ± 134% of baseline (Fig. 3C, D).  However, 
unlike during MeAIB perfusion where Glu did not increase (data not shown), after 170 minutes 
of BCH treatment Glu significantly increased to 217 ± 102% of baseline. Tau remained stable 
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throughout the BCH perfusion (Fig. 3C). Removal of BCH by flushing with aCSF fully reversed 
AAs to baseline within 3 hours (Fig. 3C).  
Since the system N transporters (SLC38A3/SNAT3 and SLC38A5/SNAT5) are abundantly 
expressed in BBB endothelial cells and astrocytes (Fig. 1), a competitive system N inhibitor, 
glutamate-γ-monohydroxamate (GAH)31, was tested. Perfusion of 50 mM GAH rapidly elevated 
Gln to ~300% of baseline levels (at 20’), however as GAH perfusion increased all AAs, a non-
specific effect could not be ruled out (Suppl. Fig. 5 A, B). Additionally, both BCH and GAH 
perfusion increased GABA, which returned to baseline upon inhibitor removal. Since neither 
inhibitor acts on known GABA transporters (SLC6A1/GAT1 and SLC6A13/GAT3), the data 
indicate the possible involvement of system L and N transporters in GABA ISF homeostasis 
(Suppl. Table 3). Finally at no time did any of the competitive inhibitor perfusions produce 
observable behavioral abnormalities in mice.  
Combined system L competitive inhibition and heavy labeled glutamine intraperitoneal 
injection  
Next we tested if the elevated Gln observed during BCH treatment resulted from increased 
transendothelial transport (by LAT1) or was due to release from another brain cell type 
expressing system L (eg. astrocyte expressed LAT2). Therefore, BCH perfusion was repeated 
with hGln IP injection (Fig. 4A, B) and compared to BCH perfusion without IP injection (Fig. 
3C, D). Fifty minutes after BCH perfusion of the brain (25’ post-hGln IP injection) total Gln 
increased significantly to 727 ± 238% in animals with hGln IP injection vs. 371 ± 27% for mice 
treated with BCH alone (Fig. 4A, 3C). The increase in Val after 50 min BCH perfusion and hGln 
IP injection (25’ post-hGln IP injection) was approximately half that with BCH alone (242 ± 
161% vs 515 ± 54%, respectively) (Suppl. Fig. 6A). As measured by LC-MS 25’ after hGln IP 
injection (i.e. 50’ after of brain perfusion with BCH), 50 ± 19% of the total microdialysate Gln 
was 
15
N2 labeled, indicating that 83% of the Gln in the ISF came from the plasma (0.53 ISF hGln 
∕ 0.64 hGln plasma). Therefore, 600% of the 730% increase in baseline Gln in the ISF came from 
the plasma (7.3 Χ 0.83) (Fig. 4B). In contrast, after 50 minutes of MeAIB perfusion + hGln IP 
injection (25’ post-hGln IP injection) no hGln was detected in microdialysis samples and at 80 
min MeAIB (55’ post-hGln IP) hGln was 0.06 ± 0.007% of total Gln vs 2.5 ± 0.4% in mice 
receiving hGln IP alone (Suppl. Fig. 6B). 
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Discussion 
Hippocampal interstitial fluid amino acids are significantly lower than in cisterna magna 
CSF indicating distinct regulation. Here we report results of a quantitative determination of 
brain ISF AA concentrations in awake, freely-moving mice. Brain concentrations were 
determined by extrapolation of hippocampal microdialysate concentrations to original ISF values 
at zero flow rate. Importantly the extrapolation to C0 was constrained by determination of the 
mass transfer coefficient K0 using the non-standard amino acid NLeu. This control was missing 
from previous studies. Consistent with previous reports steep concentration gradients from 
plasma to CSF for 16 AA (except Gln as previously reported) were observed. In addition we 
measured decreased AA concentrations in ISF vs. CSF (Table 1). For example, we measured 80 
±16 μM Gln in ISF. However, in comparison Kanamori and Ross reported 385 μM Gln in 
striatum of awake rats
5
 and Lerma and coworkers measured 190 μM in hippocampus of 
anaesthetized rats
6
. Although there are many differences between the study protocols used by us 
and others eg. physiological state (awake vs. anesthetized, fed vs. food restricted), or brain region 
(striatum vs. hippocampus), or species (mouse vs. rat) tested; the most important factor 
contributing to the discrepancies may be limitations of the measurement methods.  
In general ISF solutes have been measured by either sensor or sampling (either direct or by 
microdialysis) methods
26
. Sensor detection methods, unfortunately, are only applicable for a few 
analytes while sampling can be used to broadly screen multiple substances (such as AAs). Direct 
sampling either involves a “push-pull” method or a very low flow extraction32, 33. Microdialysis, 
while lacking the temporal sensitivity of sensor detection mitigates the tissue damage inflicted by 
the “push-pull” method of pumping fluid into to the brain to extract samples. Instead fluid is 
perfused through a semi-permeable microdialysis probe to extract brain solutes
26
. Due to 
technical limitations most microdialysis studies avoid reporting quantitative data instead 
normalizing results from experimental manipulations relative to baseline controls. However, two 
accepted methods for quantification “no-net-flux” and the “extrapolation to zero-flow” (or 
“Flow-rate”) have been developed26. The “no-net-flux” method requires a series of perfusions 
with different concentrations of the substance of interest. The brain concentration is determined 
as the concentration of the target for which no net exchange occurs during perfusion into the 
brain. Disadvantages of this method for measuring AAs are each AA concentration must be 
determined individually, and infusing AAs into the brain may trigger alterations in both brain 
levels and relative recovery 
26
. Our study and both referenced studies used the “Flow-rate” 
method. The “Flow-rate” method determines C0 (brain concentration) based on the inverse 
relationship between flow rate and mass transfer and is applicable to multiple solutes 
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simultaneously (see Methods eqn (1)). The Flow-rate method algorithm extrapolates a set of 
microdialysis data to C0, however, without constraining the mass transfer coefficient, K0, C0 does 
not resolve to a unique solution. Therefore, we, unlike the previously cited groups, used retro-
dialysis of a non-natural L-leucine analog, NLeu, to determine K0 in vivo allowing an 
unequivocal solution to C0 for ISF AAs
26
. 
A second commonly raised issue with microdialysis studies is the creation of “an area around the 
probe in which all solutes capable of crossing the probe membrane are depleted”26. For most 
experiments a perfusate flow rate of 1 µL/min was used, which yielded a relative recovery of ≈ 
10 – 20% for 1 mm probes. We examined the possible ISF depletion by comparing relative 
recovery over the first several days of microdialysis collection at 1 µL/min. Representative 
results show that mean levels of individual AAs (except proline and alanine) remained stable for 
all four days of  microdialysis (Suppl. Fig. 3A). For most mice mean levels of the sum of the 
AAs also remained stable or were only modestly changed on day 2 with only one mouse showing 
an significant change (p = 0.01) whereas by day 3 almost half of the mice had somewhat elevated 
total AA levels (p= 0.1) relative to day one (Suppl. Fig. 3B). For Gln levels were generally stable 
with only one mouse showing a trend to increasing AA levels by the fourth day (Suppl. Fig. 3C). 
Val levels were somewhat more prone to be elevated on day 2 though none of the differences 
was staticially significant (Suppl. Fig. 3D). Tau has been suggested to be a marker for ISF 
osmolality and the generally stable levels suggest no major disturbances in ISF osmotic balance 
occurred over multiple days of microdialysis for most mice (Suppl. Fig 3E). The slight increases 
in AAs observed may be due to a trauma layer surrounding the probe causing gliosis (glial 
activation and proliferation) and/or ischemia (interrupted blood flow)
26
. In our study mice, whose 
levels were significantly lower or higher relative to mean (>2 SD) were excluded. Additionally, a 
2011 study by Jaquin-Gerstl and coworkers found that although dexamethasone significantly 
reduced gliosis and ischemia, it had only minor effects on dopamine quantitation over several 
days of microdialysis in comparison to untreated control animals. These data suggest gliosis had 
a minimal impact on solute recovery during microdialysis
34
. Furthermore, Kennedy and 
colleagues reported ISF levels for some AAs using a refinement of the direct sampling method. 
They used 90 µm probes with 1-10 nl/min extraction rates to avoid the need to perfuse fluid into 
the brain for extraction of samples (“push-pull”). They found somewhat lower values than 
reported here for striatal ISF from anesthetized rats for Glu (1.8 µM) and Gly (5 µM)
33
 vs. 4 and 
8 µM, respectively, measured in the current study (Table 1)
 33 34 35 35 34 35
. Moreover recently, a 
low flow “push-pull” study by Slaney and co-authors reported ISF levels of 8.5 µM Glu and 7.2 
µM Gly in the midbrain (ventral tegmental area (VTA)) of awake, freely-moving rats
32
. 
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Therefore, our findings of low ISF AA levels are supported by both our carefully controlled 
study protocol (including the in vivo determination of K0) and the consistent literature reports 
from direct sampling data available for several AAs.  
L-glutamine but not L-valine ISF levels are strongly buffered against large acute plasma 
increases. Intraperitoneal injection of Val with an amount corresponding to ≈200 times the 
quantity present in plasma causes a rapid and significant increase in plasma (≈600%) and ISF 
Val (≈400%) (Fig. 2A). This is consistent with published data in which Val IP injection 
increased levels ≈4 – 5 fold in brain tissue and ISF, and 8.5 fold in CSF35 and is expected to be 
mediated by Lat1, which transports Val with high affinity (Km ~50 μM)36. In contrast, hGln IP 
injection significantly raised Gln levels in plasma (~tripled), but not ISF, and resulted in only 
≈4% enrichment of hGln in ISF (Fig. 2BC). Similarly, Bagga and coworkers recently reported 
that 3 minutes of [U-
13
C5]-Gln infusion did not increase total cortical Gln and Gln-C4 
13
C 
enrichment was ≈2%37. In our experiments the increase of Gln transport was low and transient, 
which may be in part due to the low affinity of the blood-brain barrier expressed Gln 
transporters, Lat1 and Snat3 that have Km values on the order of the plasma Gln concentration 
post-IP injection (1 – 2.3 mM). Additonally Gln transported from plasma may be sequestered in 
the endothelium and only slowly released abluminally, and/or transported into ISF and 
subsequently sequestered in the brain by another cell type e.g. astrocytes.  
LAT1 transporter regulates ISF influx of plasma Gln. The potential contributions of system 
A and L transporters in ISF regulation were addressed using brain perfusion with MeAIB or 
BCH, respectively. Following MeAIB perfusion total ISF Gln is only transiently significantly 
elevated and then rebounds to near baseline (Fig. 3B). However the system A substrate, Gly, is 
sustainably increased in ISF (Fig. 3A). Both SNAT1 and SNAT2 transport MeAIB, Gln, and Gly 
with similar affinities (MeAIB Km of SNAT1, 1.1 mM, and SNAT2, 0.5 mM; Gln Km of SNAT1, 
0.3 mM, and SNAT2, 1.7 mM; Gly Km of both SNAT1&2 ~0.5 mM)
12, 38
. Roughly at 
equilibrium, extraction of MeAIB from the 20 mM perfusate corresponds to 2 – 4 mM, which 
represents a large excess relative to its Km (for SNAT1 and SNAT2) and the concentrations of 
Gln (80 µM) and Gly (8 µM) in the ISF. Therefore, it is consistent with a greater relative 
competition of Gly than Gln transport. However this does not account for the “ping-ponging” of 
Gln ISF levels during MeAIB perfusion (Fig. 3B). Gln rebounding to baseline may be due to an 
unknown compensatory mechanism to restore ISF Gln (but not Gly) homeostasis. Figure 1 
shows that Gln is transported by a number of highly expressed AATs in the neurovascular unit 
including LAT1, SNAT1&2, and SNAT3&5, of which LAT1 and SNAT3 selectively transport 
Gln and not Gly 
12, 31, 39
. Finally, IP injection of Gln in combination with BCH results in a 
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significant increase of total ISF Gln from no net increase in the absence of BCH, to ~400% for 
treatment with BCH alone, to over ~700% baseline levels for IP injection in combination with 
BCH treatment (Fig. 4A). Further, BCH in the presence of increased circulating peripheral hGln 
dramatically stimulates net Gln transendothelial transport from the plasma to the ISF 
approximately 100-fold, ie. total Gln influx increased from ≈6% (IP injection without BCH 
perfusion) to ≈600% (IP injection with BCH perfusion) (Fig. 4B). Since, SNAT3 does not bind 
BCH, the data indicate LAT1 can mediate large changes in Gln influx from the plasma. This 
strong effect of BCH may be accomplished by driving the transendothelial transport of Gln from 
the blood into the ISF via transstimulation of LAT1 exchanger expressed in endothelial cell 
membranes. Indeed, he high BCH concentration in ISF could transstimulate Gln transport from 
the endothelial cells into the ISF. And BCH thereby accumulating in the endothelial cells would 
in turn transstimulate the uptake of Gln from the blood into endothelial cells. This hypothesis is 
consistent with a key role for the endothelial BBB expressed LAT1 in regulating Gln ISF 
homeostasis.  
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Titles and legends to figures 
Figure 1. Diagram of glutamine transporters expressed in neurovascular unit cells. The 
abbreviations used for the transporters are: ASCT2 (SLC1A5), B
0
AT2 (SLC6A14), LAT1 
(SLC7A5), y
+
LAT2 (SLC7A6), y
+
LAT2 (SLC7A7), LAT2 (SLC7A8), SNAT1 (SCL38A1), 
SNAT2 (SLC38A2), SNAT3 (SCL38A3), SNAT5 (SLC38A5). Expression levels are indicated 
by box borders with thick borders = high, thin solid borders = moderate, and thin dotted borders 
= low expression. BCH-sensitive system L transporters are represented by grey boxes and the 
system A transporters sensitive to MeAIB by dotted boxes. The data are based on in vivo and in 
vitro studies 
2, 3, 12-23, 40
. 
Figure 2. Plasma and brain interstitial fluid amino acid responses to intraperitoneal 
injection of L-valine or L-glutamine.  
The amount of each amino acid (AA) injected intraperitoneal (IP) in mg/kg body weight 
corresponds to ≈200 times total measured amount in plasma (concentration ˣ blood volume). A. 
Impact of L-valine (Val) IP injection (240 mg/kg Val or 0.9% NaCl vehicle (veh)) on plasma and 
interstitial fluid (ISF) Val concentration (mean ± SD from 4 animals). B. Impact of heavy labeled 
L-glutamine (hGln) IP injection (1.37 g/kg of 
15
N2 labeled Gln (hGln) vs. 0.9% NaCl vehicle 
(veh)) on plasma and ISF hGln concentration (mean ± SD from 4 animals). C. Ratio of hGln to 
total Gln (hGln/Gln) in plasma and ISF, as measured by liquid chromatography mass 
spectrometry (LC-MS). Data are presented as mean ± SEM for microdialysates from 3 
independent experiments (n=10 total mice) and mean ± SD for plasma from 1 experiment (n=4). 
For all experiments, baseline samples are indicated by solid lines and arrows indicate the time of 
AA IP injection. Statistical analysis was performed by two-way Anova with Dunnets post-test 
and statisticaly significant changes relative to baseline are indicated as: #### = p<0.0001 and ## = 
p<0.01; **** = p< 0.0001 and   ** = p<0.01. 
Figure 3. Impact of brain perfusion of system A and L competitive inhibitors on amino 
acids in brain microdialysates. Competitive inhibitors (20 mM) were introduced in the brain by 
perfusion via the microdialysis probe (as indicated by the grey area) for 3 hours. For each panel 
the indicated amino acid responses in ISF are plotted normalized to baseline values vs time in 
brain (adjusted for the time samples take to reach fraction collector). In panel A, Glycine (Gly), 
L-valine (Val) and in panel B, L-glutamine (Gln), taurine (Tau) responses as a result of 20 mM 
methylaminoisobutyric acid (MeAIB) brain perfusion. Data are mean ± SD from 3 animals. C. 
Val, Gln, L-glutamate (Glu) and Tau concentrations as a result of brain perfusion of 20 mM 2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH). Data are means ± SD from 4 animals. D. 
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Gln levels in ISF normalized to the mean baseline values prior to MeAIB or BCH perfusion, 
respectively, and compared to Gln levels at 50 and 80 minutes of perfusion with the indicated 
inhibitor. For all panels, baseline samples are indicated by the solid line. Perfusate equilibration 
without sample collection is indicated by the break in the X axis (time in brain). Inhibitor 
presence in perfusate is indicated by the shaded area of the graph and underlined X axis region. 
Statistical comparisons were performed by two-way Anova with Dunnets post-test for the 
comparision of values obtained with inhibitor versus baseline (A, B, C) and  with Bonferroni 
post-test for the comparison of values obtained with different inhibitors and with baseline (D). 
Tracked amino acids are indicated in the individual panel keys. Statistical significance for all 
panels are:  **** = p< 0.0001, *** = p<0.001, ** = p<0.01, and  * = p<0.1; #### = p< 
0.0001, ##  = p<0.01 and #  = p<0.1; $$$$ = p< 0.0001 and $ = p<0.1. 
Figure 4. Interstitial fluid total and labeled L-glutamine concentrations following brain 
perfusion with BCH without or with labeled hGln intraperitoneal injection.  
A. ISF Gln levels are plotted relative to baseline for samples collected before, during, and after 
20 mM (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) brain perfusion alone (data 
from Fig. 3B) or in combination with hGln intraperitoneal (IP) injection. Data are mean percent 
relative to baseline ± SD from 4 animals (BCH + IP). See panel for key. Vertical arrow indicates 
the time of hGln IP injection.  Data were compared by two-way Anova with Sidak post-test. 
Statistical significance indicated as *** = p<0.001 for comparison of treatments with each 
other. B. Labeled Gln (hGln) as percent (%) of total Gln (hGln/Gln) in microdialysate samples. 
Samples were collected 25 minutes post hGln IP injection in the absence (data from Fig. 3C) or 
in the presence of BCH perfusion (at 50’ of BCH perfusion, corresponding to 25’ post-IP 
injection of hGln) (panel A). Data were compared with unpaired t-test and statistical significance 
indicated as **** = p<0.0001. 
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Table 1. Mouse brain interstitial fluid, cerebrospinal fluid, and plasma amino acid concentrations 
and ratios. 
 1Concentration (µM ± SEM) Ratio 
Amino acid  2ISF 3CSF Plasma ISF/plasma CSF/plasma 
Nitrogen rich 
Glutamine (Gln) 80  ±163 517 ± 20 598 ± 29 0.13 0.86 
Asparagine (Asn) 1.4 ± 0.4 8.2 ± 2.4 68 ± 17 0.02 0.12 
Straight chain 
Alanine (Ala) 9.3 ± 1.4 57 ± 0.7 408 ± 24 0.02 0.14 
Serine (Ser) 9.8 ± 2.6 37 ± 2.3 109 ± 6.5 0.09 0.34 
Glycine (Gly) 7.8 ± 1.2 34 ± 7.9 246 ± 11 0.03 0.14 
Proline (Pro) 1.8 ± 0.2 4.2 ± 0.7 60 ± 1.7 0.03 0.07 
Threonine (Thr) 3.5 ± 1.0 22 ± 2.3 113 ± 6.4 0.03 0.19 
Branched chain 
Valine (Val) 2.9 ± 0.7 9.4 ± 1.0 173 ± 11 0.02 0.05 
Leucine (Leu) 1.5±0.1 6.6 ± 0.2 127 ± 11 0.01 0.05 
Aromatic 
Tyrosine (Tyr) 0.7 ± 0.1 7.2 ± 1.2 54 ± 6.1 0.01 0.13 
Basic 
Histidine* (His) 1.2 ± 0.2 8.9 ± 0.7 59 ± 3.6 0.02 0.15 
Lysine (Lys) 10 ± 3.1 46 ± 0.9 321 ± 35 0.03 0.14 
Arginine (Arg) 3.2 ± 0.7 18 ± 2.3 103 ± 9.5 0.03 0.17 
Acidic 
Glutamate (Glu) 4.1±0.3 21.3±4.0 37.3±6.7 0.11 0.49 
Non-proteinogenic 
Taurine (Tau) 4.9 ± 0.9 80 ± 8.6 735 ± 51 0.01 0.11 
Ornithine (Orn) 0.9 ± 0.2 3.4 ± 0.5 53 ± 8.1 0.02 0.06 
 
1Values are given as mean micromolar (µM) concentration ± standard error (SEM.) of n mice from x 
independent experiments: Plasma, n=40, x=5; CSF, n=17, x=3; ISF, n=12, x=4; 2CSF, cerebrospinal fluid; 
3ISF, interstitial fluid; 
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Supplementary Figure 1. In vivo microdialysis experimental protocols. A. Diagram of the in vivo microdialysis 
tubing set-up. Starting from the syringe pump containing the perfusion buffer there are three pieces of FEP tubing 
(numbered 1-3) with corresponding lengths of 30, 70 and 100 cm. I indicates the  microdialysis probe inlet FEP 
tubing (10 cm length), O is the probe FEP outlet (15 cm length), V is the valve, FC is the fraction collector. The 
respective volumes are: 1) the FEP tubing volume 1.2 μl/10 cm, 2) the probe inlet and outlets are each 3.6 μl, 3) the 
probe shaft is 1 μl, and 4) the probe membrane is 0.045 μl. The volumes were used to calculate the “time in brain” or 
the time each sample reaching the fraction collector was in the brain. For each experiment the sample mid-point of 
the “time in brain” was graphed. B-E show the microdialysis schedules used for: B) flow-rate, C) intraperitoneal (IP) 
AA injection (Val or hGln), D) brain perfusion with competitive inhibitors (BCH or MeAIB), and E) combined 
perfusion with competitive inhibitors (BCH or MeAIB) and hGln IP injection experiments. For each scheme the 
sample number is indicated. For the flow-rate studies (B) the flush (grey box) indicates the equilibration period at the 
subsequent perfusion flow rate. For the inhibitor perfusions there was a 40 minute equilibration prior to- and 
following perfusion with inhibitor to allow the first sample either with or without inhibitor (respectively) to reach the 
fraction collector.  For all experiments 30 µl samples were collected. For C-E the sample perfusion rate was 1 µl/min 
and the collection time was 30 min per sample.  
A 
baseline 
0.9% NaCl hGln 
C 
baseline 
1 
inhibitor 
40 min  
equilibration 
D 
E 
Insertion of probe 
connection to pump 
18 hour flush 
flush 
1 2 3 4 5 6 7 8 
1 µl/min 2 µl/min flush flush 0.5 µl/min flush 0.1 µl/min 
B 
Sample no. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
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1 
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Supplementary Figure 2. Calculation of brain interstitial fluid amino acid concentrations by extrapolation to 
zero flow (Flow-rate) method. To calculate the brain interstitial fluid amino acid concentrations the mass transfer 
coefficients (K0) for individual mice were experimentally determined.  The in vivo K0  were determined using 
retrodialysis of 100 µM (CPER) of the non-standard amino acid Norleucine (NLeu) at 0.1, 0.5, 1, and 2 μl/min. Percent 
Nleu transferred (CL ) from microdialysate samples was quantified and values fit with the equation CL=CPER-
[CPERexp(-K0A/F)], where A is probe area, and F is flow rate. A. shows representative flow rate results for individual 
mice from a single experimental determination of NLeu K0 for three mice. Both the mean (± SD) for the loss of NLeu 
and the extrapolation curves for individual mice are shown as indicated.  B. shows a representative experimental Gln 
concentration determination for four mice based on eqn 1 with constraint to experimentally determined NLeu K0 
values for each mouse. Both the mean (± SD) Gln microdialysate concentrations and the extrapolations for the 
individual mice are shown. C. shows a comparison of AA mean µM ± SD concentrations determined from two 
independent experiments using individually measured in vivo K0 values, n = 3 – 8 (depending on AA) animals. 
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Supplementary Figure 3. Comparison of amino acid levels in 
microdialysis samples. Amino acid levels in 1 μl/min samples 
collected from eight mice during three or four (depending on the 
experiment) consecutive days were normalized to day 1 levels for 
comparison. A. Levels of each AA on days 2-4 were normalized 
to day 1 and presented  are means ± SEM for 8 mice from two 
independent experiments. B. Concentration of each measured AA 
was normalized to the corresponding level on the day 1 
individually, these values were summed up for each mouse on 
each day and plotted on the graph. Data presented as mean (± 
SD), when several 1 ul/min fractions were collected on the same 
day. Panels C, D, E show the normalized (to day 1) levels of Gln 
(C), Val (D) and Tau (E) in microdialysis samples for eight mice. 
n=4 for each of two independent experiments. Levels of 
individual AAs normalized to day 1 on 3-4 consecutive days of 
mD experiment were compared between each other (A) as well as 
the total AAs concentration normalized to day 1 for each mouse 
was compared within days 2-4 of mD (B). Statistical analysis was 
performed using two-way Anova with Tukeys post-test (A, B). 
Statistical significance are **** = p<0.0001, **= p<0.01, * = 
p<0.1. 
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Supplementary Figure 4. Representative liquid chromatographs and mass spectra of glutamine and heavy 
labeled glutamine isotopes 15N2 and 
13C5
15N2.  For each sample, the representative liquid chromatographs (upper 
panel) and mass spectra (lower panel) of glutamine and the 15N2 and 
13C5
15N2 heavy labeled glutamine isotopes are 
shown. A. analysis of a representative plasma sample collected following 15N2-Gln intraperitoneal (IP) injection and 
with 13C5
15N2-Gln added as an internal control are shown. B. analysis of a microdialysate sample collected after 
15N2-Gln  IP injection and with 
13C5
15N2-Gln added as an internal control  
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Supplementary Figure 5. Impact of brain perfusion with a system N competitive inhibitor 
on amino acid levels in microdialysates. The effect of competitive inhibition of system N 
transporters was tested using brain perfusion with 50 mM L-glutamic acid-γ–monohydroxamate 
(GAH) for 3 hours. For each panel the indicated amino acid responses in ISF collected at 1 µl/min 
and normalized to baseline vs time in brain (adjusted for the time for samples to reach the fraction 
collector) are shown. A. L-glutamine (Gln) mean ± SD responses before, during and after brain 
perfusion with GAH. Statistical comparisons was performed by two-way Anova with Dunnets 
post-test and statistically significant differences to baseline are indicated: **= p<0.01, and  *= 
p<0.1. B. Percent baseline for Ala (L-alanine), Gly (Glycine), His (L-histidine), Ser (L-serine), 
Tyr (L-tyrosine), Val (L-valine) and Tau (Taurine). For both panels, data are from three animals 
from one experiment. Baseline samples are indicated by the label and solid line. Perfusate 
equilibration without sample collection is indicated by the break in the X axis (time in brain). 
GAH perfusion is indicated by underlined X axis region with label, and the shaded area of the 
graph.  
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Supplementary Figure 6. Interstitial fluid total amino acid concentrations following brain 
perfusion with inhibitor without or with labeled hGln intraperitoneal injection. A. ISF Val levels 
relative to baseline for samples collected before, during, and after 20 mM (2-aminobicyclo-(2,2,1)-
heptane-2-carboxylic acid (BCH) perfusion either alone (n = 4 animals) or in combination with hGln 
intraperitoneal (IP) injection (n = 4 animals). Data are mean percent ± SD. See panel for key. 
Comparison was performed between two types of treatment  by two-way Anova test with Sidak post-
test. B. Labeled Gln (detected by LC-MS) as percent (%) of total Gln (hGln/Gln) in microdialysate 
samples at 30 minutes post-IP alone (data from Fig. 3C) vs. IP + MeAIB (α-(methylamino)-isobutyric 
acid) perfusion (at 55’ of MeAIB perfusion, corresponding to 30’ post-IP). Data are mean ± SEM (IP 
alone, n = 10 animals in total, from three independent experiments; IP + MeAIB, n = 2 animals). 
Comparison was performed by un-paired two-sided t-test.  
For both panels, statistical significance is given as **** = p<0.0001, *** = p<0.001, **= p<0.01, * = 
p<0.1. 
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Supplementary Table 1. The in vitro microdialysis relative recovery of amino acids. The in vitro 
relative recoveries from microdialysis of 100 µM amino acids at 1 µl/min flow rates were determined 
for CMA 7 probes (1 and 2 mm lengths). Data are expressed as mean percent (n=2 for each of two 
independent experiments). 
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Supplementary Table 2. In vitro microdialysis amino acid mass transfer coefficients (K0) of CMA 7 
probes. In vitro amino acid mass transfer coefficients (K0) of CMA 7 probes (2 mm) were calculated by 
the Flow-rate method using perfusion flow rates of 0.2, 0.5, 1, and 2 µl/min and an initial concentration 
of 100 µM per amino acid. Data are expressed as mean K0 ± SD. Data is for n=2 from one experiment.  
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Supplementary Table 3. Concentrations of the inhibitory neurotransmitter, GABA, in 
microdialysis samples from brain perfusions with BCH or GAH competitive inhibitors. GABA 
concentrations (µM) in microdialysis samples collected pre-, during, and post- brain perfusion with 20 
mM BCH or 50 mM GAH at perfusion rates of 1 µl/min. Time of perfusion with inhibitor is indicated by 
bold font and grey shading. Data is for n = 4 (BCH) or n = 3 (GAH) mice for one experiment per 
inhibitor. BCH (2-amino-bicyclo-(2,2,1)-heptane-2-carboxylic acid), GABA (γ-amino butyric acid), 
GAH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid). 
Supplementary material p9. Dolgodilina, et al. 2015 
5. Manuscript
98
  
6. Discussion and outlook 
In this work existence of an AA concentration gradient between CSF and the brain ISF was 
demonstrated. Next we focused on investigation of responses in AA levels in the brain ISF to 
different challenges in order to study the roles of AATs in homeostasis. The transendothelial 
transport of glutamine and valine across the BBB after bolus IP administration was shown. For 
valine, a rapid statistically significant comparable response in both plasma and the brain ISF was 
observed. However, the acute increase in Gln plasma concentrations did not result in elevation of 
Gln in the ISF. Using hGln the presence of this isotope in mD samples collected after IP 
injection was demonstrated. Moreover, inhibition of system A and system L in vivo via perfusion 
into the brain of the competitive inhibitors MeAIB and BCH, respectively, resulted in elevation 
of Gln in the brain ISF. However, the response was more significant and stable for BCH than for 
MeAIB application, yielding 4.3 vs 2.2 fold increases, correspondingly. Furthermore, by 
simultaneous administration of system L inhibitor with bolus IP injection of hGln increased Gln 
influx from periphery into the brain ISF was observed. Taken together, these data support 
significant role for system L in the in vivo regulation of Gln in the brain ISF. System L includes 
LAT1, LAT2, LAT3, and LAT4 transporters, among which LAT1 expression is the highest in 
the BBB vs other tissues. Thus, based on expression data from different cells in the CNS and 
localization on both BBB membranes LAT1 might be a key player in Gln homeostasis for the 
brain ISF. Unfortunately, the attempt to localize SNAT5 in the BBB was inconclusive and this 
aspect of the project highlighted some limitations of antibody-based methods. A clarification of 
the role of other Gln transporters expressed in the BBB, in particular of the system N 
transporters SNAT3 and SNAT5, as well as their function in other cells in the brain (astrocytes, 
neurons) is necessary for understanding homeostatic regulation not only in the brain ISF, but 
also in the brain in general. 
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be truncated [441]. We consider that this model will allow investigation of the role of SNAT3 
expressed in the BBB and in astrocytes for regulation of Gln homeostasis in the brain ISF.  
First of all, the efficiency of SNAT3 gene abolishment in the BEC cells must be characterized, 
since this process is tamoxifen-dose and age dependent [441]. Next, the generated model can be 
characterized in terms of AA levels in the brain ISF and efficiency of transendothelial Gln 
transport as compared to wild-type animals. In addition, transport of AAs such as glycine and 
histidine across the BBB can be tested. These AA are lower affinity substrates for SNAT3 than 
SNAT5 and if SNAT3 is eliminated from the BBB, then the detection of elevation of these AA 
levels in the brain ISF would be indirect evidence of SNAT5 function in the BBB. Moreover, 
our preliminary in vivo test of L-glutamic acid-γ-monohydroxamate (GAH) resulted in the 
significant elevation of Gln in the brain ISF. Previously, this AA analog was shown to inhibit 
Gln transport in oocytes expressing SNAT5 [352]. Therefore, we assume that comparative 
analysis of changes in Gln level in the brain ISF under application GAH in wild-type versus 
SNAT3fl//fl VeCadCreERT2+//-animals might provide information about the relative 
importance of SNAT3 and SNAT5 in this regulation.  
Since SNAT3 is abundantly expressed not only in the BBB, but also in astrocytes we decided in 
parallel to generate a mouse model, in which SNAT3 expression is eliminated in astrocytes. 
Thus, we crossed available SNAT3 floxed animals with FVB,129-TG(GFAP-CreER)Fki 
generated in the lab of Frank Kirchhoff and kindly provided for our research by Prof. Isabelle 
Mansuy. Interestingly, a correlation between elevation of K
+
 and Glu in the brain interstitial 
fluid resulting from concussive brain injury has been shown [442]. However, no data were 
provided for Gln concentration under the same conditions. SNAT3 transporter expressed in 
astrocytes is considered to be an important player in glutamate/GABA-glutamine cycle. 
Temporal elevation of K
+
 via mD probe during the experiment causes neuronal depolarization 
and increase of neuronal activity and as a result release of Glu from glutamatergic neurons. 
Excess of Glu has to be taken up by astrocytes and transformed into Gln that is then thought to 
be released via SNAT3 and SNAT5 transporters and consumed by neurons for Glu synthesis 
[273]. Therefore, we consider that the described experiments performed in our SNAT3fl//fl 
GFAP-CreER +//- knockout animal model may be essential for the investigation of changes in 
ISF neurotransmitters (Glu, GABA) as well as other AAs (Gln).  
We consider that the comparative analysis of the two mouse models that lack SNAT3 expression 
in the BBB or in astrocytes will help clarify the role of this AAT for Gln homeostasis in brain 
ISF. 
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6.1. Discussion 
6.1.1 Methods of ISF measurements 
Brain ISF is the direct microenvironment for the cells in the brain and is mainly produced by the 
BBB. It has an estimated volume of only ~18-20% of total brain volume [109]. Its small volume 
and distribution throughout the brain is an obstacle for gaining information about its qualitive 
and quantitative content. Several methods have been developed for measuring the chemical 
content of the brain ISF in vivo and applied in neurobiology, physiology and pharmacology. One 
of the first developed methods was a cortical cup technique, when a small cylindric cup was 
fixed to an exposed cortical surface of an anesthetized animal [416]. This technique allowed 
measurement of the release of acetylcholine, AAs, and nucleosides. However it’s application 
was restricted to the cortex. A similar approach is used in the push-pull method that is based on 
the implantation of a cannula in the brain and subsequent simultaneous delivery (push) and 
removal (pull) of perfusion fluid [416]. Thus, in this case substances diffuse between brain ISF 
and perfusion fluid. This method was successfully used for studies of neurotransmitters, 
peptides, and proteins. However, one of the most important limitations of the technique is the 
requirement for equilibrium between delivered and extracted volumes of fluid, otherwise it 
might lead to severe lesions. Moreover, initially relatively high rates of perfusion were used. As 
a result, for a while this method was mainly replaced by other techniques. However, the design 
of a capillary push-pull cannula with a tip diameter of ~200 µm and the use of low flow rates 
reduced tissue damage. It has regained use due to its high spatial resolution [417-419]. A third 
method is an in vivo voltammetric technique, when a small electrode is implanted in brain tissue, 
and the voltammetric curve corresponds to the chemical detected at the surface of the electrode 
[420]. This technique gives high temporal (time of detection depends on substance diffusion and 
the response time of electrode) and spatial resolution (the size of targeted area corresponds the 
electrode diameter 10-20 µm) [421]. However, an essential disadvantage of the method is the 
limited number of individually detectable chemicals and generally only one compound can be 
detected by each microelectrode. Additionally, different compounds that are electrolyzed at 
similar potentials result in the same responses and cannot be distinguished. For example, the 
fast-scan cyclic voltammograms of dopamine and norepinephrine are identical [421]. Today 
microdialysis (mD) is a well-established technique widely used in neuroscience research and 
drug development. However, as any of already mentioned methods it has benefits and 
limitations. This technique has such important advantages as minimal invasiveness and 
continuous sampling from brain ISF [422]. Microdialysis is a good tool for qualitative 
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determination of relative changes in substance levels as a result of experimental manipulations. 
Additionally the semipermeable probe membrane allows application of compounds of interest 
into the brain tissue. However, one of the main limitations of mD is a low temporal and spatial 
resolution [422]. The longer mD samples are collected, the higher concentration of brain solutes 
in the recovered dialysates. However, long collection periods also decrease detection of rapid 
changes, for instance, neurotransmitter release. Another important issue is that the probe-specific 
relative recovery of different solutes impacts the estimation of solute concentration in the brain 
ISF. Nevertheless, methods for quantification (extrapolation to zero flow rate (or flow-rate 
method), no-net-flux, retrodialysis, etc.) have been developed [423].  
6.1.2 Concentration gradient for amino acids between ISF and CSF 
Taking into account the advantages and disadvantages of currently used methods for 
quantification of substances in the brain ISF, mD was chosen for determination of AA levels in 
the brain ISF. The extrapolation to zero flow rate method with retro-dialysis of a non-natural AA 
for determination of the corresponding mass transfer coefficient was used to calculate a unique 
value for initial brain AA concentrations. To our knowledge this work is the first demonstration 
of concentration gradients between ISF and CSF for 14 standard and 2 non-standard AAs. 
Moreover, we confirmed Gln to be the most abundant AA in the brain ISF as previously reported 
[171, 172]. We found that the concentration difference for Gln between plasma and CSF is 1.15 
times, while between CSF and ISF it is 6.4. The literature reports similar concentration 
differences for glucose: glucose is 1.5 times more concentrated in plasma than CSF, and ~ 5 
times lower in ISF than CSF [173-175, 177]. The CSF is mainly produced by the choroid plexus 
epithelium (CPE) with ~25% contribution from ISF [110-112], while the brain ISF is considered 
to be primarily formed by the BBB [136]. Since ependymal cells of ventricle walls do not form 
TJ complexes, ISF and CSF might exchange relatively freely in the ventricles. However, 
concentration differences between the ISF and CSF could result from the greater surface of the 
BBB compared to BCSF (~15-25 m2 vs 0.021 m2 for humans) and the nearly 10 times slower 
production of ISF than CSF [29, 113, 144, 424].  
6.1.3 Can concentration gradients be formed between ISF in different brain regions? 
Since the brain ISF exhibits bulk flow, no gradients are believed to exist between different brain 
regions [136]. The perivascular circulation route from CSF into the brain along arteries 
penetrating the outer brain surface and then back out from the brain tissue along large-caliber 
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draining veins has been shown to be an important “clearance route” [148-151, 153, 418]. 
However, all experiments that described the perivascular route involved usage of radiolabeled 
tracers not naturally found in the brain, for example horseradish peroxidase (HRP). Therefore the 
importance of this pathway for equilibration of naturally occurring solutes such as sugars, AA, 
nucleosides, etc., in ISF between different brain regions is not clear. For instance, Kanamori 
observed no statistically significant difference in Gln levels in mD samples collected from the 
somatosensory cortex, hippocampus, and thalamus [172]. In contrast, glucose levels determined 
by in vivo microdialysis by several groups varied 2 – 6 fold between striatum, hippocampus, and 
cortex [167-169, 173, 174, 176, 177]. Additionally there is evidence for heterogeneous 
distribution of enzymes, including receptors, and transporters for neurotransmitters in the brain 
that might be the basis for its functional heterogeneity. For instance, transporters for the 
inhibitory neurotransmitter, glycine, such as GlyT1, and GlyT2, and for GABA, i.e. GAT1, and 
GAT3 are relatively equally expressed in cortical neurons [425]. However, hippocampal neurons 
preferentially express GlyT1, GlyT2, and GAT1, and in thalamus Glyt2 is highly expressed 
[425]. Another important example of heterogeneity is regional distribution in the brain of 
ionotropic GABAA receptors (GABAAR) subunits. To date 19 subunits have been identified, 
these receptors are heteropentamers and generally consist of two α, two β and a variable fifth 
subunit (γ, δ, ε, θ, or π) [426]. The six known isoforms for α subunits have distinct distributions 
in the brain: α2 expression is high in the cortex, striatum, and hippocampus, and lower in the 
hypothalamus, thalamus, and cerebellum. In contrast, the α3 subunit is primarily expressed in the 
cortex, olfactory bulb, and thalamus [426]. Therefore, neurons as well as astrocytes and 
endothelial cells can significantly influence the content of the brain ISF depending on the 
particular protein expression patterns occurring in different brain regions. A recent study 
comparing ISF neurotransmitter concentrations in the ventral tegmental area (VTA; enriched 
with dopamine (DA) neurons) and red nucleus (RN) that are separated by a distance of only ~ 
200 µm [427] using low flow push-pull sampling demonstrated significant differences in DA 
levels [162]. A similar, but non-significant trend was found for glutamate [162]. This approach 
could be used to investigate metabolite concentrations in ISF from different brain regions. 
Generally, the methods used (mD, push-pull low sampling) for this type of studies require a high 
spatial resolution. 
6.1.4 Cells actively regulate ISF content 
On the one hand, brain endothelial cells control flux of substances in to and out of the brain and, 
therefore, regulate ISF qualitive and quantitative content. On the other hand, neurons, as 
6. Discussion and outlook
103
  
electrically excitable cells, along with glial (astrocytes, oligodendrocytes) and microglial cells 
consume various compounds and produce metabolites and as a result change ISF content. 
Simultaneously cells closely interact with each other in the brain and, consequently, such 
complex interactions also regulate the concentration of compounds in ISF. For instance, during 
increased neuronal activity neurotransmitter concentrations, as well as, glucose and lactate in the 
brain ISF vary highly. Currently several contradictory theories have been suggested to explain 
events occurring during increased neuronal activity [428]. According to the most accepted 
astrocyte-to-neuron lactate shuttle (ANLS) hypothesis glycolysis is increased in astrocytes and 
the produced lactate is transported from astrocytes into neurons for further oxidation [95]. This 
model relates excitatory neurotransmission of Glu, the glutamate-glutamine cycle and astrocyte-
neuron metabolic coupling. In this case glutamatergic activation leads to Glu increase in ISF, 
which is taken up by neurons and astrocytes. Glu transport occurs in Na+-dependent manner and 
increased intracellular Na+ concentration activates Na+/K+ pump. As a result, consumption of 
ATP increases due to its utilization for conversion glutamate into glutamine and for pumping 
Na+ out of the cell. In this case glycolysis is suggested to be the source for an increased ATP 
demand and consequently lactate is produced, which is then released and used by neurons as 
energy source [428]. Alternatively, another theory that explains events taking place during 
neuronal activity and changes in lactate levels in the brain ISF has been suggested by Simpson 
based on expression pattern in different brain cells of glucose transporters and their kinetic 
parameters [429]. The neuron to astrocyte lactate shuttle (NALS) model suggests that during 
increased activity neurons demand high levels of energy and consequently glucose uptake via a 
high affinity glucose transporter GLUT3 increases [429, 430]. As a result, glucose levels 
decrease in the ISF, glycolysis is upregulated in neurons and lactate released by neurons to the 
ISF. Increased lactate level in ISF is suggested to be normalized by active consumption of lactate 
by astrocytes and transport of lactate across the BBB into blood [428]. Thus, NALS model 
suggests that lactate flux between neurons and astrocytes depends on neuronal status [429]. The 
reversibility of lactate transport between neurons and astrocytes has already been described by 
Cerdán and depends on relative values of cytocolic and mitochondrial redox states in neurons 
and astrocytes [431]. Interestingly, it has been shown that upon neuronal activation glucose 
transport increases via the BBB. This increased transport might be aimed to provide glucose for 
neurons and normalize ISF glucose levels. This phenomenon was named as neurobarrier 
coupling [97]. Taken together, these examples demonstrate the direct and strong impact of 
metabolism occurring in different cells in the brain on the brain ISF.  
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6.1.5 Glutamine origin in the ISF and its regulation 
Generally, enzymes and transporters can be regarded as key molecular regulators of Gln 
concentrations in brain ISF. This can be illustrated by the glutamate/GABA-glutamine cycle 
[273]. Glu levels are tightly controlled in the CNS since its high levels are neurotoxic [234]. 
After Glu release in synaptic cleft it binds to neuronal neurotransmitter receptors, while excess 
of Glu is taken up by transporters expressed mainly in astrocytes. Next glutamate is converted by 
glutamine synthetase (GS) into glutamine [273]. Glutamine is transported from astrocytes 
mainly via SNAT3 and SNAT5 into the brain ISF [279] [275-278, 280], where it is taken up by 
neurons via SNAT1, SNAT2, and possibly SNAT7 for Glu synthesis [283, 350, 351, 366, 432]. 
Thus, here we already observe the close cooperation between receptors, transporters, and 
metabolic enzymes expressed in two cell types in Gln regulation. The picture is becoming more 
complicated, when other cell types such as BEC as well as Gln from the blood stream are 
considered. Interestingly, GS plays an important role during hyperammonemia, since it catalyzes 
the reaction between ammonia from the blood and glutamate to form Gln [322]. Experiments 
with a known GS inhibitor L-methionine-S,R-sulfoximine (MSO) significantly reduced the 
newly synthesized glutamine from (13N) labeled ammonia, in comparison to control animals that 
did not receive the inhibitor [322]. There are eleven transporters expressed in the brain, which 
can potentially play an important role in Gln homeostasis regulation. However, as usual for 
AATs none of them transports Gln exclusively. Moreover, the same AAT can be expressed in 
different brain cell types. Therefore, investigation of the roles of various Gln transporters in 
brain ISF homeostasis is challenging. First, in order to understand the role of a particular AAT in 
brain ISF Gln regulation it is important to know the relative AAT expression in various brain 
cell types. Moreover, for the BEC the membrane localization pattern (both membranes, or 
luminal, or abluminal only) must be investigated (Table 3). Next, the functional impact of 
different AAT systems has to be studied.  
In our studies we used two approaches to challenge the homeostatic conditions in the brain ISF. 
Since Gln is actively produced in astrocytes as a part of glutamate/GABA-glutamine cycle it is 
important to know how much Gln is produced in the brain and how much originates from 
plasma. We investigated transendothelial transport of AAs by acute elevation in peripheral 
circulation. This approach gives the opportunity to answer the question whether the transport of 
particular chemical is possible across the BBB into ISF in vivo and simultaneously to determine 
concentration in plasma and ISF. For example, intravenous infusion of (U-13C5) Gln in mice 
resulted in 11.8% enrichment of labeled Gln in brain lysates corresponding to plasma Gln 
concentrations greater than 1.1 mM [433]. Extrapolation to physiological plasma Gln levels 
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(~600 µM) yields 7%, including intra- and extracellular glutamine. Interestingly, in our 
experiments 15N2 Gln IP resulted in ~4% of labeled Gln in the brain ISF. Nevertheless, this 
method has two possible disadvantages. First of all, elevated levels are strongly different from 
physiological conditions and observed transport under extreme conditions might not occur under 
normal conditions. Second of all, acute manner of administration gives the possibility to observe 
changes for a relatively short period of time. As an alternative method to acute elevation an 
intravenous infusion can be used, since in this case transport under “steady state” conditions can 
be investigated. Moreover, Gln levels are known to be elevated in plasma during 
hyperammonemia. Consequently, this condition can be imitated by intravenous infusion of Gln 
alone (such as in the study by Bagga and coworkers) and the possibility of transport across the 
BBB under this pathological condition can be examined [433]. Nevertheless, the mentioned 
approach has one major disadvantage of the necessity for animals being anesthetized during the 
whole procedure.  
Some AAT systems are known to be competitively inhibited by non-natural AA analogs, for 
example, MeAIB (system A inhibitor) or BCH (system L inhibitor). Perfusion of these 
competitive inhibitors into the brain might provide a general idea about the relative importance 
of one or another AAT system for the regulation of AA homeostasis. In our study I demonstrated 
a significantly stronger impact on Gln levels in the brain ISF using BCH vs. MeAIB 
administration via the mD probe. Since these inhibitors are applied in vivo it is important to note 
that they might have an impact on cell metabolism. For example, BCH activates glutamate 
hydrogenase and as a result decreases intracellular Glu levels [434, 435]. Thus, inhibitors might 
additionally affect not only levels of the AA of interest, but also other AAs therefore adequate 
controls must be chosen. Also since the inhibitor is applied to a complex system for a relatively 
long period of time it might cause initial changes in AA levels, which might lead to subsequent 
changes in other AAs. Therefore, it might not be possible to distinguish the primary events from 
the secondary effects. The observed elevated Gln in case of competitive inhibition might come 
from periphery (blood) or from intracellular pools (cells in the brain). In order to answer this 
question about Gln source, BCH was administrated to the brain ISF with simultaneous IP 
injection of 15N2 Gln. As a result a large increase in labeled Gln in the brain ISF was observed. 
Accordingly, we assumed that BCH applied in the brain ISF transstimulated system L expressed 
in the BBB and caused the plasma Gln influx into the brain. In summary, described functional 
approaches give the opportunity to distinguish the AAT system involved in Gln concentration 
regulation, but do not allow identification of the AAT on the molecular level. 
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6.1.6 Methods for SNAT5 localization in the BBB  
Polarized expression of different transporter systems is a key basis for the BBB function as a 
transport barrier between blood and brain. Studies of AAT localization in the BBB have 
significance not only for understanding of their physiological roles, but also for potential 
applications in drug delivery to the CNS. Membrane fractionation can be used for enrichment of 
luminal and abluminal membranes in the lower and higher-density layers, respectively [436]. 
Kinetic studies using fractionated BBB membrane vesicles have been used in the investigation of 
the transport properties of luminal and abluminal membranes and, thus, for the identification of 
transporter systems [139, 372]. Based on this approach, for example, system L was shown to be 
distributed on both membranes, while system A was found to be restricted to abluminal 
membranes. However, this assay did not provide the molecular identity of transporters and 
moreover separation of luminal and abluminal fractions might have been not complete. 
Application of antibody-based methods such as immunofluorescence and western-blotting of 
biotin labeled luminal membranes resulted in identification of SNAT3 on both BBB membranes 
[3]. Nonetheless, the main limitation of antibody-based approaches is the availability of specific 
antibodies. Unfortunately, I faced this problem during my attempts to localize SNAT5 
expression in BBB membranes, since none of the anti-mSNAT5 antibodies tested recognized 
SNAT5 in microvessels. Development of new non-antibody dependent methods for localization 
of transporters on the BBB membranes represents an important area of study. For example, 
recently a method based on combination of membrane fractionation with liquid chromatography-
mass spectrometry (LC-MS/MS) was applied for localization of some transporters in luminal 
and abluminal BBB membranes [437]. In order to overcome the problem of cross-contamination 
luminal and abluminal membranes the authors suggested using a correction based on the 
absolute amounts of marker proteins specifically localized in luminal or abluminal membranes. 
Based on the fractional analysis of this study together with previous immunohistochemical and 
functional studies the authors suggested using MDR1 (multidrug resistance protein 1, or 
permeability glycoprotein 1, Pgp, or ATP-binding cassette sub-family B member 1 (ABCB1)) as 
a luminal membrane marker, and SNAT2 as an abluminal membrane marker. Interestingly, 
during preparation of different fractions from the BBB the authors did not detect SNAT1 in 
agreement with data previously published from our lab [3]. Based on this approach the ABC 
transporters, ABCG2 (or BCRP), and SLC transporters, such as the glucose transporter GLUT1 
(SLC2A1), and organic anion transporter OATP3A1 (SLCO3A1) are shown to be luminal-
dominant transporters, while ABCA1 and the long chain fatty acid transporter, FATP1 
(SLC27A1) have abluminal-dominant localization. At the same time the authors suggested that 
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the ACB subfamily C transporter (ABCC5 or MRP5) and the monocarboxylate transporter, 
MCT1 (SLC16A1), as well as the Na+/K+ ATPase have a similar distribution on the two 
membranes. Nevertheless, there are two disadvantages of this method. First, a significant amount 
of material is required, that is why in the described study porcine brains were used. Second, 
isolated microvessels can be contaminated with astrocytes, pericytes, and neurons.  
6.2. Outlook 
6.2.1 Investigation of the role of SNAT3 expressed in the BBB and glial cells in the brain ISF 
glutamine homeostasis 
During the Gln transendothelial transport study at 5 min post-IP injection, plasma Gln was 
elevated to ~ 2.3 mM. Both LAT1 and SNAT3, which transport Gln with low affinity at 
respective Km values of 1.6 and 0.9 mM, could be involved in BBB transendothelial Gln 
transport (Table 3). This suggestion is also supported by high levels of expression of mRNA of 
both transporters in the BBB and the localization of both transporters on luminal and abluminal 
membranes. Moreover, competitive inhibition by BCH in vivo during brain perfusion 
significantly increases Gln in the ISF confirming the role of system L in Gln ISF homeostasis. 
Based on the literature about LAT1 and LAT2 expression in different CNS cells, we suggest that 
the observed effect on Gln ISF level is mainly due to BBB expressed LAT1. Indeed, system L 
transporters are obligatory exchangers and transport is driven by AA gradients generated by Na+-
dependent system A and N transporters [438].  Thus, the next steps in the investigation of Gln 
homeostasis in the brain ISF must focus on understanding the roles of BBB expressed LAT1 and 
SNAT3. To perform these studies in vivo knockout SNAT3 and/or LAT1 models must be used. 
Unfortunately, the constitutive knockout mouse models for these two transporters have lethal 
phenotypes. Abolishing LAT1 resulted in death during embryonic development, while SNAT3 
loss caused death at post-natal ~18 – 21 days [439, 440]. To overcome the severe consequences 
of the constitutive SNAT3 knockout an endothelial and astrocyte targeted inducible knock-outs 
of SNAT3 were bred. This was accomplished by creating a floxed SNAT3 mouse strain from an 
ES cell clone (EPD0351_2_A12) generated by the Wellcome Trust Sanger Institute and bred by 
the KOMP Repository (WWW.KOMP.org) and the Mouse Biology Program 
(www.mousebiology.org) at the University of California Davis. Next we crossed floxed SNAT3 
with VeCadCreERT2 mice kindly provided by Dr. Luisa Iruela-Arispe. In this case Cre-
recombinase expressed under VE-Cadherin promoter will be activated in all endothelial cells 
including the BBB by tamoxifen administration, and as a result of recombination Snat3 gene will 
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be truncated [441]. We consider that this model will allow investigation of the role of SNAT3 
expressed in the BBB and in astrocytes for regulation of Gln homeostasis in the brain ISF.  
First of all, the efficiency of SNAT3 gene abolishment in the BEC cells must be characterized, 
since this process is tamoxifen-dose and age dependent [441]. Next, the generated model can be 
characterized in terms of AA levels in the brain ISF and efficiency of transendothelial Gln 
transport as compared to wild-type animals. In addition, transport of AAs such as glycine and 
histidine across the BBB can be tested. These AA are lower affinity substrates for SNAT3 than 
SNAT5 and if SNAT3 is eliminated from the BBB, then the detection of elevation of these AA 
levels in the brain ISF would be indirect evidence of SNAT5 function in the BBB. Moreover, 
our preliminary in vivo test of L-glutamic acid-γ-monohydroxamate (GAH) resulted in the 
significant elevation of Gln in the brain ISF. Previously, this AA analog was shown to inhibit 
Gln transport in oocytes expressing SNAT5 [352]. Therefore, we assume that comparative 
analysis of changes in Gln level in the brain ISF under application GAH in wild-type versus 
SNAT3fl//fl VeCadCreERT2+//-animals might provide information about the relative 
importance of SNAT3 and SNAT5 in this regulation.  
Since SNAT3 is abundantly expressed not only in the BBB, but also in astrocytes we decided in 
parallel to generate a mouse model, in which SNAT3 expression is eliminated in astrocytes. 
Thus, we crossed available SNAT3 floxed animals with FVB,129-TG(GFAP-CreER)Fki 
generated in the lab of Frank Kirchhoff and kindly provided for our research by Prof. Isabelle 
Mansuy. Interestingly, a correlation between elevation of K+ and Glu in the brain interstitial 
fluid resulting from concussive brain injury has been shown [442]. However, no data were 
provided for Gln concentration under the same conditions. SNAT3 transporter expressed in 
astrocytes is considered to be an important player in glutamate/GABA-glutamine cycle. 
Temporal elevation of K+ via mD probe during the experiment causes neuronal depolarization 
and increase of neuronal activity and as a result release of Glu from glutamatergic neurons. 
Excess of Glu has to be taken up by astrocytes and transformed into Gln that is then thought to 
be released via SNAT3 and SNAT5 transporters and consumed by neurons for Glu synthesis 
[273]. Therefore, we consider that the described experiments performed in our SNAT3fl//fl 
GFAP-CreER +//- knockout animal model may be essential for the investigation of changes in 
ISF neurotransmitters (Glu, GABA) as well as other AAs (Gln).  
We consider that the comparative analysis of the two mouse models that lack SNAT3 expression 
in the BBB or in astrocytes will help clarify the role of this AAT for Gln homeostasis in brain 
ISF. 
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